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QUILL ON SCALPEL
Is Multimodality Therapy an Option to 
Surgery Alone in Adenocarcinoma of the 
Gastroesophageal Junction?
W.J. Temple, MD, FRCSC, FACS
Member, Editorial Board, Canadian Journal o f  Surgery. Tom Baker Cancer Centre, University o f  
Calgary, Calgary, Alta.
Esophagogastrectomy, particu­larly for an obstructing adeno­
carcinoma of the esophagus, has 
been the “gold standard” of treat­
ment for cure and for palliation. A 
report on this procedure by Smith 
and Kwan in this issue (pages 97 to 
100) is timely because esophageal 
adenocarcinoma may be increasing 
in frequency.1 Two other large re­
trospective studies23 have recently
been published on surgical resec­
tion and bypass for adenocarcinoma 
of the esophagus, and the results 
parallel those of Smith and Kwan. 
However, the literature in general 
documents much more grief with 
this approach than the 4% death 
rate and the average 3-week hospi­
talization these studies report. 
These good results are, I am sure, 
due mainly to the technical skill of
the surgeons but may also be relat­
ed to the referral pattern and the 
preselection of patients. In Smith 
and Kwan’s report we learn only 
about those who the authors ulti­
mately treated, who do not repre­
sent the true picture of this disease 
in that hospital or community. For 
example, preselection in this article 
is evidenced by the fact that only 2 
of the 21 patients had lost weight
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TEMPLE
before surgery. This group of pa­
tients tolerates major surgery rela­
tively well.
What worries me, however, is the 
danger of considering surgery as 
having only palliative value when 
the disease in at least 15% of such 
patients may be curable. By consid­
ering only a palliative surgical ap­
proach to this disease when it is 
only locally extensive, we may limit 
our therapeutic interventions to in­
complete resections and, even 
worse, we may not look beyond our 
discipline for help. In the report of 
Smith and Kwan, the proximal eso­
phageal margins were involved in 
24% of cases. There is no discus­
sion of whether some of these pa­
tients were presumed incurable by 
virtue of only extensive local dis­
ease. I suspect that unrecognized 
esophageal extensions may play a 
part in the relatively high local 
recurrence rate, despite resection, 
reaching up to 35% in the litera­
ture. In 30% of patients with local 
recurrence, it may be the first and, 
less commonly, the only site identi­
fied before death.
This problem of local recurrence 
challenges us to rethink our ap­
proach and to identify an effective 
local adjuvant therapy. The dramat­
ic results locally of adjuvant preop­
erative treatment with radiation or 
chemotherapy, or both, in squa­
mous cell carcinoma of the esopha­
gus, which has similar biologic fea­
tures, are not well documented in 
adenocarcinoma of the esophagus. 
The latter has traditionally been 
considered both radioresistant and 
relatively chemo-insensitive. These 
observations, I suspect, reflect the 
fact that the tumour is rarely com­
pletely sterilized or shrinks rapidly, 
rather than that adjuvant therapy
has a negligible effect. If radiation 
therapy could sterilize the periphery 
of the tumour, the lymphatics and 
minimally involved nodes, preopera­
tive therapy might improve local 
control. In similar diseases, such as 
in fixed and unresectable rectal ade­
nocarcinoma, which is another rela­
tively radioresistant disease, preop­
erative therapeutic radiation works 
extremely well when combined with 
surgery for local control and, in 
many patients, results in cure.4
To support further this therapeu­
tic concept in adenocarcinoma of 
the esophagus, MacFarlane and as­
sociates,5 in a recent preliminary 
report of experience with preopera­
tive chemotherapy and radiothera­
py, obtained sterilization of adeno­
carcinoma prior to resection in 23% 
of cases, a dramatic increase in the 
incidence of stage I and stage II 
lesions (from 3% to 38% compared 
with historical controls) and a total 
absence of local recurrence in their 
21-month follow-up. Although 
there was no increase in operative 
mortality in these patients, in my 
experience they are more prone to 
complications. We have used preop­
erative therapeutic radiation in 
three patients with adenocarcinoma 
of the esophagus and have been 
encouraged by the impressive 
shrinkage (more than 50%), lack of 
involved nodes or subsequent re­
sectability at surgery. A preopera­
tive approach, whether it be radio­
therapy alone or radiotherapy and 
chemotherapy, has the advantage 
also of providing a biological win­
dow to assess the progress of re­
gional and systemic disease so that 
surgery, which is both expensive 
and morbid, may be limited to those 
who have the most chance of bene­
fit. Furthermore, some of the pa­
tients considered only for palliation 
may subsequently be considered to 
have curative disease by virtue of 
local regression. In the experience 
of MacFarlane and colleagues5 ap­
proximately 20% of patients with 
the preoperative treatment did not 
undergo surgery, a group that is 
comparable to the patients who 
underwent surgery and had short­
term survival reported by Smith and 
Kwan.
In conclusion, Smith and Kwan 
are to be congratulated on an excel­
lent technical experience. I agree 
with their conclusion that a surgical 
bypass alone, by surgeons skilled in 
this operation, is indicated for se­
lected patients if palliation is the 
only goal. However, in the future 
treatment of this disease we must 
explore preoperative adjuvant ther­
apy for its value in increasing re­
sectability and local control for both 
palliation and cure.
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QUILL ON SCALPEL
Biliary Colic
Nis Schmidt, MD, FRCSC
Member. Editorial Board. Canadian Journal o f Surgery. Clinical Professor, Department o f 
Surgery. University o f  British Columbia. St. Paul's Hospital, Vancouver. BC
C olic (as in biliary tract disease) has occurred on occasion 
amongst those who care for the 
patients, through debate and pos­
turing over which doctor should be 
doing what for whom.
Historically, it is just over 100 
years since Langenbuch first per­
formed cholecystectomy (1882) and 
Kummel explored the common bile 
duct (1884). During that time there 
has been little choice other than a 
standard cholecystectomy to treat 
symptomatic biliary stone disease, 
and general surgeons have handled 
the procedure. There were, of 
course, variations, and many modi­
fications have been reported to the 
techniques of cholecystostomy, cho­
lecystectomy, indications for com­
mon-bile-duct x-ray and explora­
tion, as have ideas for retrieving 
common-bile-duct and intrahepatic 
stones, and indications and recom­
mendations for duodenostomy, 
sphincterotomy or sphincteroplasty.
In the February 1990 issue of the 
Journal (pages 13 and 14) Bickel 
and colleagues from the Nahariya 
Government Hospital in Nahariya, 
Israel, described their technique for 
managing high-risk patients who 
require cholecystectomy. They pre­
sented a series of eight patients in 
whom they carried out a modified 
subtotal cholecystectomy. The tech­
nique they used is similar to that 
recommended by Thorek (1946) 
and is familiar to most experienced 
general surgeons doing frequent ab­
dominal operations. The authors
advise this technique in difficult 
cases of cholecystitis, acute or 
chronic, in patients with liver dis­
ease, portal hypertension and possi­
bly gallbladder perforation. Their 
advice is well taken, but the opera­
tion itself in the presence of in­
creased risk factors, in sick pa­
tients, may be a thing of the past.
Since the mid-1960s the modali­
ties available for the management of 
biliary tract problems have mush­
roomed. Retained common-bile-duct 
stones after cholecystectomy meant 
certain repeat surgery until Bur- 
henne (1973) perfected his steerable 
catheter to facilitate the percutane­
ous removal of stones through the 
T-tube tract. This obviated a gener­
al surgical procedure on the biliary 
tract, reducing the risk and morbid­
ity of difficult reoperations. Endo­
scopic retrograde cholangiopan­
creatography (ERCP) also was per­
fected and, by 1975, a number of 
centres around the world were ad­
vocating this procedure as the pri­
mary one for common-bile-duct 
stones with or without cholecystec­
tomy in chronic and acute situa­
tions. Percutaneous transhepatic 
techniques advanced to the point at 
which radiologists also could drain 
the common bile duct, dissolve or 
crush ductal stones and provide 
drainage in cases of ascending cho­
langitis. Once again the general 
abdominal surgeon was relieved of 
emergency cholecystectomy and 
common-bile-duct exploration in pa­
tients who were often critically ill.
Technologic advances, however, 
did not stop there. From Munich, 
Germany, in 1980 came a report of 
extracorporeal shock-wave lithotrip­
sy for renal stone therapy which, 
within 3 years, reduced the surgery 
for urolithiasis from 30% to 1% of 
urologic procedures. General sur­
geons did not feel threatened by 
this advance until it became avail­
able for clinical use in biliary tract 
procedures in Munich (1985) and 
Vancouver (1987). The prospect of 
gallstone lithotripsy, ERCP papil­
lotomy and percutaneous cholecys­
tostomy for biliary sludge extrac­
tion and gallbladder sclerosis as the 
future basic treatment for choleli­
thiasis sent shock waves also 
through the general surgical com­
munity. Now, in addition to this, for 
selected patients with uncomplicat­
ed chronic cholelithiasis and chole­
cystitis, is the choice of day-care 
percutaneous or laparoscopic chole­
cystectomy with or without opera­
tive cholangiography, minus the ab­
dominal incision. Standard chole­
cystectomy appears to be going the 
way of the dodo.
A major characteristic of modern 
health care is the proliferation of 
single disease and single treatment 
specialists. This is good and neces­
sary, because advancement usually 
arises from determined individuals 
with a focused interest. It becomes 
totally impossible, however, if the 
treatment of biliary tract disease is 
a cafeteria approach where a patient 
passes through a lineup of menus
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and offerings all advocating ways 
and means of treatment. Someone 
must take charge of the decision­
making. Endoscopists, radiologists, 
medical gastroenterologists all have 
an important part to play in this 
process. However, there are not 
enough facilities, resources or “su- 
perlaparoscopists” available for all 
centres to offer all possible treat­
ments to all biliary tract sufferers, 
unless some order prevails. The 
general surgeon should therefore 
play a central role in communica­
tions with the family physician, 
with the patient and with other 
specialists, in making the diagnosis,
BOOK REVIEWS
LOWER EXTREMITY AMPUTA­
TION. Edited by Wesley S. Moore and 
James M. Malone. 354 pp. Illust. W.B. 
Saunders Company Canada Limited, 
T oronto , 1989. $93.75. ISBN
0-7216-6485-7.
This monograph advances the art and 
science of prosthetics and amputation 
of the lower limb. It is the hope of the 
editors that this information will meet 
the needs of the surgeon caring for 
patients who require amputation and 
will ensure the health and optimal reha­
bilitation of those who possess the 
maximal length of residual extremity.
Throughout the text, the authors 
emphasize the importance of a multidis­
ciplinary team approach in which the 
patient is the principal member.
The chapters on surgical technique 
at various levels are clearly presented 
and stress the need for a senior surgeon 
to perform or closely supervise the 
surgery and the patient’s subsequent 
rehabilitation.
The success rates of lower-extremity 
arterial reconstruction in the 1980s are 
accurately recorded. The early and late 
postoperative complications of lower- 
limb amputation are described, with
CJS, VOL. 33. NO. 2, APRIL 1990
and in evaluating and recommend­
ing, on the basis of illness or 
health, simplicity or complexity, 
available resources and technolo­
gies, the best possible and least 
difficult approach to treatment.
Standard uncomplicated chole­
cystectomy for chronic cholelithia­
sis is still the basic and best, low- 
risk, inexpensive, expedient, perma­
nent cure available for symptomatic 
gallbladder disease in all communi­
ties. All other modern techniques 
available and accessible are impor­
tant advances and additions when 
more than a simple standard ap­
proach is needed, but they are not a
substitute for basic treatment. The 
supervision of overall care should 
be assumed by clinically involved 
surgeons who are capable of man­
aging the patient’s response to 
treatment, since complications can 
and do arise; overall care should not 
be handled by clinical diagnosti­
cians and technicians who do not 
have access to hospital beds or 
patient follow-up.
A general-surgeon-directed ap­
proach should help to cure biliary 
colic with the least morbidity and 
mortality and reduce the personal 
colic that has arisen among those 
who deliver the care.B
1
emphasis on associated cardiovascular 
and diabetic problems in the elderly.
I have some minor criticisms. The 
chapters on amputation level and selec­
tion by noninvasive methods are too 
long and may confuse the reader. Al­
though immediate postoperative fitting 
is recommended, many centres do not 
possess the available facilities. My pref­
erence is for prosthetic fitting within 7 
to 10 days of the amputation. The three 
pages on upper-extremity amputations 
are irrelevant in a text specifically re­
stricted to lower-extremity amputation. 
The chapters on lower-limb prosthetics 
do not contain sufficient basic princi­
ples to allow the reader to prescribe a 
suitable prosthesis. Prosthetic rehabili­
tation has become of international con­
cern, and I would have preferred more 
references from outside the United 
States.
It is estimated that approximately 
50 000 lower-extremity amputations 
are performed each year in the United 
States alone, and the incidence of major 
lower-limb amputation in high-risk, dia­
betic patients ranges from 6% to 12% 
per year.
This monograph provides state-of- 
the-art information on all aspects of
lower-extremity amputation. It is essen­
tial reading for those concerned with 
the care of the amputee and should be 
available in every hospital library in 
order to provide physicians with suit­
able reference material for postgraduate 
specialty examinations.
Gordon Hunter, MB, FRCS, FRCSC
University o f Toronto.
Sunnybrook Medical Centre.
Ste. 315.
2075 Bay view Ave.,
Toronto. Ont.
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TEXTBOOK OF MICROSURGERY. 
Edited by G. Brunelli. 1038 pp. Illust. 
Masson, Milano, 1988. Price not stat­
ed.
All the leading experts in reconstructive 
microsurgery from around the world 
have contributed to this impressive 
work. Although microsurgery involves 
all of the surgical specialties, from 
ophthalmology to neurosurgery, this
continued on page 134
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HOW I DO IT
Improved Technique for Insertion of a 
Dual Chamber Port-A-Cath
C. Del Campo, MD, FRCSC
The Port-A-Cath totally implant­able drug-delivery system has 
become a popular therapeutic meth­
od. The system is used most com­
monly for bolus injections and con­
tinuous infusions of chemothera­
peutic agents. It can also be used 
for blood sampling, transfusions 
and administration of parenteral nu­
trition. These systems greatly facili­
tate therapy, minimize patient dis­
comfort and increase compliance.
Recently, a dual chamber system 
(Figs. 1 and 2) has been introduced 
by Pharmacia Canada Inc., Dorval, 
PQ, for patients in whom two ve­
nous routes are required. The sys­
tem is composed of two independ­
ent chambers in a single device, 
joined to a double-lumen catheter 
with a double-barrel shotgun-type 
configuration at the distal end. It is 
recommended that this catheter be 
installed through a no. 13F peel- 
back cannula by way of the subcla­
vian vein.
I present an improved technique 
for implantation and use of this 
device, using an independent cathe­
ter for each chamber instead of the 
conventional double-lumen cathe­
ter.
Technique
Under sterile conditions in the 
operating room, the nondominant
shoulder and pectoralis area are 
selected for insertion under local 
anesthesia. The technique for inser­
tion of a single-lumen Port-A-Cath 
has been described previously.1 A 
similar technique is used with the 
following modifications. Once the 
vessel dilator and sheath have been 
inserted in the subclavian vein, the 
dilator is removed. A regular single­
lumen silicone rubber catheter is 
precut to the desired length. It is 
then threaded over the wire and 
guided fluoroscopically to the area 
where the superior vena cava joins 
the right atrium (Fig. 3). The J 
guide wire is then removed and 
reinserted through the same cannu­
la (Fig. 4). The peel-back sheath is 
then removed (Fig. 5) and a second 
dilator and cannula are introduced 
into the subclavian vein parallel to 
the first silicone catheter so that 
the catheter stays outside the new 
cannula (Fig. 6). The second sili­
cone catheter is then introduced
FIG. 1. Single and dual chamber 
Port-A-Cath systems.
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FIG. 2. Dual chamber Port-A-Cath ins­
erted with its conventional double­
lumen catheter. Notice proximity of 
both lumina at exit site.
FIG. 3. Silicone rubber catheter is 
inside cannula. Catheter has been 
threaded over J wire. Note that peel- 
back cannula appears larger than its 
real size for clarity.
FIG. 4. J guide wire has been removed 
from silicone catheter and reinserted 
through lumen of same peel-back can­
nula.
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over the J wire, as before, and 
positioned at the opposite end of 
the superior vena cava. The intro­
ducer is then completely removed 
(Fig. 7). Both catheters are tunnel­
led subcutaneously and connected 
to the dual chamber. The more 
proximal catheter (second) is always 
connected to the lateral chamber so 
it can be easily identified as a 
dedicated total parenteral nutrition 
(TPN) line if so desired. The final 
steps of this procedure remain un­
changed.
Discussion
This system has been marketed 
as a dual lumen Port-A-Cath, which 
has led to misinterpretation by a 
number of physicians and nurses 
who believed that the device had a 
single chamber and a second back­
up catheter to be used in case the 
first one clotted. This assumption 
could lead to errors in flushing 
techniques and it would prevent the 
dual system from being used to its 
full potential (i.e., simultaneous ad­
ministration of incompatible drugs). 
For this reason I like to refer to it 
as a dual chamber or dual system 
Port-A-Cath.
The intravenous dual chamber 
Port-A-Cath has a number of advan­
tages over the single chamber ver­
sion: (a) simultaneous administra-
FIG. 5. Peel-back cannula has been 
removed. Catheter and J wire remain 
in place inside subclavian vein and 
superior vena cava.
tion of incompatible drugs, (b) ad­
ministration of drugs through one 
chamber, dedicating the second one 
to TPN and (c) use of the system 
without surgical revision when one 
catheter becomes occluded.
The standard technique for in­
serting this catheter calls for the 
use of a no. 13F introducer for its 
insertion. The outside diameter of 
the double-lumen catheter is 3.9 
mm and fits well through the 4.33 
mm internal diameter of 13F intro­
ducer. Smaller introducers do not 
allow this maneuver when the 
added space occupied by blood (vis­
cosity) between the two is consid­
ered. When I first used this cathe­
ter, I found it very difficult in 
muscular patients to thread the 
double-lumen catheter because of 
compression of the cannula by the 
pectoralis muscle and fascias. A
FIG. 6. Second dilator and cannula 
have been inserted over J guide wire.
FIG. 7. Second silicone rubber catheter 
has been positioned under fluoroscopic 
control much more proximally than 
first catheter. Both are now connected 
to dual chamber Port-A-Cath.
diameter reduction or deformity of
0. 4 mm is all that is needed to 
prevent this step. The catheter can­
not be directed by the J wire be­
cause of the small inside lumina, so 
I modified the technique as de­
scribed. The silicone catheter of a 
regular intravenous Port-A-Cath 
was used. This catheter is long 
enough to be cut and used for both 
portals.
This technique has become my 
procedure of choice for this system 
because it minimizes blood loss and 
may decrease the possibility of air 
embolism by using smaller intro­
ducers. Thus, larger introducers, 
which may otherwise have no pur­
pose, do not have to be kept in 
stock. It also allows positioning of 
the second catheter much more 
proximally than the first, so it can 
be used as a dedicated TPN line 
(remember, it is always connected 
to the lateral catheter for universal 
identification). Since blood flows 
away from the exit orifice of the 
second catheter and toward the 
first, contamination is much less 
likely. When two incompatible 
drugs are used simultaneously, they 
are more likely to mix with blood 
before coming in contact with each 
other.
It is conceivable that in the fu­
ture this dual chamber catheter 
might have one catheter dedicated 
to intravenous use and the second 
for regional intra-arterial chemo­
therapy. However, in this situation 
the margin for error is high, and 
the wrong route of administration 
could be used inadvertently. In this 
case it would be safer to use two 
separate systems in different ana­
tomical locations for easy identifica­
tion.
Reference
1. Del Campo C: Simplified insertion of the
Port-A-Cath implantable drug-delivery
system. Can J Surg 1985; 28: 435-436
90 CJS, VOL. 33, NO. 2, APRIL 1990
CANADIAN ASSOCIATION OF CLINICAL SURGEONS
Kock to Urethra: Continent Functional 
Bladder Replacement
William L. Orovan, MD, FRCSC, FACS; Ian R. Davis, MD, FRCSC
Since 1950 when Bricker first described the construction of the ileal conduit, this 
procedure has become a standard method of urinary diversion after pelvic 
exenteration. Recently, increasing interest in continent diversions has resulted in 
the development of several new procedures, using both small bowel and large bowel 
to produce an internal urinary reservoir. Such reservoirs still maintain a urinary 
stoma which requires periodic catheterization for emptying. With the development 
of the Kock low-pressure urinary reservoir, it has now become possible to 
re-establish the continuity of the urinary system by anastomosing this internal 
reservoir to the posterior urethra. This procedure utilizes the distal urethral 
sphincter as a continence mechanism and allows functional bladder emptying 
without a stoma. An antireflux valve is constructed to protect the kidneys. The 
authors report their experience with 20 such diversions, describing the operative 
technique, detailing the perioperative complications and providing urodynamic 
evidence of restored bladder function.
Depuis la premiere description de la construction d’un conduit ileal par Bricker, en 
1950, cette intervention est devenue la methode standard de derivation urinaire 
apres une exenteration pelvienne. L’interet qui s’est developpe recemment pour les 
derivations continentes a entraine la mise au point de plusieurs nouvelles 
techniques faisant appel aussi bien a l’intestin grele qu’au gros intestin pour la 
construction d’un reservoir urinaire interne. De tels reservoirs conservent un stoma 
urinaire necessitant un catheterisme periodique pour assurer la vidange. Avec la 
mise au point du reservoir urinaire a faible pression de Kock, il est maintenant 
possible de restaurer la continuite du systeme urinaire par anastomose de ce 
reservoir interne a l’uretre posterieure. Cette intervention utilise le sphinctere 
externe distal de l’uretre comme mecanisme de continence et permet la vidange 
fonctionnelle de la vessie sans recourir a un stoma. Une valvule antireflux est 
introduite afin de proteger les reins.
Les auteurs commentent les resultats obtenus avec 20 diversions de ce type; ils 
decrivent la technique operatoire, signalent les complications peroperatoires et 
fournissent les preuves urodynamiques du retablissement de la fonction vesicale.
In 1950 Bricker1 documented the ease of construction and the low 
complication rate of the ileal con­
duit urinary diversion. Since then,
this procedure has become the stan­
dard for urinary diversion after pel­
vic exenteration. This simple con­
duit, which utilizes a 20-cm seg­
ment of distal ileum, drains continu­
ously and uses an external collect­
ing device for storing urine. Al­
though the ileal conduit is an effec­
tive low-pressure urinary diversion, 
many patients suffer slow but pro­
gressive renal deterioration second­
ary to chronic pyelonephritis, which 
results from the reflux of urine 
from the conduit.
The concept of replacing the 
bladder with a longer segment of 
bowel to create a continent, nonre­
fluxing, urinary reservoir was first 
proposed by Gilchrist and col­
leagues2 in 1950. This concept was 
not widely accepted because of its 
complexity and high rate of compli­
cations. It was not until 1982, 
when Kock and associates3 reported 
the construction of a continent, 
nonrefluxing urinary reservoir 
using distal ileum alone, that atten­
tion returned to the concept of 
continence with respect to urinary 
diversion.
A continent urinary reservoir may 
be defined as one which duplicates 
the storage function of the bladder 
internally and permits passive emp­
tying at convenient intervals, usual­
ly by intermittent self-catheteriza­
tion. In most cases, these reservoirs 
do not duplicate the bladder’s emp­
tying function. An ideal urinary 
diversion would be both continent 
and nonrefluxing, provide active 
emptying and avoid creation of a 
separate urinary stoma by re-estab­
lishing normal continuity of the 
urinary tract. Camay and LeDuc,4 in 
1979, first demonstrated the feasi­
bility of such a functional bladder 
replacement. The Camay procedure
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includes an intact segment of distal 
ileum in the form of a large U, the 
distal portion of which is anas­
tomosed to the proximal membra­
nous urethra. Unfortunately, in­
traluminal pressures within this in­
tact, tubular segment of ileum 
occur as a result of ongoing peri­
stalsis and often lead to inconti­
nence, especially at night when res­
ervoir pressures exceed the resting 
tone of the urinary sphincter. It 
remained for Weinberg and col­
leagues5 to define a method of 
combining the low-pressure, detu- 
bularized, Kock reservoir with anas­
tomosis to the proximal membra­
nous urethra to produce a truly 
functional, nonrefluxing, continent 
urinary diversion without any uri­
nary stoma. We report here our 
initial experience with 20 patients, 
all of whom underwent radical cys­
tectomy for high-grade bladder can­
cer and had urinary diversion using 
the Kock to urethra continent func­
tional urinary reservoir.
Patients and Methods
Between Jan. 1 and Dec. 31,
1988, 20 men underwent radical 
cystectomy and pelvic lymphadenec- 
tomy for high-grade invasive blad­
der cancer. The patients ranged in 
age from 54 to 80 years (mean 65 
years). All patients had full preoper­
ative work-up which included chest 
roentgenography, computed tomog­
raphy of the abdomen and pelvis 
and bone scanning. The alternatives 
for urinary diversion, including a 
standard ileal conduit and a conti­
nent reservoir involving an abdomi­
nal stoma, were discussed at length 
and informed consent was obtained 
from all patients. Preoperative renal
FIG. 1. Portion of distal ileum used for reservoir (63 cm).
FIG. 3. Mucosa approximated with double layer of 3-0 Vicryl.
FIG. 2. Two 22-cm segments are anastomosed side to side 
with 3-0 Vicryl and then opened longitudinally 5 mm from 
suture line.
FIG. 4. Mesenteric “window” is formed by denuding 8 cm of 
small-bowel mesentery.
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function was assessed by measure­
ment of the serum creatinine and 
blood urea nitrogen levels; no pa­
tient had a pre-treatment serum 
creatinine level exceeding 120 
mmol/L.
Surgical Technique
The technique is similar to that 
previously described for the stan­
dard Kock to skin continent diver­
sion,6 but the efferent limb and its
FIG. 5. Three rows of 4.8-mm staples 
are placed using TA-55 stapler.
accompanying second intususscept- 
ing nipple valve are unnecessary.
The basic steps are outlined in 
Figs. 1 to 7 as follows.
•  A three-segment portion of 
distal ileum is isolated (Fig. 1), 
beginning proximal to the ileocecal 
valve at the mesenteric avascular 
plane of Treves. The segment is 
marked off in 22-, 22- and 19-cm 
lengths.
•  The body of the pouch is 
formed by anastomosing the two 
22-cm segments side to side (Fig. 
2), with first a serosal suture and 
then, after longitudinally opening 
the bowel (Fig. 3), with a two-layer 
mucosal closure with absorbable su­
ture.
•  An intususscepted antireflux­
ing nipple valve is constructed at 
the afferent-limb (19 cm) segment 
by stripping the mesentery over 8 
cm of bowel, creating a “window” 
(Fig. 4) and intususscepting the 
bowel onto itself. A 2.5-cm serosal 
collar of Vicryl mesh soaked in a 
5% tetracycline solution encircles 
the bowel. Additional nipple stabili­
zation is achieved using three rows 
of AMS 4.8-mm staples applied with 
the TA-55 Auto-Suture (Auto Su­
ture Co., Division of U.S. Surgical 
Corp., Norwalk, Conn.) device (Fig. 
5).
•  The body of the pouch which 
was opened in a longitudinal direc­
tion is now closed transversely. 
This produces disordered peristalsis 
and maintains intraluminal pres­
sures below 20 cm H20. A lateral 
corner of the transverse closure is 
left open to a diameter of 2 cm for 
anastomosis to the proximal ureth­
ral stump (Fig. 6).
•  Ureters are implanted into the 
afferent limb of the pouch.
•  The pouch is anastomosed to 
the posterior urethra (Fig. 7).
Results
Operative time ranged from 4 to 
6.5 hours (mean 5.3 hours). The 
hospital stay ranged from 21 to 39 
days (mean 31 days). There were no 
perioperative deaths. Complications 
included deep venous thrombosis, 
requiring anticoagulant therapy, in 
seven patients and a superficial 
wound abscess in one. One patient 
had a urethral cutaneous fistula 
which was closed without difficulty 
and another had a fistula from the 
Kock pouch to the rectum. This 
was repaired through a posterior 
transanal approach, and the patient 
is now fully continent of both urine 
and stool.
FIG. 6. Pouch is dosed transversely with 3-0 Vicryl, leaving 
2-cm opening at one corner.
FIG. 7. Pouch is anastomosed to posterior urethra using 2-0 
Vicryl.
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Our longest follow-up is 16 
months and results have been excel­
lent. Two patients died of progres­
sive malignant disease and 1 re­
mains alive, with disease, on chemo­
therapy. Of the 18 survivors, 10 
have complete continence both day 
and night; 6 have partial continence 
with some night-time dribbling or 
stress-type incontinence; 2 patients 
suffer from incontinence which is 
sufficiently severe that they must 
wear anti-incontinence garments 
and pads or condom catheter drain­
age devices. We have found that up 
to 3 months may be required for the 
patient to recover continence, and 
some show improvement even be­
yond that time. Urodynamic assess­
ment was carried out on 15 patients 
after a minimum postoperative fol­
low-up of 4 months (Table I). Good 
reservoir volumes were noted and 
filling pressures were less than 20 
cm H20  in every case. Voiding was 
done by Valsalva's maneuver, which 
generated adequate flow rates in 
most cases. The sensation of blad­
der fullness was noted as abdominal 
cramping, making volitional voiding 
possible. Voiding times were occa­
sionally prolonged, but reservoir 
emptying was good in every case. 
Initially, because of the heavy pro­
T a b le  1. U ro d y n a m ic  A s s e s s m e n t in  15 
P a tie n ts  M o re  Than  4  M o n th s  A fte r  S u rge ry
P ou ch  v o lu m e , m l 2 5 0  - 1 000
In fu s io n  p re s s u re , cm  H20 <  20
V o id in g  p re s s u re s , cm  H 20 2 0 - 4 0
P eak f lo w ,  m l / s 1 3 .8 - 1 9 .2
M ea n  f lo w ,  m l / s 4.1 - 5 . 5
V o id in g  t im e ,  s 4 5  -  2 4 7
P o s t-v o id  re s id u u m , m l <  50
duction of mucus by the reservoir, 
patients are encouraged to self- 
catheterize and irrigate with 50 to 
100 ml of normal saline twice daily. 
As mucous production decreases, 
the frequency of catheterization is 
also decreased and is usually not 
necessary after 4 months. The 
avoidance of an abdominal wall sto­
ma, even a continent stoma, as in 
the Kock to skin diversion, has 
been a very positive factor for all 
patients, who have been extremely 
satisfied with the results of the 
procedure.
Discussion
Other forms of continent urinary 
diversion are possible. Most use 
intact tubular bowel segments — 
either large bowel (cecum) or small 
bowel, or some combination of dis­
tal small bowel and cecum. All of 
these produce elevated intraluminal 
pressures which can overcome rest­
ing urethral sphincter tone and re­
sult in night-time incontinence. The 
particular construction of the Kock 
pouch eliminates the problem and 
continence has been excellent. The 
Kock to urethra continent and func­
tional reservoir is now our first 
choice for men who undergo radical 
cystectomy. The only definite con­
traindications are diminished renal 
function with a serum creatinine 
level greater than 120 mmol/L or 
tumour involvement of the prostatic 
urethra, which necessitates total in­
continuity urethrectomy.
Establishment of relatively nor­
mal voiding without any urinary 
stoma and without the need for 
regular self-catheterization has 
been well received by patients. It 
may be that some will require an 
artificial bulbous urethral sphincter 
to overcome persistent inconti­
nence, but our experience suggests 
that this will be 10% or less of the 
total. We believe this technique rep­
resents an important addition to our 
armamentarium of urinary diver­
sions and seems to provide an im­
proved quality of life for patients 
who must undergo radical pelvic 
exenteration.
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Pyloromyotomy of Ramstedt: Experience 
of a Nonspecialized Centre
S. Dube, MD, FACS, FRCSC;* P. Dube, MD;* J.F. Hardy, MD, FRCPC;t 
R.E. Rosenfeld, MD, FRCPCJ
In a general hospital over a period of 6 years 57 infants with congenital 
hypertrophic stenosis underwent a Ramstedt pylorotomy. In most cases a surgical 
resident-in-training performed the operation under the direct supervision of a 
general surgeon. There were no complications of anesthesia, no deaths and no 
substantial morbidity. The majority of infants left the hospital within 48 hours. The 
results in this series compared favourably with those reported from more specialized 
centres.
Au cours des 6 dernieres annees, 57 enfants souffrant d’une stenose hypertrophique 
congenitale du pylore ont ete operes dans l’hopital general. La majorite des patients 
ont ete operes par un resident en chirurgie, sous la supervision directe d’un 
chirurgien general. II n’y a eu aucun probleme anesthesique ni aucune morbidity 
significative. La majorite des enfants ont quitte l’hopital en dedans de 48 heures. 
Cette serie se compare favorablement avec les resultats obtenus dans les centres 
specialises. La pyloromyotomie de Ramstedt a pu etre completee de facon securitaire 
dans l’Hopital Maisonneuve-Rosemont de Montreal et les auteurs croient que malgre 
qu’ils soient un centre de chirurgie generate, qu’ils peuvent continuer a proceder a 
cette intervention.
The general surgeon’s field of activity has narrowed dramati­
cally in recent years. Moreover, 
standards for certain types of opera­
tion have increased because of 
overspecialization. It is necessary, 
therefore, that nonspecialist sur­
geons prove their competence. Con­
genital hypertrophic pyloric steno­
sis used to be treated by general 
surgeons, but today it is more likely 
to be managed by a pediatric sur­
geon. Because this operation is 
never performed as an emergency, 
it is perhaps safer to transfer the 
baby to a specialized centre.
McDonald1 has reported that in 
some district hospitals in England 
the rates of wound infection and
Accepted for publication Oct. 27, 1989
dehiscence for the Ramstedt proce­
dure are 6% and 4%, respectively. 
These rates are much higher than 
those reported by specialized cen­
tres (0.5% and 0.2%).2 Despite that, 
district hospitals still continue to do 
this operation. Anesthesia can also 
present a problem for physicians 
unaccustomed to administering an­
esthesia to infants.
The aim of this study was to 
review the complication rate of an­
esthesia and surgery, the outcome 
of the Ramstedt procedure with 
respect to refeeding and length of 
stay in our general hospital, and to 
compare these results with those 
from specialized centres, to deter­
mine if we should continue to per­
form this procedure at our institu­
tion.
Patients and Methods
A retrospective study was under­
taken of 57 consecutive patients 
(46 boys, 11 girls) with congenital 
hypertrophic stenosis seen at the 
Hopital Maisonneuve-Rosemont be­
tween 1978 and 1986. The opera­
tions were performed by second- to 
fourth-year residents under the di­
rect supervision of several general 
surgeons. All operations were per­
formed under general anesthesia, 
administered by residents-in-train- 
ing, also under the immediate su­
pervision of an anesthesiologist, or 
by the anesthetist himself. Thirteen 
infants were intubated awake, and 
44 were intubated after rapid- 
sequence intravenous induction of 
anesthesia and cricoid pressure. All 
infants were extubated awake. All 
the abdominal incisions were trans­
verse rectus skin incisions, and the 
muscle was split vertically. The 
wounds were closed with absorb­
able interrupted sutures. A standard 
longitudinal Ramstedt pyloromyoto- 
my was carried out as described 
previously.3 Any perforation of the 
duodenal mucosa that was noted 
was sutured with Dexon or Vicryl. 
The infants were treated before and 
after surgery by pediatricians and 
surgeons, and an early feeding pro­
tocol was implemented. No antibiot­
ics were used.
Results
The clinical manifestations of 
congenital hypertrophic stenosis
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were typical; in the majority of 
cases they were mild or moderate. 
Only 50% of infants presented with 
metabolic alkalosis. A palpable py­
loric tumour was present in half the 
cases. In the majority a barium 
meal radiologic examination or ab­
dominal ultrasonography were done 
to confirm the diagnosis. The mean 
duration of anesthesia and surgery 
was 40 minutes. There was only 
one difficult intubation and no aspi­
ration occurred. There were seven 
duodenal perforations; all were re­
paired by simple suture. No further 
leak or complication occurred.
There were no deaths, wound 
infection, dehiscence, hernia or 
need for reoperation.
These results are compared with 
those from other series in Table I. 
For the majority, refeeding was 
started 8 hours postoperatively and 
a standardized protocol was imple­
mented. Those in whom the duode­
nal mucosa was repaired were not 
fed orally for 24 hours. The postop­
erative hospital stay was 48 hours 
except in children who required 
duodenal repair whose stay was 72 
hours.
Discussion
The majority of infants in this 
study of Ramstedt’s procedure in a 
general hospital did not present 
with severe dehydration and were 
well prepared by pediatricians pre- 
operatively. They had mild to mod­
erate symptoms according to Ben­
son’s classification.3 The fact that 
only 50% had a palpable tumour 
compared with 90% reported by 
others4 suggests that physicians 
now are more inclined to rely on 
tests than on a physical examina­
tion or that the cases are diagnosed 
earlier. Barium meal radiologic ex­
amination has an accuracy of 95%, 
but abdominal ultrasonography is 
now the test of choice for confirm­
ing the diagnosis.5 In our study all 
anesthetics were uncomplicated. In 
particular, no gastroesophageal re­
flux with subsequent aspiration of 
gastric contents was noted. Adher­
ence to well-accepted guidelines for 
the practice of anesthesia in these 
cases (induction sequence for the 
patient with a “full stomach”) and 
ultrasonography rather than barium 
meal examination to confirm the 
diagnosis help to explain these re­
sults. Furthermore, extubation of 
the trachea when the infant is 
awake ensures that no marked aspi­
ration occurs during emergence 
from anesthesia. Seven duodenal 
perforations were noted, a rate 
higher than that reported by spe­
cialized centres.6'8 In order to re­
duce this complication, the surgeon 
must stop the original incision just 
short of the white line that demar­
cates the true junction of the stom­
ach and duodenum. This must be 
taught to residents with greater 
emphasis. Our wound infection and 
dehiscence rates were similar to 
those of specialized centres and our
results were superior to those re­
ported by English district hospi­
tals.19
We agree with Condon,10 when 
he questioned the safety of pyloro- 
myotomy in certain district general 
hospitals. If a nonspecialist team 
cannot attain the current standards 
of care, it should not be doing this 
procedure.
Our study has demonstrated that 
Ramstedt’s pyloromyotomy can be 
performed safely in our general hos­
pital. Regular appraisal of our re­
sults is, however, mandatory in 
order to compete with specialized 
centres.
We thank Mrs. Claire Lemyre for her 
technical assistance.
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T a b le  1. Modern Results o f Pyloromyotomy
S e r ie s N o .
D e a t h s ,  
n o . ( % )
W o u n d  in f e c t io n ,  
n o . ( % )
D e h is c e n c e ,
n o . ( % )
R e o p e r a t i o n ,  
n o . ( % )
Specialized centres
Bell,7 305 1 (0.3) 1 (0.32) 1 (0.32) 1 (0.32)
De Jaureguizar, and
associates8 314 2 (0.6) 1 3 (4 .4 ) 2 (0.6) 0
General hosp ita ls
Bristol and Bolton9 78 0 7 (9 ) 3 (3.8) 0
M cDonald1 47 0 3 (6.3) 2 (4 .2 ) 1 (2.1)
Present s tudy 57 0 0 0 0
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Palliative Surgery for Adenocarcinoma of 
the Gastroesophageal Junction
Ian F. Smith, MD, FRCSC; Alan Kwan, MD, FRCSC
Adenocarcinomas of the gastroesophageal junction are usually incurable at the time 
the patient is first seen. The charts of 21 consecutive patients with this condition 
were reviewed. All had histologically documented transmural extension of tumour 
and lymph-node or distant metastases. A variety of surgical techniques were used to 
restore the ability to swallow. From the charts of these 21 cases, the authors 
analysed the success in restoring swallowing, the length of hospital stay, the 
surgical death rate, complications, survival and the ability to swallow normally at 
the time of death.
Restoration of normal or near-normal swallowing appears to be a realistic goal. 
Selection of an appropriate surgical option, with resection of the primary tumour 
when technically feasible, allows this to be done with negligible mortality and 
acceptable morbidity.
Les adenocarcinomes de la jonction oeso-gastrique sont habituellement deja 
incurables lorsque les patients sont vus pour la premiere fois. On a etudie les 
dossiers de 21 patients consecutifs souffrant de cette affection. Tous montraient 
des preuves histologiques d’extension transmurale de la tumeur et de metastases 
ganglionnaires ou a distance. Diverses techniques chirurgicales ont ete utilisees 
pour restaurer la capacite de deglutition. Les auteurs ont analyse, a partir de ces 21 
dossiers, le succes de l’ intervention destinee a retablir le mecanisme de deglutition, 
la duree d’hospitalisation, la mortalite operatoire, les complications, la survie et la 
capacite d’avoir une deglutition normale au moment du deces.
La restauration d’une deglutition normale ou quasi normale paratt etre un objectif 
realisable. Le choix d’une approche chirurgicale appropriee comprenant la resection 
de la tumeur primitive, lorsque cela s’avere techniquement possible, permet 
d’atteindre cet objectif avec un taux de mortalite negligeable et une morbidity 
acceptable.
it with squamous cell carcinomas 
and adenocarcinomas of the esopha­
gus or with carcinomas of the stom­
ach. The few reports dealing specifi­
cally with adenocarcinoma o f the 
gastroesophageal junction focus 
primarily on curative resection. 
However, most patients have incur­
able disease at the time of presenta­
tion.2 We believe that the goal of 
therapy in these patients should be 
to restore normal or near-normal 
swallowing and relieve pain through 
the safest and easiest operation 
available. To justify resection as the 
treatment of choice, it must be 
applicable to most patients with 
incurable adenocarcinoma of the 
gastroesophageal junction, be ac­
companied by low morbidity and 
mortality, and be successful in re­
storing the swallowing mechanism. 
In the present report we focus on 
these points.
Patients and Methods
A denocarcinomas of the stom­ach and in particular those of 
the gastroesophageal junction have 
a poor prognosis, as shown by 
Webb and Busuttil.1 Treatment re­
mains controversial, especially
when the lesion is found to be 
incurable at the time o f presenta­
tion. Unfortunately, most previous 
reports in the literature address 
adenocarcinoma of the gastroeso­
phageal junction either by grouping
We reviewed records o f all the 
patients we treated at the Health 
Sciences Centre, Memorial Universi­
ty of Newfoundland between 1980 
and 1987, who had a diagnosis of 
adenocarcinoma of the gastroeso­
phageal junction. Patients who un­
derwent potentially curative resec­
tion were excluded from the study. 
There were 21 patients (16 men, 5 
women) available for study. All had 
advanced tumours documented his­
tologically by extension o f tumour 
into adjacent structures, lymph-
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node metastases or distant metasta- 
ses. No patient had clinically detect­
able ascites preoperatively although 
in several patients peritoneal seed­
lings and small volumes of malig­
nant ascites were found at opera­
tion.
The patients ranged in age from 
36 to 99 years (mean 67.8 years). 
Most patients had dysphagia, dis­
comfort, anorexia and weight loss 
(Table I). All underwent endoscopy 
preoperatively and had a biopsy 
confirming adenocarcinoma of the 
gastroesophageal junction, as well 
as a preoperative barium swallow. 
Seventeen patients underwent com­
puted tomography of the chest and 
upper abdomen preoperatively. All 
had intravenous or enteral nutri­
tional support preoperatively and 
postoperatively until they were eat­
ing normally; however, no opera­
tion was delayed in an attempt to 
improve a patient’s nutritional sta­
tus.
All 21 patients in the study un­
derwent a surgical procedure. No 
patient was denied palliative surgi­
cal treatment because of advanced 
disease or other medical illness and 
no patient with advanced adenocar­
cinoma of the gastroesophageal 
junction had an alternative form of 
therapy. The surgical procedures 
included 17 resections and 4 by­
passes (Table II). No patient re­
ceived adjuvant radiotherapy or 
chemotherapy.
Transabdominal esophagogas- 
trectomy was the most commonly 
performed procedure. Using the 
upper hand retractor and with re­
section of a portion of diaphragm in 
the region of the hiatus, where 
necessary, 7 to 10 cm of distal 
esophagus was resected and the 
EEA stapler (Auto Suture Co., Divi­
sion of U.S. Surgical Corp., Nor­
walk, Conn.) was used to perform 
an anastomosis between the end of 
the esophagus and the anterior wall 
of the gastric remnant. A pyloro-
myotomy or pyloroplasty was done 
to facilitate gastric drainage on all 
patients who underwent a resection 
or substernal gastric tube bypass.
A thoracoabdominal approach 
was used for patients with gross 
tumour extending up the esopha­
gus for a distance that made ab­
dominal resection and reconstruc­
tion unsafe or impossible.
Bypasses were performed in 
those patients who had local exten­
sion to and invasion of adjacent 
structures, particularly the aorta, 
precluding resection. Our first 
choice in this situation was a sub- 
sternal esophagogastrostomy be­
cause it avoids the need for a 
thoracotomy. A tube of stomach 
was created from the greater curva­
ture using stapling devices and 
avoiding gross tumour at the gas­
troesophageal junction. An appro­
priate length of stomach was 
achieved by full mobilization of the 
distal stomach and kocherization of 
the duodenum. When the tube was 
passed substernally into the neck, 
the distal cervical esophagus was 
transected using a TA-55 stapler 
(Auto Suture Co.) and the proximal 
cervical esophagus was anas­
tomosed to the anterior wall of the 
transposed greater curvature using 
one layer of interrupted 3-0 Prolene 
sutures.
If the size of the primary tumour 
made development of a satisfactory 
length of gastric tube impossible, a 
Roux-en-Y loop of jejunum was 
brought up via a separate hole 
created in the left hemidiaphragm 
and an esophagojejunal anastomo­
sis was performed 3 to 5 cm above 
the gross tumour. The distal esoph­
agus above the tumour was stapled 
and transected to facilitate this 
anastomosis, if necessary.
We always inserted a feeding je- 
junostomy in patients who under­
went surgery for carcinoma of the 
gastroesophageal junction. Al­
though hyperalimentation was used
both pre- and postoperatively, a 
feeding jejunostomy allows early 
enteral feeding if anastomotic or 
other complications do arise.
Results
The resectability rate was 80.1% 
(17 of 21 patients) as noted in Table 
II. The 30-day operative death rate 
was 4.8% (1 of 21 patients). The 
one death occurred in a patient with 
a documented seizure disorder who 
underwent a thoracoabdominal eso- 
phagogastrectomy. The patient died 
of massive aspiration following a 
grand mal seizure. Three days be­
fore the seizure a Gastrografin 
swallow had shown that the anasto­
mosis was intact and the patient 
had been started on an oral intake.
All patients had roentgenography 
after a Gastrografin or barium swal­
low 6 to 9 days postoperatively. 
Leaks were demonstrated radiologi- 
cally in 19% (four patients). None of 
the leaks was clinically serious and 
on repeat examination after 1 week
Table 1. D om inant Preoperative Sym ptom s
Symptom No. of patients
A bso lu te  dysphagia 
D ysphagia fo r liqu ids and
2
so lids 2
D ysphagia fo r so lids on ly 
Epigastric o r re trosternal
10
pain 5
Anorexia  and w e igh t loss 2
Table II. Operations Performed
Procedure No. of patients
Resection
Transabdom ina l
17
esophagogastrectom y
Thoracoabdom inal
13
esophagogastrectom y 
Tota l esophagectom y 
and proxim al
3
gastrec tom y 1
Bypass
S ubsternal
4
esophagogastrostom y
Thoracoabdom inal
esophagojejunal
2
bypass 2
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had healed spontaneously in three 
of the four patients. In the fourth 
the leak sealed spontaneously 3 
weeks postoperatively. There were 
no leaks in the 13 patients who 
underwent transabdominal eso- 
phagogastrectomy.
The patient’s ability to swallow 
was assessed both before discharge 
and at outpatient follow-up and is 
summarized for the 20 discharged 
patients in Table III. Preoperatively 
81% (17 patients) had some degree 
of dysphagia, with dysphagia being 
the dominant symptom in 66.7% 
(14 patients). All patients who had 
dysphagia preoperatively reported 
marked improvement postoperative­
ly, with 80% (16 of 20 patients) 
having normal or near-normal swal­
lowing. The six patients classified 
as near normal noted minimal sub­
jective differences in their ability to 
swallow from their normal precan­
Table III. Postoperative  A b ility  to  Swallow
Swallowing No. of patients
ability %
Normal 1 0 (5 0 )
Near normal 6 (3 0 )
Occasional dysphagia fo r 
solids 3 (1 5 )
In te rm ittent dysphagia 
requiring d ila tation 1 ( 5 )
Table IV. C om plications
Complication No.
Pneumonia 2
Empyema 2
C lin ically im portan t ate lectasis 5
Right lower lobe co llapse 1
Bile reflux 1
Table V. Length o f H ospita l S tay According 
to  Operation
Procedure
Duration, d 
(range)
Transabdom inal
esophagogastrectom y 14.5 ( 1 0 - 2 7 )
Thoracoabdom inal
esophagogastrectom y 21.3 ( 9 - 3 5 )
Total esophagectom y 29.0
Substernal bypass 23.0  ( 1 6 - 3 0 )
Esophagojejunal bypass 20.5  ( 1 6 - 2 5 )
cerous state; however, they had no 
dysphagia. Those classified as nor­
mal noted no differences whatsoev­
er. Even the four patients who had 
residual dysphagia were markedly 
improved and were able to resume a 
normal diet with only the occasional 
need (once or twice a week on 
average) to clear a bolus of solid 
food with large volumes of liquid. 
One patient required dilatations 
every month postoperatively. She 
complained of dysphagia almost as 
soon as she resumed oral feeding. A 
barium swallow showed no evidence 
of a leak and only minimal anasto­
motic narrowing. Despite her need 
for dilatation, there was a marked 
improvement over her preoperative 
absolute dysphagia.
All patients had complete relief of 
preoperative epigastric or retroster­
nal pain. Dysphagia due to recur­
rent tumour did not develop even 
though 23.8% (five patients) had 
positive esophageal resection mar­
gins. No patient had a deterioration 
in the ability to swallow during the 
follow-up.
In addition to the one death and 
the four leaks there were 11 other 
complications (Table IV). Only one 
case of atelectasis occurred in the 
13 patients who underwent transab­
dominal esophagogastrectomy. No 
other complication was seen in this 
subgroup.
Table V indicates length of hospi­
tal stay for surviving patients.
Three of the 20 patients who 
were discharged were alive and well 
at 5, 8 and 50 months respectively 
after operation; 17 patients died of 
progressive disease and had a mean 
survival of 6.6 months (range from 
2 to 16 months). None of these 17 
patients had dysphagia at the time 
of death.
Discussion
Unlike previous reports in which
small numbers of patients who had 
advanced adenocarcinoma of the 
gastroesophageal junction were in­
cluded in much larger series of 
patients with esophageal or gastric 
cancer, many of whom underwent 
resection for cure, this study deals 
only with those proven histological­
ly to have incurable lesions. Despite 
this, our resectability rate of 80.1% 
stands up well against collected 
series in which resectability rates 
ranged from 32% to 67% and aver­
aged 50%.3 Likewise, our operative 
death rate of 4.8% for the whole 
group and 0% for those who under­
went transabdominal esophagogas­
trectomy compares favourably with 
that of other studies in which 7% to 
30% of patients died in the immedi­
ate postoperative period.1' 6
In other reports, the most fre­
quent cause of death was anasto­
motic leakage, with rates ranging 
from 5% to 50%.3 We had no clini­
cally serious leaks, and the rate of 
radiologically detected leaks was 
19% for the entire group and 0% for 
those having a transabdominal eso­
phagogastrectomy.
The fact that some anastomoses 
leak is not surprising, considering 
the dysphagia, marked weight loss, 
general debility and immunocom­
promised nature of these patients. 
However, we consider that pre- and 
postoperative hyperalimentation, 
emphasis on careful surgical tech­
nique and placement of the anasto­
mosis in either the abdomen or the 
neck are important in reducing the 
number of leaks. Preoperative ra­
diotherapy was not used because of 
its proven association with pulmo­
nary complications and anastomotic 
leaks.7
In those with radiologically iden­
tified leaks in our series the clinical 
course did not differ from that of 
the other patients except that the 
hospital stay was longer. The leaks 
healed spontaneously in all patients.
The objectives of treatment for
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patients who have advanced carci­
noma of the gastroesophageal junc­
tion must be restoration of normal 
or near-normal swallowing and re­
lief of pain. The techniques of sur­
gical treatment are not important as 
long as these objectives are met, 
although resection of a primary 
tumour is generally associated with 
longer survival than bypass proce­
dures.8 Although computed tomog­
raphy of the chest and upper abdo­
men was done in 17 patients, its 
value in preoperative planning of 
surgical treatment for carcinoma of 
the gastroesophageal junction is 
limited.9 Surgical exploration has 
proven to be the only accurate 
method to determine tumour ex­
tent.1011
Procedures requiring transgres­
sion of the thoracic cavity were 
associated with a significantly lon­
ger hospital stay (Table V), even 
though they were equal to trans­
abdominal esophagogastrectomy in 
terms of relieving pain and re­
storing normal or near-normal swal­
lowing.
In our study, all patients with 
dysphagia preoperatively reported 
marked improvement postoperative- 
ly. The operation relieved preopera­
tive pain in all. None had a deterio­
ration in the ability to swallow 
during the follow-up period. Hence, 
it seems safe to conclude that the 
procedures employed were success­
ful in meeting these objectives.
Series which include patients 
with adenocarcinoma of the gastro­
esophageal junction as part of a 
larger study group usually quote 
median survival rates of 10 to 20 
months.3-412 Those dealing only 
with adenocarcinoma of the gastro­
esophageal junction have median 
survivals in the range of 10 
months.2 All these studies have in­
cluded patients with lesions resect­
ed for cure as well as those treated 
for palliation only. Perhaps the me­
dian survival of 6.6 months in this 
report more accurately reflects the 
prognosis for patients who undergo 
surgical treatment for palliation 
only.
Some recent reports in the litera­
ture suggest improved resectability 
rates and decreased local recurrence 
rates with combined preoperative 
radiotherapy and chemotherapy.13 
However, we do not consider this to 
be of great benefit in those with 
advanced carcinoma of the gastro­
esophageal junction; 15% to 20% 
of patients never undergo surgery if 
started on a multimodality proto­
col.13 Furthermore, combined radio­
therapy and chemotherapy does not 
immediately relieve the patient’s 
symptoms or control distant recur­
rence, which remains the major 
cause of death.13
Conclusions
The data suggest that, despite 
the dismal long-term prognosis, res­
toration of normal or near-normal 
swallowing and relief of pain are 
realistic goals in patients with ad­
vanced adenocarcinoma of the gas­
troesophageal junction. Selection of 
an appropriate surgical option al­
lows this to be done with acceptable 
morbidity and mortality. In our se­
ries, transabdominal esophagogas­
trectomy was the quickest, easiest 
and safest way to achieve effective 
palliation.
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Dietary Habits After Ileal Pouch-Anal 
Anastomosis
C. Chartrand-Lefebvre, BSc; J. Heppell, MD, FRCSC; I. Davignon, BSc; S. Dube, MD, FRCSC, FACS; 
A. Pomp, MD, FRCSC
Dietary habits of patients who had undergone ileal pouch-anal anastomosis were 
assessed and correlated with bowel function. Twenty-four well-adapted patients (11 
women, 13 men; mean age 32 years) voluntarily entered the study 30 ± 4 months 
after closure of the diverting ileostomy. A standardized questionnaire on 108 food 
items and a 3-day food journal were used in the assessment. Twenty-one patients 
had no difficulty in selecting an appropriate diet. Caloric intake was adequate. 
Specific symptoms associated with several foods were as follows: increased stool 
frequency (beer, spirits, Chinese food), decreased stool consistency (beer, wine, fried 
fish), perianal irritation (spicy foods), undigested particles (grapefruit, lettuce), 
odours (eggs). Pasta and bananas were associated with increased stool consistency. 
The authors believe that these observations may help in dietary counselling after 
ileal pouch-anal anastomosis.
Les habitudes alimentaires apres anastomose ileo-anale et leur relation avec le 
resultat fonctionnel ont ete evaluees. Vingt-quatre patients (11 femmes, 13 hommes; 
age moyen 32 ans) ont participe a l’etude, apres 30 ±  4 mois d’adaptation. Un 
questionnaire portant sur 108 aliments et un journal alimentaire ont ete utilises. 
Vingt-et-un patients ont une diete convenable. L’apport energetique est adequat. Les 
symptomes specifiques associes aux aliments sont: frequence des selles augmentee 
(biere, spiritueux, mets chinois), consistance diminuee (biere, vin, poisson frit), 
irritation peri-anale (mets epices), particules non digerees (pamplemousse, laitue), 
odeurs (oeufs); pates et bananes ont ete associees a une consistance augmentee. Ces 
observations aideront au conseil dietetique apres anastomose ileo-anale.
I leal pouch-anal anastomosis is an alternative to permanent ileos­
tomy for well-selected patients with 
ulcerative colitis and familial poly­
posis. The reported long-term func­
tional results are encouraging.12 
However, optimal dietary manage­
ment of patients after this proce­
dure has not been clearly defined. 
Often our patients empirically asso­
ciate their pouch function with vari­
ations in diet. This study was car­
ried out to determine the eating 
habits of patients after ileal pouch- 
anal anastomosis and to correlate 
diet with bowel function. We
wished to identify factors that 
would be of use in dietary counsel­
ling and eventually to improve func­
tional outcome.
Patients and Methods
Patients
Twenty-four patients (11 women, 
13 men) who underwent an endo­
rectal ileoanal anastomosis with 
construction of an ileal reservoir 
entered the study voluntarily; 20 
were operated on for ulcerative coli­
tis, 3 for familial polyposis coli and 
1 for multiple colonic carcinomas. 
During the primary surgery, pa­
tients underwent total colectomy, 
mucosal proctectomy and endorec­
tal ileoanal anastomosis with con­
struction of a “J”-type ileal reser­
voir in each patient, using the tech­
nique of Beart and colleagues.3 A 
diverting loop ileostomy protected 
the reservoir after the procedure; it 
was closed an average of 3 months 
after the initial operation. The di­
verting ileostomy had been closed 
for less than 1 year in 5 patients 
and for longer than 1 year in 19 
(mean interval ± SEM of 30 ± 4 
months). The mean age of the pa­
tients was 32 ± 3 years (range from 
19 to 50 years).
Medications to modify intestinal 
transit were used occasionally in 
only five patients. Ten patients used 
psyllium, 3.6 g daily, routinely.
Assessment o f Functional Outcome
The functional outcome after the
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operation was evaluated by two in­
dependent observers (C.C.L. and 
I.D.), using a standardized question­
naire during a personal interview. 
Patients were asked to assess their 
well-being on a scale of 1 (poor) to 
10 (excellent) during the disease 
period, during the loop ileostomy 
interval and at the time of inter­
view. The functional parameters in­
vestigated were: stool frequency 
and consistency, perianal irritation, 
continence during day and night, 
evacuation of intestinal gas and 
undigested particles, and the modi­
fication of stool odours.
Assessment of Dietary Habits
Two methods were used to evalu­
ate dietary habits. First, a food 
journal was kept by the patients to 
document their usual intake of solid 
foods, liquids and medications over 
a 3-day period. This journal includ­
ed the mean consumption of food 
for 2 days during the week and 1 
day during the weekend. The data 
was entered in a Microvax II com­
puter (Digital Equipment of Canada, 
St. Laurent, PQ) and was analysed 
by a professional dietitian, using 
software based on the Canadian 
Nutrient File, Food Directorate.4 
Second, a detailed standardized 
questionnaire on 108 food items 
was discussed with the patients dur­
ing an interview. The patients were 
asked whether they were eating 
each food item and if a given symp­
tom could be associated with a 
specific item. Table I illustrates the 
15 symptoms that were presented 
to the patients.
Associations
An association between consump­
tion of a given food item and a 
specific symptom was considered if 
at least 10 of the 24 patients had 
consumed the food item since clo­
sure of the diverting ileostomy and
at least 20% of them had reported 
the symptom.
Statistical Evaluation
Student’s t test was used to com­
pare the means of data with normal 
distribution. Body weight and sub­
jective well-being were analysed 
using analysis of variance for re­
peated measures, the within-subject 
factor having three levels. Whenev­
er the overall variance ratio (F) was 
significant, a multiple comparison 
procedure (Tukey B technique5) was 
used to identify where the differ­
ences were. A Pearson linear corre­
lation coefficient was used to estab­
lished a correlation between food 
intake and specific symptoms.
Results
Of the 24 patients, 20 were fully 
employed and involved in sports 
and social activities after the opera­
tion. Their body weight was stable 
or increased postoperatively. When 
the patients were healthy, their re­
ported mean body weight (± SEM) 
was 62.1 ± 3.5 kg; during their 
disease it was 53.2 ± 3.0 kg and 
after the surgery it was 63.8 ± 3.5 
kg. There was substantial variability 
in these weights and no statistically 
significant differences could be ob­
tained by analysis of variance (p > 
0.05).
Subjective Well-being
A score of subjective well-being 
of 4.2 ± 0.6 was recorded for the 
disease period, of 5.6 ± 0.5 for the 
diverting ileostomy period and of 
8.4 ± 0.4 postoperatively. By analy­
sis of variance the last score was 
significantly (p < 0.05) better than 
either the first or second. There was 
no bias between observers (Stu­
dent’s t- test.
Function
All patients were able to evacuate 
spontaneously. The mean number 
of stools per 24 hours was 6.8 ± 
0.5 (range from 2 to 11). Nineteen 
patients woke at night to empty 
their bowel (mean frequency 1.2 ± 
0.2 stools). Eleven patients com­
plained of occasional abdominal 
cramping. The majority had no dis­
comfort with passage of intestinal 
gas. Perianal irritation was not a 
major problem; however, 50% of 
the patients occasionally used oint­
ments to protect the skin. Anal 
soiling occurred in 12 patients -  
during day and night in 4 and 
during the night only in 8. The type 
of soilage was mucoid in seven 
patients and stool in five.
Alimentary Habits
Twenty-one patients (88%) were 
satisfied with the diet they chose. 
Dinner was considered the largest 
meal of the day and most patients 
kept to the same schedule of daily 
meals as before the operation.
Food Journal
Food journals were completed by 
20 patients. According to standards 
determined by Canada’s food 
guide,6 17 patients had a deficiency 
in consumption of dairy products, 
11 in fruit and vegetables and 8
Table I. Symptoms Sought During Patient 
Interview
Increased stool frequency 
Decreased stool frequency 
Increased stool consistency 
Decreased stool consistency 
Increased stool volume 
Decreased stool volume 
Perianal irritation 
Incontinence 
Gas
Undigested particles in the stool 
Modification of stool odours 
Abdominal cramps 
Abdominal discomfort 
Diarrhea
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patients in meat and meat substi­
tutes. No deficiency in bread and 
cereals was detected. The content of 
fibres in the diet varied considera­
bly; the mean total fibre content of 
the diet was 10.8 ± 1 .4  g /d  (range 
from 2 to 20 g/d). Again, on a 
daily basis, total energy intake was
8735 ± 822 kJ (2086 ± 196 kcal); 
protein intake was 85.6 ± 6.5 g; 
lipid intake was 89.2 ± 8.1 g; 
carbohydrate intake was 250.3 ± 
27.2 g, in which there was 66.5 ± 
13.1 g of concentrated sugar; po­
tassium intake was 2895.6 ± 252.7 
mg; calcium intake was 887.9 ±
95.7 mg; phosphorus intake was
1434.0 ± 121.2 mg; iron intake 
was 13.48 ± 1.04 mg; and sodium 
intake (excluding added salt) was
3177.0 ± 282.7 mg.
During the period in which the 
patients kept the journal, half of 
them consumed alcohol. Assuming 
beer as 13 g, a glass of wine as 18 
g and liquor as 15 g of alcohol, the 
mean daily alcohol consumption 
was 12.8 ± 5.3 g (range from 0.0 
to 90.9 g).
Questionnaire
Figure 1 demonstrates that the 
effect on bowel function varies be­
tween food items. For example, cab­
bage, beer and corn were associated 
with symptoms by more than 75% 
of patients. However, potatoes, 
pastry, hot dogs and coffee were 
troublesome in less than 21% of 
patients. Overall, one food item out 
of four (25%) was frequently associ­
ated (i.e., by more than 50% of 
patients) with symptoms.
Several food items were eliminat­
ed from the diet after trial by more 
than 20% of patients because of 
associated problems. These includ­
ed cabbage, corn, coleslaw, legumi­
nous foods, turnips, boiled broccoli, 
whole wheat cereals and spicy 
foods.
Associations
Various foods were associated 
with specific symptoms in more 
than 20% of patients as shown in 
Table II; 25% of the 108 foods 
analysed were so associated.
Abdominal cramping and anal 
soilage could not be correlated with 
specific food items in this question­
naire. Interestingly, pasta and ba­
nanas increased the consistency of 
stools. The total fibre content of the 
diet correlated only with perianal 
irritation (Pearson coefficient, p < 
0.05).
Item s
P o ta to e s  
P a s try  
H ot D ogs  
C o ffe e  
M ilk + eggs  
P a s ta  
R a w  c a rro ts  
W in e + sp irits  
C orn  
B e e r  
C a b b a g e
0 10 20  30  40  50  60  70  80  90 100
% of p a tie n ts  w ith  s ym p to m s
Fig. 1. Sample of food items associated with symptoms.
T a b le  II. A sso c ia tio n  o f S y m p to m s  W ith  S p e c if ic  Foods
S ym ptom Food item %  of p a tie n ts
Inc reased  s to o l fre q u e n c y B eer 36
S p ir its 33
C h inese  fo o d s 26
W h o le  w h e a t ce rea ls 25
C orn 25
A p p le 25
W in e 24
S p ic y  fo o d s 20
F ried  fo o d s 20
S tra w b e rr ie s 20
D ecreased  s to o l c o n s is te n c y B eer 43
W in e 41
Fried  f is h 29
S tra w b e rr ie s 25
C orn 25
P o p c o rn 25
S p ir its 25
M o la s s e s 23
C o le s la w 23
G ra p e fru it 21
T u rn ip s 21
R a sp b e rrie s 21
P erianal ir r ita tio n S p ic y  fo o d s 50
R aw  c a rro ts 20
U n d ig e s te d  p a rtic le s  in s to o l G ra p e fru it 27
L e ttu c e 23
R aw  to m a to e s 20
S to o l o d ours E ggs 20
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Discussion
The majority of our patients were 
satisfied with their diet after ileal 
pouch-anal anastomosis. However, 
we observed that diet can influence 
the functional outcome after this 
procedure; 25% of the 108 food 
items analysed were associated with 
specific symptoms. Similar findings 
have also been noted after ileorectal 
anastomosis7 and after the con­
struction of a permanent ileosto­
my.89
Bingham and colleagues8 and 
Thomson and associates9 have 
shown that the ileostomates modify 
their diet by avoiding foods that 
they think produce an ileal effluent 
which is excessive in amount, very 
fluid, odoriferous or contains recog­
nizable food particles. Wexner and 
colleagues2 reported that 32% of 
patients needed dietary adjustment 
after the construction of an ileoanal 
reservoir. Of our 24 patients, 21 
(88%) had no difficulty in choosing 
a diet. The sensitivity of patients for 
specific items in the diet was vari­
able. Although no single food ad­
versely affected all patients inter­
viewed, 25% of food items were 
upsetting in more than 50% of the 
patients. The most common of 
these were cabbage, beer and corn.
The foods that caused problems 
after ileal pouch-anal anastomosis 
did not always cause upsets in pa­
tients who underwent ileostomy or 
ileorectal anastomosis. For exam­
ple, in the latter group cabbage 
seemed to be tolerated but onions 
caused problems. Alcoholic bever­
ages, especially beer, were reported 
to decrease the consistency of the 
output after ileostomy89 and ileo­
rectal anastomosis.7 Although al­
coholic beverages decreased stool 
consistency and increased the fre­
quency of evacuation they were not 
usually avoided by our patients who 
had undergone ileal pouch-anal 
anastomosis. Patients with an ileos­
tomy eat more in the morning than 
those without and less during the 
evening, probably to minimize the 
ileal flow at night when it may 
disturb sleep.8 After ileoanal anasto­
mosis, Wexner and associates2 re­
ported, patients can avoid nocturnal 
emptying by eating an early dinner. 
In our study, patients did not 
change their daily schedule of 
meals, and dinner was the largest 
meal of the day, which may explain 
the high nocturnal stool rate.
Wexner and colleagues2 also re­
ported that stool frequency is asso­
ciated with alcohol, spicy foods, 
chocolate and a large quantity of 
fluids. However, Kramer,10 in a con­
trolled study of patients who had an 
ileostomy, failed to demonstrate 
this. It is interesting that when 
objective measurements are made, 
many dietary substances generally 
avoided by or forbidden to ileosto­
mates do not notably increase the 
amount of ileal excreta. Wexner 
and colleagues, like us,2 noted that 
starchy foods like pasta and rice 
were related to decreased stool fre­
quency.
The relation of fibre intake to 
functional outcome is controversial 
and deserves comment. In patients 
who have a standard ileostomy, 
Dalhamn and associates11 have 
shown that the addition of bulk to 
the diet resulted in a more viscous 
ostomy effluent. It facilitated stoma 
management and diminished peris­
tomal skin problems. In our study, 
the mean daily fibre intake was 
relatively low (10.8 ± 1 . 4  g). Ray­
mond and Becker12 recommended a 
daily intake of 30 g of fibre to 
obtain coarser stools and decrease 
stool frequency. Spiller and col­
leagues13 showed that the addition 
of cellulose to the diet decreased 
intestinal transit time and increased 
the total fecal wet weight, but that 
pectin had no such effects. This 
implies that the effect of “dietary 
fibre” cannot be generalized and
that individual fibre components 
should be examined separately, as 
demonstrated by Anderson14 with 
hydrosoluble and insoluble fibre. 
We found a positive correlation be­
tween dietary fibre and anal irrita­
tion, which may be attributed to the 
adsorption of biliary acids by di­
etary fibres. Bosaeus and col­
leagues15 demonstrated that biliary 
acid excretion is significantly in­
creased by addition of pectin to the 
diet. However, Raymond and associ­
ates16 showed that loperamide 4 mg 
and psyllium 30 g, each given twice 
daily, reduced stool frequency but 
had no apparent effect on stool 
content, including biliary acids.
Newton and Baker7 reported that 
after ileorectal anastomosis, body 
weight remained steady or in­
creased. This was also noted in our 
patients. The mean daily intake of 
energy calculated from our food 
journal suggests that patients main­
tain an adequate caloric intake after 
ileal pouch-anal anastomosis.
Two methods were used to evalu­
ate diet and its relation to function­
al outcome -  a questionnaire com­
pleted at a personal interview and a 
food journal. A standardized ques­
tionnaire was used by McDonald 
and Fazio17 to assess the diet of 
patients with Crohn’s disease not 
operated on, by Bingham and col­
leagues8 and Thomson and associ­
ates9 for patients with an ileostomy 
and by Newton and Baker7 for 
patients with an ileorectal anasto­
mosis. The advantage of a question­
naire is that it is easy to complete 
and computerize; however, it relies 
on a subjective report by the pa­
tient. It may be difficult for a pa­
tient to identify accurately the prop­
er effect of a specific food, especial­
ly when it is consumed with other 
foods. A food journal is preferable 
for identifying a relation between 
food and pouch function, especially 
for less overt food items such as 
fibre.
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Patients who undergo ileal 
pouch-anal anastomosis usually 
complain about the effect of various 
foods on functional outcome. Clini­
cians lack pertinent data to give 
dietary advice. This systematic eval­
uation of the effect of more than 
100 food items on functional out­
come, based on several months ex­
perience with the 24 subjects, can 
be used to provide improved dietary 
counselling. The number of patients 
in our study who completed the 
questionnaire and the food journal 
constitute a group that is similar in 
age, sex, lifestyle and functional 
results to the group as a whole. It 
would appear reasonable to assume 
that their experience with the food 
items is representative of that en­
countered by all patients after ileal 
pouch-anal anastomosis in our 
country. Other controlled studies of 
diet after ileal pouch-anal anasto­
mosis are warranted to improve 
dietary counselling, even if they 
involve methodologic challenges.
We thank Mrs. Linda Gagne for secre­
tarial assistance.
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SESAP VI Question
Items 82-84
82. Ulcer recurrence rate 10% to 20%
83. Indicated for treatment of perforation in low-risk patients with 
long-term history of peptic ulcer disease
84. Indicated for high-risk patients with acute perforation of duodenal 
ulcer
(A) Ulcer plication (Graham closure)
(B) Ulcer plication (Graham closure) plus proximal gastric vagoto­
my
(C) Both
(D) Neither
For the numbered statements above choose the appropriate lettered 
answer.
For the critique of Items 8 2 -8 4  see page 142.
(Reproduced by permission from SESAP VI Syllabus; Surgical Educa­
tion and Self-Assessment Program No. 6. For enrolment in the Surgical 
Education and Self-Assessment No. 6, please apply to the American 
College of Surgeons, 55 East Erie St., Chicago, IL 60611.)
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Recurrent Acute Pancreatitis — Rarely 
Idiopathic: 1989 Du Pont Lecture
L.C. Carey, MD, FACS*
The majority (about 75%) of patients who suffer from acute pancreatitis do so as a 
consequence of gallstones or alcohol abuse. The other 25% of patients often present 
difficult diagnostic problems. Over several years the author has accumulated a series 
of patients with remedial causes of pancreatitis. They include a group of congenital 
conditions such as pancreas divisum, choledochal cysts and congenital abnormalities 
of the pancreatic ductal system.
Patients who have had pancreatitis and who have an intact gallbladder often have 
stones that are difficult to identify. Repeated attacks of pancreatitis in the absence of 
any other apparent cause justifies cholecystectomy, which will often identify the 
cause so that recurrence can be prevented.
A group of nonanatomic causes are also known. They include hyperlipidemia, 
drugs and toxins, certain systemic illnesses such as systemic lupus erythematosus, 
pregnancy, hypercalcemia, hereditary causes and occasionally cancer.
In his lecture the author reviews the various etiologies of acute pancreatitis and 
describes an algorithm that can be used when the diagnosis is difficult.
La majorite (environ 75%) des cas de pancreatite aigue est la consequence de calculs 
biliaires ou de l’alcoolisme. L’autre 25% des patients pose souvent des problemes 
diagnostiques. Sur une periode de plusieurs annees, l’auteur a identifie une serie de 
patients dont les causes de pancreatite pouvaient etre gueries. On compte parmi 
celles-ci, des problemes congenitaux tels que division du pancreas, kystes choledo- 
ciens et anomalies congenitales des canaux pancreatiques.
Les patients qui ont eu une pancreatite et dont la vesicule biliaire est intacte, ont 
souvent des calculs difficiles a identifier. Des attaques repetees de pancreatite en 
l’absence de toute autre cause apparente justifient une cholecystectomie qui, bien 
souvent, permettra d’identifier la cause et de prevenir la recidive.
Un nombre de causes extra-anatomiques sont aussi connues. On compte parmi 
celles-ci, l’hyperlipidemie, des medicaments et des toxines, certaines maladies 
generalises telles que le lupus erythemateux dissemine, la grossesse, l’hypercal- 
cemie, des causes hereditaires et, occasionnellement, un cancer.
Dans cette communication, l’auteur passe en revue les diverses etiologies de la 
pancreatite aigue et il decrit un algorithme qui peut etre utilise lorsque le diagnostic 
est difficile.
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M ost practitioners are well aware of the relation of acute 
pancreatitis to gallstones and alco­
hol abuse. Of unselected patients 
with pancreatitis about 75% will 
have one of the two as an etiologic 
factor; the remaining 25% often 
present difficult diagnostic prob­
lems. Thompson and associates,1 in 
an epidemiologic study in northeast 
Scotland found that alcohol and 
gallstones accounted for about 60% 
of all cases of pancreatitis. The next 
most common cause was “ idiopath­
ic” (19% in men, 22% in women).
Most patients with “idiopathic” 
pancreatitis can be helped if the 
practitioner is aware of all the con­
ditions with which pancreatitis is 
associated. When an exhaustive 
search is made by a knowledgeable 
clinician, few patients are found to 
have true idiopathic pancreatitis.
This lecture is intended to outline 
a number of factors known to be 
related to the development of acute 
pancreatitis and to describe a sys­
tematic approach to identifying the 
cause.
Very little is known about the 
cause of pancreatitis. However, the 
literature describing conditions 
which seem to produce pancreatitis 
is extensive even though the mech­
anism by which they do so remains 
obscure. In an attempt to organize 
this literature I will categorize the 
causative factors into anatomic and 
non-anatomic, but I will not address 
treatment of the various conditions 
or the related pancreatitis. My pur­
pose is to emphasize that the diag­
nosis of conditions causing pan­
creatitis is difficult, time-consuming
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and tedious. But the benefit to the 
patient makes this effort worth­
while.
Anatomic Factors
Congenital
Pancreas division. In 1978 Heiss 
and Shea2 reported four patients 
with recurrent pancreatitis who had 
abnormal ductal anatomy, a condi­
tion now known as pancreas divi- 
sum.
Pancreas divisum, present in 7% 
to 10% of the population, appears 
to result from improper fusion of 
the pancreatic ducts of the dorsal 
and ventral primordia of the gland. 
The consequence is a ductal system 
with two totally separate compo­
nents — a small duct joins the 
common bile duct as it enters the 
duodenum and vents the uncinate 
process. The second duct provides 
drainage for the cephalad portion of 
the head of the pancreas and the 
entire body and tail of the gland. 
This duct enters the duodenum 1.5 
to 2 cm proximal to the papilla of 
Vater.
Most patients with pancreas divi­
sum have no symptoms. A few have 
recurrent attacks of pancreatitis 
with no other identifiable cause. 
Another group has recurrent ab­
dominal pain without elevation of 
serum enzyme levels.
Several factors are noteworthy. 
Although the condition is present at 
birth, pancreatitis does not become 
apparent until the third to fifth 
decade of life in most cases, and 
although the variant seems to be 
equally distributed by sex, pan­
creatitis occurs more frequently in 
women. In two series, totalling 80 
patients, there were 56 women and 
14 men.3 4
Finally, although there have been 
vigorous efforts to demonstrate an 
impediment to ductal emptying, 
none has withstood the test of
prospective analysis, comparing pa­
tients with the variant who have 
pancreatitis with those who do not. 
It has been suggested that there is 
a measurable dysfunction of the 
papilla at the duct of Santorini, but 
the data are inadequate to draw 
conclusions.5
Physicians with an interest in the 
disease believe that there is an 
acquired stenosis at the terminus of 
the duct. Their prejudice is support­
ed by relief of symptoms provided 
by enlarging the ductal opening, 
but persuasive preoperative proof of 
ductal stenosis has been elusive. 
Some patients with pancreas divi­
sum clearly suffer recurrent pan­
creatitis as a result of the anatomic 
variant. Continued efforts will no 
doubt lead to more precise ways to 
identify these patients preoperative-
ly-
Pancreas divisum and small gall­
stones explain the majority of ob­
scure cases of pancreatitis, but 
there are a number of less common 
anatomic problems which must be 
considered.
Other Congenital Abnormalities
These usually occur at the termi­
nus of the pancreatic duct. We 
treated a patient with one such 
abnormality, involving the uncinate 
process, by resection of the abnor­
mal duct and the uncinate (Fig. 1). 
This procedure was curative. Four 
others had recurrent attacks of pan-
FIG. 1. Patient with congenital abnor­
mality of pancreatic duct involving 
uncinate process. Resection of unci­
nate process was curative.
creatitis; three were under 20 years 
of age with one child having had 
attacks from 9 months of age until 
treatment at 5 years of age. These 
three children underwent pan- 
creaticojejunostomy which provided 
relief. The fourth patient was ma­
naged by pancreaticoduodenectomy. 
None had evidence of either endo­
crine or exocrine pancreatic insuffi­
ciency and all were followed up for 
more than 2 years. We are presently 
managing a young woman with a 
duplicate pancreatic ductal system 
who has recurrent pancreatitis (Fig. 
2 ) .
Choledochal cysts. Another 
group of five patients had choledo­
chal cysts. Initially in this group, 
communication of the cyst with the 
pancreatic ductal system was not 
divided and recurrent pancreatitis 
persisted. Reoperation with resec­
tion of the intrapancreatic portion 
of the cyst with division of the 
pancreatic ductal communication 
was curative.
A cyst-pancreatic duct communi­
cation is not demonstrable in all 
patients with choledochal cyst. It 
was present, however, in all those 
who had recurrent pancreatitis. 
When a choledochal cyst is discov­
ered in a patient with recurrent 
pancreatitis, the ductal communica­
tion must be identified, the in­
trapancreatic portion of the cyst 
removed and the direct communica­
tion divided. Choledochal cyst has 
rarely been associated with pan-
FIG. 2. Duplicate pancreatic ductal 
system in young woman causing recur­
rent pancreatitis.
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creatitis,6 since in most cases the 
pancreatitis has been related to 
choledochocele, a variant of chole­
dochal cyst.
Aberrant gastroduodenal artery.
One other patient was treated by 
resection of an aberrant branch of 
the gastroduodenal artery, which 
resulted in ductal obstruction at the 
junction of the neck and head of 
the pancreas. In this patient pancre­
atic ductal occlusion was demon­
strated on endoscopic retrograde 
cholangiopancreatography. Resec­
tion of the aberrant vessel was 
curative.
Pancreas sequestrum. A series of 
patients who begin to suffer attacks 
of pancreatitis months to years after 
pancreatic trauma has been report­
ed.7 They had what we have called 
pancreas sequestrum. Resection of 
the sequestered segment of pancre­
as was curative in all but one who 
was managed by pancreaticojejun- 
ostomy.
Duct entry through the Oddi 
sphincter. In another group of pre­
viously reported cases,8 the pancre­
atic duct was found to enter the 
duodenum through the fibres of the 
sphincter of Oddi with no common 
channel; these patients were ma­
naged by sphincteroplasty of the 
common bile and pancreatic ducts. 
The majority had undergone chole­
cystectomy previously and none had 
common-duct stones. The average 
patient had been hospitalized re­
peatedly with acute pancreatitis. 
The diagnosis remains one of exclu­
sion and is only entertained after an 
in-depth search for other causes 
and after several well-documented 
attacks. The operation of double 
sphincteroplasty provided relief 
from further attacks in more than 
80%.
Diverticula. In an occasional pa­
tient, a duodenal diverticulum has 
resulted in acute pancreatitis. The 
phenomenon may be the result of a 
diverticulum with a narrow orifice
which becomes filled with inspissat­
ed material and produces pancreatic 
ductal occlusion. The treatment is 
careful removal of the diverticulum, 
avoiding injury to the pancreatic 
duct. Others have reported pan­
creatitis with intraluminal diver­
ticula.9 Kune’s group10 pointed out 
the increase in frequency of both 
gallstones and pancreatitis with du­
odenal diverticula.
An alternative arrangement may 
be a diverticulum into which the 
common and pancreatic ducts enter 
the duodenum at the apex of the 
diverticulum (choledochocele). In 
this condition, resection of the di­
verticulum with reimplantation of 
the bile-pancreatic duct complex 
into the duodenum is curative. This 
is a difficult operation requiring 
considerable care to avoid damage 
to the terminal pancreatic duct.
Gallstones
When gallstones are found in 
patients who have acute pancreati­
tis, cholecystectomy and removal of 
common-duct stones, if present, will 
cure the pancreatitis in more than 
90%.n It is well known that small 
gallstones are more likely to result 
in pancreatitis than large ones.12 
Logic suggests that biliary lithotrip­
sy then may result in an increase in 
gallstone pancreatitis — a question 
as yet unanswered.
How should we best manage a 
patient who has recurrent attacks 
of pancreatitis but in whom an 
exhaustive search for gallstones 
and other causes has been fruitless. 
Inevitably, gallbladder ultrasonogra­
phy will be carried out, and, if 
normal, oral cholecystography will 
be done. Aspiration of duodenal 
contents may help in identifying 
microstones or cholesterol crys­
tals.13
What should be done if all tests 
are negative? The answer is to re­
move the gallbladder. If a truly
diligent search has been made for 
alternative causes, gallstones will 
nearly always be found.14 The 
stones will be tiny, explaining the 
difficulty in diagnosis. It is unac­
ceptable to watch helplessly while a 
patient has multiple attacks of pan­
creatitis and assume that the dis­
ease is idiopathic.
Non-anatomic Factors
Alcohol
There is certainly a well-estab­
lished relationship between alcohol 
consumption and pancreatitis. Al­
though the causative mechanism 
remains obscure, there is some evi­
dence of a metabolic disorder. 
Sarles15 has studied a protein in 
pancreatic juice (pancreatic stone 
protein). His studies suggested that 
in chronic pancreatitis this protein 
is deficient and its deficiency leads 
to calcium precipitation resulting in 
stone formation. Others have noted 
an increase in serum triglyceride 
levels after alcohol consumption, 
suggesting an alternative mecha­
nism of pancreatitis.16
Other possible mechanisms have 
been considered but were either not 
confirmed or rejected because of 
lack of information.
Of interest is the fact that most 
heavy drinkers suffer from neither 
pancreatitis nor cirrhosis. Of those 
who suffer from cirrhosis, only a 
few get pancreatitis and of those 
who suffer from pancreatitis, only a 
few also have cirrhosis. These find­
ings suggest that pancreatitis oc­
curs in alcoholics who have a pecu­
liar reaction to alcohol; this reac­
tion may be a metabolic variant 
resulting in a pancreas-specific tox­
in.
Two errors are commonly made 
by physicians in establishing a diag­
nosis of alcoholic pancreatitis. First 
is a lack of vigour in obtaining a 
history of alcohol addiction. Many
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“closet alcoholics” are quite deft at 
concealing their addiction, and con­
siderable effort may be required to 
obtain a proper history. Second, a 
casual drinking history is incrimi­
nating as the cause of pancreatitis 
and other possibilities are ignored.
The amount of alcohol necessary 
to induce pancreatitis is quite vari­
able but generally 150 to 200 g /d  
of pure alcohol are required.
In most reported experience, 25% 
to 50% of patients with pancreatitis 
are heavy alcohol drinkers. That 
fact should focus attention on the 
critical importance of an accurate 
drinking history in all patients with 
pancreatitis.
Hyperlipidemia
As early as 192917 a relationship 
between serum lipids and acute pan­
creatitis was recognized. Since then 
a great deal has been learned, but 
much remains unknown.
As with most factors related to 
pancreatitis, the mechanism re­
mains obscure. However, a clever 
experiment by Saharia and col­
leagues18 has cast some light on 
this issue. Isolated dog pancreases 
were perfused with free fatty acid 
(oleic) and with triglycerides. In 
both groups of animals, pancreatic 
edema and hemorrhage occurred. In 
the venous effluent of the glands 
perfused with triglycerides, the con­
centration of free fatty acids in­
creased, suggesting that neutral fat 
may be converted to free fatty acids 
in the intact pancreas leading to 
inflammation in a mechanism such 
as that proposed in 1969 by Ha­
vel.19
In the clinical setting several fac­
tors are known to produce hyper­
lipidemia and to be associated with 
pancreatitis. They include estrogen 
ingestion, oral contraceptives, preg­
nancy, lipid infusion, lipoprotein 
C-II deficiency, alcohol and beta 
blockers. Most patients with hyper­
lipidemia and acute pancreatitis 
have Fredrickson type V hyperlipo­
proteinemia but patients with types 
I and IV have also been reported.
Confounding the issue is the ob­
servation that in some patients pan­
creatitis may produce hyper­
lipidemia. Whether or not this phe­
nomenon is associated with under­
lying lipoprotein abnormality is un­
clear. Care must be taken in mak­
ing the diagnosis since the hyper­
lipidemia may mask an elevation of 
the serum amylase level.20
All patients with unexplained re­
current pancreatitis should have 
serum lipid measurement as well as 
lipoprotein electrophoresis.
Drug- and Toxin-Induced Factors
It is clear that certain drugs are 
associated with acute pancreatitis 
and the list continues to grow.21 
Table I describes those agents that 
have resulted in acute pancreatitis 
and upon rechallenge have pro­
duced the disease again.
Some of these agents may induce 
secondary conditions, for example 
estrogen resulting in hyperlipidemia 
and vitamin D causing hypercal­
cemia. Others appear to produce a
direct effect on the pancreas. Other 
agents (Table II) have been incrimi­
nated as causing acute pancreatitis, 
but the relationship has not been 
proven. Organophosphates22 which 
are anticholinesterase agents have 
been noted to induce severe and 
often fatal acute pancreatitis. Both 
ingestion and transcutaneous ab­
sorption have been toxic. Other 
industrial compounds such as pen- 
tachlorophenol have been implicat­
ed in causing pancreatitis.23
A species of scorpion, Tityus tri- 
nitatis,24 is known to cause pan­
creatitis in 80% of those stung. 
Pseudocyst formation as evidence 
of the severity of pancreatitis may 
occur. No other species of scorpion 
has been responsible for acute pan­
creatitis.
Infections
Both coxsackievirus and mumps 
virus have been reported to cause 
acute pancreatitis. In mumps infec­
tion, there has often been evidence 
that the hyperamylasemia may be 
from parotid inflammation without 
pancreatic disease. There are cases 
of true pancreatitis in patients with 
mumps.25
Table 1. Drugs Associated With Acute Pancreatitis. Causal Relationship Established
Azathioprine Nitrofurantoin
Calcium Pentamidine
Corticosteroid (dexamethasone) Procainamide
Cytosine arabinoside (ARA-C) Sulfonamide
Estrogen Tetracycline
Furosemide Thiazide diuretics
6-mercaptopurine
Methyldopa
Vitamin D
Table II. Drugs Associated With Acute Pancreatitis. Causal Relationship Not Established
Acetaminophen Ethacrynic acid
Amphetamines Histamine
Anticoagulants Indomethacin
Asparaginase Isoniazid
Chlorthalidone Meprobamate
Cholestyramine Methanol
Cimetidine Opiates
Clonidine Phenformin
Corticosteroids Propoxyphene
Cyproheptadine Propylthiouracil
Diazoxide Rifampin
Enalapril Salicylates
110 CJS, VOL. 33. NO. 2. APRIL 199C
RECURRENT ACUTE PANCREATITIS
Coxsackievirus has been shown 
to be injurious to the pancreas in 
experimental animals. Further, ele­
vated antibody titers have been 
noted in patients with acute pan­
creatitis. Imirie and colleagues26 
studied prospectively 116 patients 
with acute pancreatitis and found 
rising viral titers in 5 (4%). Howev­
er, two patients also had gallstones. 
These studies suggest a possible 
relation between acute viral infec­
tions and pancreatitis.
Systemic Illness
Systemic lupus erythematosus 
(SLE) has been found to be associ­
ated with acute pancreatitis. Reyn­
olds and associates27 reported 20 
cases and reviewed the world litera­
ture. The issue is complicated by 
the use of corticosteroids to treat 
pancreatitis. Gastrointestinal in­
volvement is found in more than 
33% of patients with SLE, 20% 
have abdominal pain and in 10% 
abdominal pain is the initial com­
plaint. It is quite clear that pan­
creatitis develops in patients with 
SLE who are not and in some cases 
have never been on steroid medica­
tion. To further complicate the mat­
ter, SLE may cause hyperlipidemia.
Pregnancy
Acute pancreatitis in young 
women who are pregnant is uncom­
mon but well described.28 Both gall­
stones and hyperlipidemia are also 
known to be increased in frequency 
in pregnant women. The majority of 
cases occur late in pregnancy and 
recurrence early post partum is 
common. Most have gallstones. A 
family history of hyperlipidemia 
should alert one to the need for 
lipoprotein electrophoresis.29
Hypercalcemia
Calcium is known to be a catalyst
for some pancreatic enzymes. It is 
also clear that hypercalcemia is as­
sociated with acute pancreatitis. 
The hypercalcemia may be second- 
aiy io Hyperparathyroidism, viuuniii 
D ingestion, metastatic cancer or 
excess calcium. In searching for 
causative factors in acute pancreati­
tis serum calcium levels, total and 
ionized, should be measured. It 
must be remembered that acute 
pancreatitis lowers the serum calci­
um level. We have demonstrated 
the effect to last as long as 5 days 
(unpublished data). Several calcium 
levels should be measured, but this 
should be done well after the acute 
attack has subsided.
Cancer
Cancer of the pancreas may re­
sult in acute pancreatitis.30 This is 
an unusual event. Logic suggests 
that ductal obstruction may be a 
factor, and, indeed, at operation 
most pancreatic cancers occlude the 
duct and result in an indurated 
abnormal gland. However, acute 
pancreatitis is less common. In 
three of our own cases and one in 
the literature, no ductal involve­
ment was demonstrable with cancer 
of the pancreas associated with 
acute pancreatitis.
Heredity
Hereditary pancreatitis generally 
has two forms — one related to a 
primary hereditary disease as de­
scribed with hyperlipidemia and the 
other idiopathic. There are several 
hundred patients now recognized to 
have idiopathic hereditary pan­
creatitis.31 This condition starts at 
an early age; other causative condi­
tions such as gallstones, alcoholism 
and hyperlipidemia are absent and 
pancreatic calcification is common. 
In the initial phase of the disease 
repeated attacks of pancreatitis are 
the rule. A careful family history
often leads to the proper diagnosis. 
Afferent Loop
When gastric resection and gas­
trojejunostomy have been per­
formed the afferent loop of bowel is 
the conduit for pancreatitis secre­
tion. Obstruction of the loop may 
impair pancreatic drainage, result­
ing in acute pancreatitis.
In addition, chronic or acute af­
ferent-loop obstruction may result 
in abdominal pain and an elevated 
serum amylase level closely mimick­
ing acute pancreatitis.32 In one pa­
tient with chronic obstruction and 
symptoms suggesting pancreatitis, 
the initial computed tomogram was 
thought to show a pancreatic pseu­
docyst. An awareness of the possi­
bility will often lend to the proper 
diagnosis.
Comment
In three of four patients with 
recurrent bouts of acute pancreati­
tis, the underlying cause will be 
easily identified. The other 25% will 
test the diagnostic skills of the 
most astute clinician. Paramount in 
this effort is an awareness of the 
possibilities. The algorithm in Fig. 
3 is an effort to assist in establish­
ing a sequence of diagnostic proce­
dures. In modern medicine, we are 
indeed blessed with a wonderful 
menu of diagnostic tools. The trick 
is to know which one to use in what 
sequence and how to interpret the 
result.
With knowledge of where to look 
and the tools available to allow us 
to look we can reduce the incidence 
of true idiopathic pancreatitis to a 
very few cases.
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The annual incidence of head injuries has increased to be­
tween 2.2 and 4 per 1000 popula­
tion,1-2 the majority of these being 
due to motor-vehicle accidents and 
falls.3 Although many injuries are 
still fatal, improved medical care 
has decreased the death rate subs­
tantially,4 so the health-care system 
is faced with an increasing number 
of patients who suffer residual psy­
chosocial, physical and cognitive 
im pairm ent.5 Therefore, rapid 
screening techniques are needed so 
that physicians can predict long­
term outcome for patients with 
traumatic brain injury (TBI) and 
allocate resources appropriately. 
The purpose of this study was to 
determine if a set of regularly ob­
tained admission variables can serve 
as accurate predictors of later defi­
cits. Kassum and associates6 recent­
ly reported that biochemical data 
collected within 6 hours of admis­
sion can be used to predict survival 
in TBI patients. Glasgow Coma 
Scale (GCS) score, plasma glucose 
and serum potassium levels and the 
leukocyte count were found to be 
related to outcome in terms of 
survival versus death. Such early 
predictors are important for triage, 
in determining the level of care 
required and in allocating re­
sources. Although children differ 
from adults in their response to 
TBI,7 both were included in Kas- 
sum’s study,6 as were patients with 
multisystem injury, a factor that 
may obscure the effects of the TBI 
itself. In the current study, the
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same biochemical variables were 
evaluated within 24 hours of admis­
sion and only adults with TBI with­
out other system trauma were in­
cluded. Outcome was examined in 
patients 1 to 7 years after injury 
and was assessed in terms of quality 
of life as reported by both the 
patient and a close relative.
Assessment of quality of life en­
compassed psychosocial, emotional, 
role functioning and interpersonal 
domains in a manner similar to 
“operationalizations” reported by 
McSweeny and colleagues.8
Patients and Methods
Sixty-one patients with TBI and 
no other initial injury admitted to 
St. Boniface General Hospital or the 
Health Sciences Centre in Winnipeg 
between 1981 and 1987 were the 
subjects of the study. Medical re­
cords were reviewed and the follow­
ing information was obtained: GCS 
score on admission, duration of 
coma and of post-traumatic amnesia 
(PTA), plasma glucose and serum 
potassium levels and leukocyte 
count. The patient and a close 
relative completed a series of ques­
tionnaires including the Profile of 
Mood States (POMS9), Sickness Im­
pact Profile (SIP10) and the Katz 
Adjustment Scale — Relatives 
Form (KAS-R).11 Patients were cate­
Tab le  1 P a tie n t D ata
V aria b le No. %
S u b je c ts 61 100
Sex
M ale 56 9 1 .8
Fem a le 5 8 .2
S e v e rity  g ro u p
M ild 9 14 .8
M o d e ra te 27 4 4 .2
S evere 25 4 1 .0
C ause o f  in ju ry
M o to r  v e h ic le 28 4 5 .9
Fall 23 3 7 .7
A s s a u lt 1 1.6
C a r/p e d e s tr ia n 2 3 .3
O ther 7 11 .4
gorized into three groups according 
to the severity of their initial injury: 
severe — when the GCS score on 
admission was equal to or less than 
8; moderate — when the GCS score 
on admission was greater than 8 
and less than 13, or greater than 13 
with neurologic damage evident on 
computed tomography or when 
neurosurgical intervention was re­
quired; mild — when GCS was 
greater than 13, the computed to­
mograms appeared normal and no 
neurosurgical intervention was re­
quired. These criteria are consistent 
with those used by other research­
ers examining psychosocial out­
comes after TBI.512 Patients who 
died were excluded from the study.
Comparisons of the groups were 
made using univariate two-tailed t- 
tests. Multiple regression analysis 
was used to assess early predictors 
of quality of life.
Results
Of the 61 patients, males out­
numbered females (Table I), as re­
ported by others, and the main 
causes of injury were motor- vehicle 
accidents or falls.13 Most patients 
were in the moderate or severe 
groups. Metabolic and neurologic 
findings are shown in Table II. 
When the moderate and severe 
groups were compared using 
univariate two-tailed f-tests (Table 
III), it was noted that demographic 
variables (age, months after injury)
were not significantly different. Sig­
nificant differences were document­
ed, however, with patients in the 
severe group having, by definition, 
a lower GCS score, and a higher 
leukocyte count, longer coma and 
PTA. There were insufficient data 
for similar analyses with the mild 
group.
Quality o f Life
Significant differences also exist­
ed between the moderate and severe 
groups with respect to quality of 
life (Table III). The severe group 
reported significantly (p < 0.008) 
higher depression/dejection as 
measured by the POMS, more resid­
ual problems (p < 0.05) and greater 
difficulty with work-related activi­
ties (p < 0.002) as measured by the 
SIP, and relatives reported higher 
general psychopathologic problems 
(p < 0.003) and less social activity 
(p < 0.05) as measured by the 
KAS-R.
Early Predictors o f Quality o f Life
In the sequential stepwise multi­
ple regression analysis the early 
predictor variables (age, GCS score, 
leukocyte count and glucose and 
potassium levels) were used as the 
independent variables and the quali­
ty of life outcome measures in­
dividually, as dependent measures. 
Months after injury did not enter 
the equation and this variable was 
not considered further. The results
T a b le  II. M e ta b o lic , N e u ro lo g ic  and D e m o g ra p h ic  D ata on  61 P a tien ts
S tandard
V ariab le M ean dev ia tion R ange
A ge, y r 42 .71 17 .45 2 0  -  85
M o n th s  a fte r in ju ry 4 3 .6 7 2 0 .3 7 4 - 8 9
G lasgow  C om a Sca le  sc o re  on  a d m iss io n 10.61 3 .94 3 - 1 5
Leukocy te  co u n t, X  109/ L 16 .13 7 .1 3 4 .7  -  3 6 .3
P o ta ss ium  leve l, m m o l/L 3 .6 7 0 .4 7 2 .3  -  4 .4
G lucose  leve l, m m o l/L 9 .0 8 3 .3 2 5 .0  -  17 .0
D ura tion  o f co m a  (GCS sc o re  <  8 ), d 1 .53 3.81 0 - 3 1
D ura tion  o f p o s t- tra u m a tic  a m n e s ia  (GCS <  1 5 ), d 8 .98 16 .05 0 -  >  90
B iochem ica l p re d ic to rs  w e re  sa m p le d  w ith in  2 4  h o f  in ju ry .
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Table III. Comparison of Moderate and Severe Groups 
Moderate
Variable
(n =
Mean
27)
SD
Severe (n 
Mean
i =  25) 
SD df t p value
Descriptive variables 
Age, yr 43.59 20.96 40.64 13.29 50 0.63 NS
Months after injury 41.78 21.23 42.60 18.59 50 -  0.15 NS
GCS score on admission 13.56 2.04 6.52 1.50 50 14.21 < 0.001
Leukocyte count, x  109/L 14.54 6.35 18.70 7.00 43 -  2.09 < 0 .05
Potassium level, mmol/L 3.65 0.49 3.65 0.45 44 0.00 NS
Glucose level, mmol/L 8.94 3.46 9.65 3.21 41 -  0.69 NS
Duration of coma (GCS 
score < 8), d 0.45 0.58 4.40 5.64 44 -  3.48 < 0.002
Duration of PTA (GCS 
score < 15), d 2.25 4.98 20.89 22.12 41 -  3.42 < 0.003
Quality of life variables 
POMS depression/dejection 21.29 7.64 28.96 10.95 48 -  2.82 < 0.008
Residual problems 33.07 5.58 37.54 8.61 49 -  2.17 < 0.05
SIP work 15.84 28.21 45.30 33.05 46 -  3.31 < 0.002
SIP physical 4.39 6.39 7.20 8.20 48 -  1.29 NS
SIP psychosocial 11.73 10.83 16.71 12.91 48 -  1.46 NS
KAS-R general 
psychopathology 35.00 8.13 47.67 14.28 38 -  3.35 < 0.003
KAS-R amount of social 
activity 38.90 4.93 34.61 7.09 38 2.18 < 0.05
are summarized in Table IV. The 
set of early predictor variables was 
significantly related to many of the 
measures of quality of life outcome 
on the KAS-R, POMS and SIP. 
Early trauma severity variables pre­
dicted, for example, later belliger­
ence, verbal expansiveness, negativ­
ism, general psychopathology, help­
lessness and amount of free-time 
activity and work. Biochemical 
markers added substantially to the 
outcome predictability. Multiple 
correlation coefficients ranged from 
0.35 predicting POMS vigour/ac- 
tivity to 0.81 predicting KAS-R 
general psychopathologic problems. 
Thus, 12% to 66% of the variability 
in psychosocial outcome was pre­
dictable from demographic, neuro­
logic and biochemical data within
Table IV. Prediction of Outcome After Injury Using Predictors Available 24 Hours After Injury
Amount of variance accounted for by predictor, %
Glucose Leukocyte Potassium
Scale description Mult R R2 p value GCS Age level count level
Katz adjustment scale
Belligerence 0.66 0.43 < 0.005 1 4 ( 1 ) [ - ] 12(2) [+ ] 1 7 ( 3 ) [ - ]
Verbal expansiveness 0.59 0.35 < 0.006 1 4 ( 2 ) [ - ] 21 (1 ) [+ ]
Negativism 0.65 0.42 < 0.002 3 2 ( 1 ) [ - ] 1 0 ( 2 ) [ - ]
Helplessness 0.80 0.64 < 0.0002 31 (1 )1 -1 15(2) [+] 9 ( 4 ) [ - ] 9 (3) [+ ]
Suspiciousness 0.36 0.13 < 0.07 13(1 )1+ ]
Withdrawal and retardation 
General psychopathologic
0.38 0.14 < 0.06 1 4 (1 ) [+ ]
problems 0.81 0.66 0.0001 1 9 ( 2 ) [ - ] 35 (1 ) [+ ] 1 2 ( 3 ) [ - ]
Nervousness 0.49 0.24 < 0.01 2 4 ( 1 ) [ - ]
Hyperactivity 0.62 0.38 < 0.01 1 4 ( 3 ) [ -1 14(1 )1+ ] 11 (2)1+1
Amount of social activity 0.41 0.16 < 0.04 1 6 (1 ) [+ ]
Expected social activity 0.35 0.13 < 0.07 1 3 (1 ) [+ ]
Amount of free-time activity 0.73 0.53 < 0.0002 31 (1 )1 -1 21 (2 )1 -1
Expected free-time activity 
Profile of mood states
0.40 0.16 < 0.04 1 6 (1 ) [+ ]
Anger/hostility 0.45 0.20 0.02 2 0 ( 1 ) [ - ]
Vigour/activity 0.35 0.12 < 0.08 1 2 ( 1 ) [ - ]
Confusion/bewilderment 
Sickness impact profile
0.50 0.25 < 0.04 11 (1 )1 -1 1 3 ( 2 ) [ - ]
Sleep and rest 0.38 0.14 < 0.06 1 4 (1 )1 + ]
Emotional behaviour 0.41 0.17 < 0.04 1 7 (1 )1 -1
Home management 0.37 0.14 < 0.07 1 4 (1 )1 + ]
Mobility 0.38 0.14 < 0.06 1 4 (1 )1 + ]
Social interaction 0.38 0.14 < 0.06 1 4 (1 )1 -1
Alertness behaviour 0.44 0.20 < 0.03 20 (1 ) [+ ]
Work 0.75 0.57 < 0.001 2 8 ( 1 ) [ - ] 9 (4) [+ ] 1 0 ( 2 ) [ - ] 9 (3) [+ ]
Recreation and pastimes 0.44 0.20 < 0.03 20 (1) [+ ]
Physical dimension 0.49 0.24 < 0.04 1 2 ( 2 ) [ - ] 1 2 ( 1 ) [+ ]
( )  following the variance accounted for by each predictor, variable contains the step number at which that variable entered the equation. [1 indicates the
relation of the variable to a higher score on that scale, e.g., for the Katz belligerence scale, the lower [ - ] the GCS score, the higher the glucose level
[+ ], and the lower the WBC [ - ], the higher the belligerence score.
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24 hours of injury. The Glasgow 
Coma Scale score and biochemical 
indicators are powerful predictors 
of long-term outcome with lower 
GCS scores, higher plasma glucose 
and serum potassium levels and 
lower leukocyte count being related 
to poorer psychosocial prognosis.
Discussion
These results demonstrate that 
there are early markers of injury 
severity after TBI that can predict 
psychosocial and behavioural out­
come. This study expands on that 
of Kassum and associates6 by using 
traumatic brain injured patients 
with no other system damage, and 
by focusing on quality of life in 
survival. Predicting outcome after 
TBI is important not only in deter­
mining patient management, but 
also in allowing the family to pre­
pare for changes in the patient’s 
psychosocial, physical and cognitive 
functioning. However, biochemical 
predictors can only provide a rough 
estimate of outcome since it is not 
only the injury itself, but the pa­
tient’s response to that injury, as 
well as pre- and postmorbid social 
factors which affect later function­
ing.512
Glasgow Coma Scale score still 
appears to be the one variable most 
highly predictive of outcome with 
higher admission scores being relat­
ed to better prognosis. In terms of 
the other measures of severity, due 
to the physical stress associated 
with any type of injury, plasma 
glucose levels tend to rise. There­
fore, it follows that the more severe 
the TBI, the higher will be the 
plasma glucose, which is correlated 
with poorer outcome. In univariate 
analyses, a higher leukocyte count
was found to be associated with 
more severe injury in our series. 
However, in multiple regression 
analyses, worse outcome was asso­
ciated with a lower leukocyte count. 
This finding may be an artifact of 
the multiple regression procedure 
when leukocyte count enters the 
equation later than GCS score and 
plasma glucose level. Potassium 
was a weak predictor of outcome 
with higher serum levels often 
being associated with poor out­
come. This agrees with the older 
literature, in which hyperkalemia is 
stated to occur after injury due to a 
release of cellular potassium, but 
not with recent literature1415 which 
suggests an adrenergic mechanism 
producing a lower serum potassium 
level in the severely stressed pa­
tient.
With biochemical data available 
to physicians within 6 to 24 hours 
of injury, outcome predictability is 
enhanced compared with that using 
the GCS score alone. With this 
approach, and by developing and 
cross-validating regression equa­
tions predictive of outcome, it may 
be possible to identify those pa­
tients who can benefit from cogni­
tive and psychosocial rehabilitation 
programs leading to more effective 
long-term management. Further re­
search will need to examine these 
issues and to identify whether long­
term outcome can be modified by 
such programs.
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Prosthetic Replacement of the Arthritic 
Knee After Patellectomy
H.U. Cameron, MB, ChB, FRCSC;* Y.B. Jung, MDt
The results of total knee replacement with a semiconstrained prosthesis after 
patellectomy are poor because the stabilizing effect of the patella is lost. A series of 
bicompartmental unicompartmental knee replacements (five patients) carried out for 
this condition was compared with a series of Insall-Burstein posterior stabilized 
knee prostheses (six patients). If both cruciate ligaments are present the results are 
not notably different, but those with an Insall-Burstein prosthesis generally fared 
better at stair-climbing using the replaced side as the lead leg. Since the Insall- 
Burstein knee is technically easier to implant there seems little to recommend the 
bicompartmental unicompartmental prosthesis in this condition.
Les resultats des arthroplasties totales du genou a l’aide de protheses semi-contrain- 
tes sont mauvais, a cause de la perte de l’effet stabilisateur de la rotule. Cinq 
patients qui avaient subi une arthroplastie bicompartimentale-unicompartimentale 
apres patellectomie ont ete compares a six autres qui avaient re?u une prothese 
Insall-Burstein avec stabilisation posterieure du genou. En presence des deux 
ligaments croises, les resultats n’etaient pas tellement differents mais ceux qui ont 
refu une prothese Insall-Burstein etaient generalement avantages pour monter les 
escaliers, alors qu’ils pouvaient utiliser la jambe operee pour amorcer leur escalade. 
Comme la prothese Insall-Burstein est techniquement plus facile a implanter, il y a 
done peu de raisons de recommander une prothese bicompartimentale-unicomparti- 
mentale.
The patella acts as an an­teroposterior stabilizer in total 
knee replacement.1' 3 In a previous 
study,4 it was shown that the re­
sults of total knee replacement after 
patellectomy with excision of the 
cruciate ligaments were not particu­
larly good, and when revision was
needed in these cases, far superior 
results were obtained with a stabi­
lized knee.4 Some of these patients, 
however, continued to have patel- 
lofemoral pain because the patellar 
tendon rubbed on the anterior metal 
flange.
In a small series of cases, there­
fore, we inserted bicompartmental 
unicompartmental knees in patients 
who had severe osteoarthritis of the 
knee and had previously undergone 
patellectomy. The objectives were 
to determine if retention of both 
cruciate ligaments provided an­
teroposterior stability and if the 
incidence of patellar pain was less­
ened by allowing the patellar ten­
don to articulate with the natural 
articular cartilage covering the 
trochlear groove.
Since completion of that study, 
we have also tried the Insall-Bur­
stein posterior stabilized knee pros­
thesis and the results achieved with 
each type of prosthesis have been 
compared.
Patients and Methods
Eleven patients who had previ­
ously undergone patellectomy had 
replacement by either a bicompart­
mental unicompartmental knee 
prosthesis (5) or an Insall-Burstein 
knee prosthesis (Johnson and John­
son, New Brunswick, NJ). The pro­
cedures were carried out by the 
senior author and the patients re­
viewed prospectively at 6-month in­
tervals using the Hospital for Spe­
cial Surgery rating system5 and 
3-foot standing films and lateral 
x-ray films.
The unicompartmental knee was 
the Tricon P (Richards Manufactur­
ing Co., Memphis, Tenn.). It con­
sists of a cemented femoral compo­
nent and an uncemented plastic
From the Department o f  Surgery, The Orthopaedic and A rth ritic  Hospital, University o f 
Toronto, Toronto, Ont.
*Assistant Professor, Department o f  Surgery, Department o f  Pathology and Department o f  
Engineering, University o f  Toronto. Staff orthopedic surgeon, the Orthopaedic and Arthritic 
Hospital, Toronto, Ont.
f  Associate Professor, Chung-Ang University, Seoul. S. Korea 
Accepted for publication May 5, 1989
Reprint requests to: Dr. H.U. Cameron, Ste. 318. 43 Wellesley St. E, Toronto, Ont. M4 Y 1H1
CJS, VOL. 33, NO. 2, A P R IL 1990 119
CAMERON &  JUNG
tibial component, which is held in 
place by a ridged plastic peg driven 
into an undersized hole drilled in 
the tibia (Fig. 1). The peg provides 
initial stability and the flat cut sur­
face of the intercondylar eminence 
provides rotatory stability. The In- 
sall-Burstein knees were all ce­
mented in place (Fig. 2).
Results
The results are shown in Table I.
Of the unicompartmental group 
(cases 1 to 5), one patient scored 
excellent, two good, one fair and 
one poor. Two of the five can use 
the replaced knee as the lead leg 
when climbing stairs. In the Insall- 
Burstein group two scored excel­
lent, two good, one fair and one 
poor. Five of the six can use the 
replaced knee as the lead leg on 
stairs.
No knees have loosened and none 
have been revised. The only radiolu- 
cency seen is under the medial tibial
FIG. 2. (a) Posterior cruciate ligament 
was absent in this medial unicompart­
mental knee. Tibia tended to sublux 
posteriorly on femur, (b) Joint was 
revised to Insall-Burstein posterior 
stabilized knee.
FIG. 1. Bicompartmental unicompartmental knee in place for 4 years and 
functioning reasonably well. Femoral components are cemented. Tibial components 
are plastic and held in place with ridged plastic peg.
Table I. Data and Results in 11 Patients
Case Age,
no. Sex yr Previous operation Surgical findings Knee used Complications Results
1 F 55 Patellectomy Cruciate ligaments OK BUP None G
2 F 72 Patellectomy Absent anterior band anterior 
cruciate ligament
BUP None E
3 F 57 Patellectomy +  high tibial 
osteotomy
Cruciate ligaments OK BUP Avulsion of the anterior band of the 
anterior cruciate ligaments
G
4 M 67 Patellectomy Ankylosed knee BUP Severe wound breakdown F
5 F 44 Patellectomy Absent anterior cruciate ligament BUP Deep vein thrombosis P
6 F 70 Patellectomy +  
unicompartmental knee
Absent posterior cruciate ligament IB None E
7 F 54 Patellectomy +  high tibial 
osteotomy
None IB Tibial crack fracture F
8 F 75 Patellectomy Lateral patellar ligament 
subluxation
IB None E
9 M 61 Patellectomy +  total knee 
replacement
None IB None P
10 M 74 Patellectomy None IB None G
11 F 73 Patellectomy None IB None G
BUP =  bicompartmental unicompartmental prosthesis, IB =  Insall-Burstein prosthesis. G =  good, E =  excellent, F =  fair, P =  poor.
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FIG. 3. Crack fracture of tibial cortex 
in case of revision of tibial osteotomy 
occurred when stem hole was punched 
out. It was stabilized with one screw. 
Use of burr is probably preferable 
when preparing canal for prosthetic 
stem after previous osteotomy. There 
is some radiolucency under medial tibi­
al plateau.
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plateau in the patient who had a 
crack fracture of the tibia stabilized 
by one screw (Fig. 3).
Discussion
This is the first report in the 
literature of the use of bicompart- 
mental unicompartmental knee 
prostheses implanted in the absence 
of the patella. Although our num­
bers of patients are small, which 
tends to skew results, it is also the 
largest reported series of posterior 
stabilized knee prostheses used in 
the absence of the patella.
Bicompartmental unicompart­
mental prostheses do work in the 
absence of the patella, but only if 
both cruciate ligaments are present. 
The operation is technically more 
difficult than an Insall-Burstein
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lust. American Association of Neurolog­
ical Surgeons, 22 South Washington 
St., Park Ridge, 111. 60068. 1990. $35 
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and David A. Lubarsky. 199 pp. Butter- 
worths, Stoneham, Mass. 1990. $29.95 
(US). ISBN 0-409-90207-1
Principles of Surgical Research. R.T. 
Mathie, K.M. Taylor and J.S. Calnan. 
211 pp. Illust. Butterworth & Co. (Pub­
lishers) Ltd., London. 1989. $54.95 
(US). ISBN 0-7236-0929-2
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180 pp. Illust. Heinemann Medical 
Books, Oxford; Butterworths, Stone­
ham, Mass. 1989. $34.95 (US). ISBN 
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knee replacement and the results 
are not superior. There seems little 
reason, therefore, to use bicompart­
mental knee prostheses to treat 
patients with severe osteoarthritis 
in the absence of a patella.
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Perioperative Cefazolin Prophylaxis in 
Hip Fracture Surgery
Richard Buckley, MD, FRCSC;* Gary N.F. Hughes, MD, FRCSC, FAAOS;t Tom Snodgrass, BSc;$ 
Shirley A. Huchcroft, PhDJ
Antibiotics given perioperatively are thought to decrease the occurrence of 
postoperative wound infection. The duration of treatment for hip fracture surgery is 
empirical. This randomized, double-blind, single-hospital clinical study was carried 
out to assess the effect of both antibiotic use and duration of use on wound 
infections in hip fracture surgery. Wound infection rates in three groups of patients 
were compared: those who received four doses of cefazolin (108 patients), those who 
received one dose of cefazolin and three doses of placebo (83 patients) and those 
who received four placebo doses (121 patients). Results showed an infection rate of 
1.6% for the four-dose group, 2.4% for the one-dose group and 3.7% for the placebo 
group. These differences were not statistically significant, even when both treatment 
groups were combined and compared with the placebo group. The authors conclude 
that until more patients are added, empirical use of antibiotics should be continued 
in patients who undergo hip fracture surgery.
On croit generalement que les antibiotiques administres en peroperatoire diminuent 
l’incidence des infections de plaie postoperatoires. En ce qui concerne la chirurgie 
des fractures de la hanche, la duree de traitement est empirique. La presente etude 
clinique, randomisee, a double insu et realisee dans un seul hopital, a ete menee 
dans le but d’evaluer l’effet de l'antibiotherapie et de sa duree sur les infections de 
plaie consecutives a la chirurgie des fractures de la hanche. Les taux d’infections de 
plaie ont ete compares chez trois groupes de patients: ceux qui recurent quatre 
doses de cefazoline (108 patients), ceux qui refurent une dose de cefazoline et trois 
doses de placebo (83 patients) et ceux a qui on donna quatre doses de placebo (121 
patients). Les resultats ont montre un taux d’infections de 1.6% pour le groupe qui 
re?ut quatre doses, de 2.4% pour ceux qui recurent une dose et de 3.7% pour le 
groupe placebo. Aucune de ces differences n’atteint le seuil de signification 
statistique, meme lorsque tous les patients traites sont regroupes et compares au 
groupe placebo. Les auteurs concluent que d’ici a ce qu’on ait augmente les effectifs 
de l’etude, l’utilisation empirique des antibiotiques devrait etre poursuivie chez les 
patients qui subissent une operation pour fracture de la hanche.
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W ound infection is an infre­quent complication of hip 
fracture surgery, but, as recently as 
15 years ago, infection rates rang­
ing from 9.4% to 16%1-4 were docu­
mented in a number of studies in 
which the follow-up was meticu­
lous. What are the reasons for this 
discouragingly high rate of infec­
tion in clean wounds after hip sur­
gery? Hip surgery is performed 
most often in patients with systemic 
disease in their seventh to ninth 
decades who are poor surgical risks 
and have chronic disease.4
Recently, antibiotics have been 
used prophylactically to decrease 
wound infection rates in hip frac­
ture surgery (0.7% to 9%).5-10 How­
ever, in many of these reports, the 
study design and statistical analysis 
were open to question. For exam­
ple, total joint surgery was included 
with hip fracture surgery,5 multiple 
antibiotics were used,610 antibiotics 
were given over different prospec­
tive time periods (from one dose to 
2 weeks)5-10 and many types of hip 
operation were performed.8-9 Stan­
dardization of protocol is difficult 
because of multiple factors, which 
include the type of fracture, type of 
antibiotic, duration of antibiotic ad­
ministration and implant selection. 
However, the principles of effective 
prophylaxis are becoming more 
finely tuned.1112 The trend in antibi­
otic use in orthopedic implant sur­
gery is to give high-dose, single­
dose, first-generation cephalos­
porin.12'14 Effective selection of an­
timicrobial agents, low toxicity and 
good tissue levels are all important 
factors in effective prophylaxis.
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In this single-hospital, prospec­
tive, clinical study, cefazolin is eval­
uated as a prophylactic agent 
against wound infection after hip 
fracture surgery. The principal area 
of interest was whether or not cefa­
zolin decreased early postoperative 
wound infection rates, and whether 
single-dose cefazolin was as effec­
tive as multiple-dose cefazolin in 
preventing early postoperative 
wound infections.
Patients and Methods
All adults admitted to the Footh­
ills Hospital, Calgary, with an inter­
trochanteric or subcapital hip frac­
ture between Dec. 1, 1985 and Dec. 
1, 1988 were eligible for study. 
There were 387 such patients. 
Twenty-five patients were excluded 
for one of the following reasons: 
cephalosporin allergy, a pathologic 
fracture due to tumour, previous 
surgery on the fractured hip, treat­
ment with an antibiotic other than 
cefazolin, or a preoperative course 
in hospital longer than 7 days. This 
left 352 patients in the trial after 
informed consent was obtained.
The patients were allocated blind­
ly and at random to one of the 
following three groups: group 1 — 
cefazolin, 2 g intravenously when 
anesthesia was induced, then 1 g 
every 6 hours intravenously for 
three doses, making a total of four 
doses of cefazolin; group 2 — cefa­
zolin 2 g intravenously upon induc­
tion of anesthesia, then saline for 
three doses; group 3 — saline intra­
venously for four doses. No-one 
involved in the patient’s primary 
care was aware of the group to 
which each patient had been as­
signed. An unpublished retrospec­
tive study, done previously at the 
Foothills Hospital by staff of the 
Division of Orthopedic Surgery, 
demonstrated infection rates in hip 
fracture surgery without antibiotics 
of 12% and with four doses of
antibiotics of 4%. This was used as 
a model for our prospective study. 
We decided to compare three 
groups because we did not know 
whether a single preoperative dose 
would result in a low rate of infec­
tion. We selected a sample size of 
about 120 patients in each of three 
groups in the study. Such a sample 
size would detect a difference in 
infection rates of 9% with a proba­
bility of an a-type error of less than 
0.10 and a /3-type error of less than 
0.20. Before the study began, we 
decided that upon analysis of the 
first 180 patients, if there was a 
statistical difference between 
groups the trial would be discontin­
ued.
Surgery and Follow-up
The fractured hip was treated by 
either hip pinning (with compres­
sion screw or multiple pins) or an 
Austin-Moore hemiarthroplasty. 
Postoperatively, at the surgeon’s 
discretion, a Hemovac drain was 
placed for subcutaneous tissue 
drainage. All patients had their 
wounds checked by the hospital 
wound-study nurse, and all patients 
had a complete follow-up 6 weeks 
after operation. Uniform clinical 
criteria were used to define infec­
tion.15 Wounds were considered un­
infected if they healed primarily and 
definitely infected if there was a 
purulent discharge, whether or not 
organisms were cultured. Wounds 
that were inflamed without dis­
charge and wounds that drained 
culture-positive serous fluid were 
considered possibly infected and the 
patient was followed up until the 
wound either healed or drained pus. 
Material was cultured from all 
wounds in which infection was 
questionable.
For the first 14 patients, serum 
and bone levels or cefazolin were 
examined intraoperatively. This was 
done by the cylinder-plate bioassay
technique.16 Serum levels 15 min­
utes after 2-g intravenous bolus 
dose yielded mean levels of 121 
Mg/ml. Bone levels 1 hour after the 
bolus dose averaged 33 /ug/ml. 
These levels of cefazolin are at least 
10 times the MIC90 (minimal inhibi­
tory concentration-90) for common 
wound pathogens including Sta­
phylococcus aureus.17-19
Statistical Analysis
Using the x2 test with the Yates 
correction or Fisher’s two-tailed 
exact test, we compared propor­
tions of patients in each group who 
had a wound infection. Due to the 
low infection rate, the cefazolin 
groups (1 and 2) were combined in 
an effort to increase the power of 
detecting a statistical difference be­
tween those who received cefazolin 
and those who received the placebo. 
All statistical procedures with re­
spect to wound infections were per­
formed using these two groups 
(1 /2  and 3). Since age in all three 
study groups was skewed to the 
upper limit, the Kruskal-Wallis 
one-way analysis of variance was 
used to assess the comparability of 
the three groups.
Findings
Of the 352 patients initially in­
cluded in the trial, 40 were exclud­
ed because the trial protocol was 
not completed. This left 312 pa­
tients who completed the 6-week 
study. Group 1 comprised 108 pa­
tients, group 2, 83 patients and 
group 3, 121 patients. The three 
groups were similar in sex (x2 = 
0.586, df =  2, p =  0.75) and age (H 
= 0.297, df =  2, p =  0.86) distribu­
tion (Table I).
Of the 312 fractures, 121 were 
treated by Austin-Moore hemiar­
throplasty — 56 in group 1, 32 in 
group 2 and 33 in group 3. The 
remaining 191 were treated by hip
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pinning; of these, 170 had a com­
pression screw — 57 in group 1, 46 
in group 2 and 67 in group 3; the 
remaining 21 had multiple pins 
placed — 8 in group 1, 5 in group 
2 and 8 in group 3. No difference 
existed between groups with regard 
to the presence of a Hemovac drain 
(X 2 = 0.33, df =  2, p = 0.85) 
(Table II). The type of operation 
was not evenly distributed between 
the three groups (x2 = 5.95, df = 
2, p = 0.05). The fact that the type 
of operation performed was not a 
predictor of wound infection indi­
cated that this variable was not a 
confounder in the study.
Eight postoperative wound infec­
tions occurred — two (1.6%) in
group 1, two (2.4%) in group 2 and 
four (3.7%) in group 3. The infec­
tions were all superficial except for 
one in group 3, a deep infection in a 
96-year-old woman which was im­
plicated in her death 14 days after 
operation. All the infections were S. 
aureus (sensitive to cephalothin), 
and all superficial infections cleared 
after a course of intravenous antibi­
otics. All infected patients (except 
the one who died) were discharged 
from the study after 6 weeks with 
healed wounds. Because of the 
small number of infections in each 
group we had to combine the antibi­
otic treatment groups (1 and 2) to 
make a comparison with the control 
group (3). This comparison demon­
strated no statistically significant 
difference by Fisher’s two-tailed 
exact test (p =  0.46) between those 
hip fractures treated with antibiot­
ics and those without (Table III). 
The average age of the infected 
patients was 84.2 years, 8 years 
older than that of noninfected hip 
fracture patients. This was not sta­
tistically significant using a pooled 
variance estimate (t = 1.61, df = 
310, p = 0.11).
The type of operation performed 
had little effect upon the likelihood 
of a wound infection developing 
(Table IV). There was no difference 
in infection rates between the Aus- 
tin-Moore hemiarthroplasties (in- 
tracapsular surgical approach) and 
the hip pinnings (extracapsular sur­
gical approach) (Fisher’s exact test, 
p = 0.72).
Fifteen deaths occurred (4.8%), 3 
in group 1, 4 in group 2 and 8 in 
group 3. The cause of all deaths 
was cardiopulmonary except for the 
one patient in group 3 who died of 
multiorgan system failure; her deep 
wound infection possibly contribut­
ed to her death. All patients who 
died were in their ninth or tenth 
decade of life.
There were no anaphylactic reac­
tions, allergies or renal toxicity re­
lated to cefazolin administration. 
There were no cefazolin cross-reac­
tions with patients who claimed a 
history of “penicillin rashes”. No 
patient’s hospital stay was length­
ened because of a drug-related com­
plication.
Discussion
Postoperative infections after hip 
fracture surgery are devastating, 
particularly in patients who are de­
mented and debilitated. Historically, 
the infection rate has been between 
10% and 15% in hip fracture pa­
tients14 and at the Foothills Hospi­
tal between 1983 and 1984 the rate 
was 12% without antibiotics. In the
Table 1. Sex and Age
Group No.
Sex Age, yr
Male Female Mean ± SD Range
1 (4 doses) 121 32 89 76.3 ±14.9 18-100
2 (l dose) 83 22 61 77.1 ± 12.1 33- 94
3 (placebo) 108 3 75 76.1 ± 13.4 29- 96
Totals 312 87 225
Table II. Type of Operation and Hemovac Drainage 
Operation
Multiple Compression
Group No. Austin-Moore pins screw Yes No
1 121 56 8 57 67 54
2 83 32 5 46 49 34
3 108 33 8 67 63 45
Totals 312 121 21 170 179 133
Table III. Wound Infection
Wound infection
Group Yes (%) No Total no.
1,2 4 (2.0) 200 204
3 4 (3.7) 104 108
Totals 8 304 312
Table IV. Type of Operation and Wound Infection
Group
Austin-Moore
(infection)
Operation
Multiple pins 
plus compression 
screw (infection) Totals (infection)
1,2 88 (2) 116 (2) 204 (4)
3 33 (2) 75 (2) 108 (4)
Totals 121 (4) 191 (4) 312 (8)
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1980s, antibiotics have been used in 
all surgical subspecialties to de­
crease postoperative wound infec­
tions, but the principles of antimi­
crobial prophylaxis are still being 
elucidated.18 Few well-designed tri­
als to assess the role of periopera­
tive antibiotics in preventing post­
operative wound infections in hip 
fracture patients have been con­
ducted.67-9
First-generation cephalosporins 
have been shown to be more effec­
tive and less troublesome than 
other cephalosporins,18-20 but the 
number of doses needed periopera- 
tively is unknown. Antibiotics stud­
ied have been given in dosage 
schedules ranging from one dose to 
2 weeks.5-10 Burnett and col­
leagues,7 in a double-blind prospec­
tive study of hip fracture patients, 
had a placebo infection rate of 4.7% 
and a cephalothin-treated infection 
rate of 0.7%. Cephalothin was used 
for 3 days. Tengve and Kjellander6 
reported a placebo infection rate of 
16.9% and a cephalothin-treated in­
fection rate of 1.8%. Cephalothin 
and cephalexin were used for 2 
days. These studies suggested defi­
nite value of first-generation ceph­
alosporins, but the dosage schedule 
used was for 2 or more days.
Conte and colleagues21 used sin­
gle-dose cephalothin in cardiovascu­
lar surgery and proved its efficacy 
in a double-blind study. Hedstrom 
and associates,10 in a double-blind 
study with hip fracture patients, 
found no difference between their 
two groups (1 day of cefuroxime 
and 1 day of cefuroxime plus 6 days 
of cephalexin). Gatell’s group8-9 
noted a higher infection rate in 
patients who received one dose of 
cephamandole than in those who 
received five doses during Austin- 
Moore surgery. The second-genera­
tion cephalosporin was used be­
cause of a high institutional inci­
dence of gram-negative infections. 
With all of these studies in mind, it
was our objective to determine 
whether single-dose prophylaxis 
was as effective as multiple-dose 
prophylaxis.
Our study failed to demonstrate a 
significant difference in wound in­
fection rates in the antibiotic 
groups compared with the placebo 
group. Infection rates in all three 
groups were much lower than his­
torical figures from the 1970s and 
from our own retrospective review 
of 1983-84. We believe that the 
surgical wound environment has be­
come more antiseptic, possibly be­
cause of surgical draping, technique 
or some other factor. This may be 
supported by our placebo infection 
rate of only 3.7% which is lower 
than any recent study involving hip 
fractures.6-7 Because of the low pla­
cebo infection rate, the study does 
not have the power to demonstrate 
a statistically significant difference 
between groups. Indications from 
other studies certainly point to anti­
biotics as being helpful in wound 
infection prophylaxis in hip fracture 
surgery.5-10 In no study over the 
last 20 years has there been a 
suggestion that antibiotics increase 
infection rates.
One dose of cefazolin may be as 
effective as four doses of cefazolin, 
but our study sample size was too 
small to draw any conclusions. Until 
there is definitive proof of single­
dose antibiotic effectiveness, four 
doses of a first-generation cephalos­
porin can easily be justified on a 
cost basis. The first-generation 
cephalosporins cost only dollars a 
day and the alternative is a small 
risk of developing a devastating 
wound infection. We feel there is a 
trend toward having a smaller risk 
of infection with antibiotic than 
without.
In this study, no difference exist­
ed between the operation performed 
and the rate of wound infection. 
Other researchers have found that 
certain procedures and approaches
to the hip are associated with a 
higher infection rate.1-3 Sample size 
must be much larger than ours to 
reach conclusions in this area, but 
trends suggest that hemiarthro­
plasties are associated with a higher 
infection rate.
All of the infections grew S. 
aureus as the primary wound patho­
gen. No gram-negative bacteria 
were isolated. Even with antibiotics, 
there seems to be a low basal rate 
of infection. Other studies have 
demonstrated this with rates be­
tween 0.7% and 1.8%.6-7 Perhaps 
these elderly, debilitated patients 
are unable to defend against specif­
ic, virulent S. aureus or there are 
other, as yet undetermined, patho­
genetic factors. No major complica­
tions occurred with cefazolin use, 
making it a safe prophylactic antibi­
otic.
In conclusion, cefazolin adminis­
tered perioperatively for prophylax­
is to patients operated on for frac­
tures of the hip did not decrease 
postoperative wound infection. Very 
large studies, possibly multicentre 
trials, will be needed to elucidate 
this difficult problem of prophylaxis 
in settings in which wound infec­
tions are rare.
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Cesarean Section in Ontario: Practice 
Patterns and Responses to Hypothetical 
Cases
Janet M. Barnsley, MES;* Eugene Vayda, MD, FRCPC;* Jonathan Lomas, MA;t
Murray W. Enkin, MD, FRCSC;t Karin Domnick Pierre, MSc;* Geoffrey M. Anderson, MD, MSc;J
Betsy A. MacKinnon, MSct
A 40% random sample of Ontario’s obstetricians were asked to respond to 
hypothetical scenarios for previous cesarean section, breech presentation and 
dystocia, and to describe their practice patterns. Their responses confirmed findings 
from other studies, which reported differences between physicians’ responses to 
hypothetical cases and their actual practice. In this study, 18% chose a cesarean 
section for the hypothetical case of a patient who had previously undergone 
cesarean section and 2% chose a cesarean section for the hypothetical case of breech 
presentation. However, in practice, the obstetricians reported that they do cesarean 
section on 71% of their previous section patients and on 57% of their breech 
patients. Physicians in teaching hospitals were less likely than those in community 
hospitals to choose cesarean section for a woman who had previously undergone 
cesarean section both hypothetically and in practice. For breech presentation, no 
difference was found. The discrepancy between responses to the hypothetical cases 
and practice patterns could not be attributed to the absence of anesthesia services or 
to restrictive hospital policies.
Un echantillon aleatoire compose de 40% des medecins obstetriciens de l’Ontario a 
ete soumis a un questionnaire concernant la marche a suivre dans des cas 
hypothetiques de femmes ayant deja subi une cesarienne, de presentations de siege 
et de dystocie; on leur demanda egalement de decrire leur profil de pratique. Leurs 
reponses confirment les resultats d’autres etudes, a savoir qu’il existe des 
differences entre leurs reponses a des cas hypothetiques et leur pratique reelle.
Dans cette etude, 18% ont choisi une cesarienne dans le cas hypothetique d’une 
patiente qui avait deja eu une cesarienne et 2% choisirent une cesarienne dans 
l’hypothese d’une presentation de siege. Par contraste, en pratique, les medecins 
obstetriciens rapportaient qu’ils executent une cesarienne dans 71% de femmes 
ayant deja subi une cesarienne et dans 57% de femmes ayant un presentation de 
siege. Les medecins pratiquant dans un hopital universitaire etaient moins 
susceptibles que ceux des hopitaux communautaires de choisir la cesarienne en 
presence d’antecedents de cesarienne, aussi bien face a une situation hypothetique, 
qu’en pratique. Aucune difference n’a ete constatee en ce qui concerne la 
presentation de siege. La divergence entre les reponses a des cas hypothetiques et le 
profil de pratique ne peut etre expliquee par l’absence de services d’anesthesie ou 
par des politiques hospitalieres restrictives.
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T he debate over the appropriate use of cesarean section (CS) 
has escalated recently because the 
procedure has become an increas­
ingly frequent response to obstetric 
conditions such as breech presenta­
tion, previous CS, dystocia and fetal 
distress. The criteria suggested for 
CS differ, depending on whether 
they focus on clinical practice,1-5 
health care expenditures,6-8 con­
sumer concerns,9-13 medicolegal 
considerations9-11 or implications 
for medical education.14
Between 1970 and 1979, CS 
rates in Canada more than doubled, 
from 6.0 to 13.9 per 100 live 
births.15 Recent data for Ontario16 
show a further increase from 16.5 
per 100 live births in 1979 to 19.9 
in 1984, with increases reported in 
both teaching and community hos­
pitals.117-18
Of the major indications for CS, 
previous section was the indication 
in approximately 40%, breech pre­
sentation in 10% and dystocia in 
more than 18% of the sections 
performed in the 1980s1-16 Previous 
CS and breech presentation were 
responsible for 74% of the increase 
in the CS rate between 1979 and 
1984 (Table I).
Two consensus conferences9-10 at­
tempted to determine whether CS 
or a trial of labour should be the 
preferred method of management 
for previous section, breech presen­
tation and dystocia. These confer­
ences examined research evidence 
on the impact of CS, trial of labour 
and vaginal delivery on infant and 
maternal mortality and morbidity.
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As part of the background for the 
Canadian consensus conference, a 
survey of Ontario obstetricians col­
lected information on the use of CS 
in patients who had previously had 
CS, in those who had breech pre­
sentation and those who had dys­
tocia. The survey included back­
ground information, responses to 
hypothetical cases, and the self- 
reported practices of Ontario obste­
tricians. This report examines the 
responses to questions on previous 
CS and breech presentation. Lack 
of agreement as to the diagnosis 
and treatment of dystocia was ex­
tensive; as a result no conclusions 
could be drawn.
Methods
A 40% random sample was select­
ed from the Ontario Medical Associ­
ation (OMA) mailing list for the 
section on obstetrics and gynecolo­
gy in August 1985. The question­
naire, mailed to 234 physicians 
practising obstetrics or gynecology, 
or both, yielded a response rate of 
81.3% after 42 invalid responses 
were removed. Data on the respon­
dents are summarized in Table II. 
When compared to the Ontario 
Physician Manpower Data Centre 
register of obstetricians and gyne­
cologists, survey respondents were 
similar in age, and country and 
decade of graduation.
With the help of representatives 
from the Society of Obstetricians 
and Gynaecologists of Canada and 
the Association of Professors of 
Obstetrics and Gynaecology, a hy­
pothetical case was developed for 
uncomplicated previous CS and for 
breech presentation. No information 
was introduced that would indicate 
the need for an emergency CS (e.g., 
placenta previa) in either case. The 
obstetricians were asked to respond 
to the hypothetical scenarios and 
then to describe their actual prac­
tice patterns (i.e., the proportion of 
patients with breech presentation 
and a history of CS whose infants 
they currently deliver by cesarean 
section).
The Hypothetical Cases
Previous Cesarean Section
This hypothetical case was as 
follows: A 22-year-old woman, para 
1 gravida 2, is at the end of 36 
weeks of gestation and has had an 
uncomplicated pregnancy. The 
fetus is in vertex presentation, aver­
age size for dates. Her first delivery
was by lower segment cesarean sec­
tion for breech presentation. She 
would prefer a vaginal delivery on 
this occasion. The question was: 
“Would you permit a trial of labour 
for this patient or would you sched­
ule her for elective CS?”
Breech Presentation
The breech presentation hypo­
thetical case was as follows: A 
34-year-old woman, para 1, gravida 
2, enters hospital in active labour. 
Her cervix is 4 cm dilated, with 
membranes intact. An x-ray film 
confirms the examination findings 
of breech presentation and shows
Table I. Percentage of All Infants Delivered by Cesarean Section by Diagnostic Categories (1979
and 1984, Ontario)
Category
Year % change due to diagnostic 
category1979 1984
Previous cesarean section 5.7 7.9 +63
Breech presentation 1.7 2.1 +11
Dystocia 3.3 3.7 +11
Fetal distress 1.2 1.8 +17
Other 4.6 4.5 -  3
Totals* 16.5 20.0 99*
'Due to rounding.
Table II. Sample Data
Data % (N =  156)
Gender
Male 96
Female 4
Country of training
Canada 70
British Isles 21
Other 9
Started practice of obstetrics
Before 1950 4
1950 - 1959 18
1960 - 1969 33
1970 - 1979 27
1980 or later 18
Practice arrangements
Solo practice 66
Group practice 14
University affiliation 13
Mixed 7
Number of deliveries performed in last 12 mo
<100 17
101 - 200 42
201 - 300 30
> 301 11
Mean no. of deliveries 206
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that it is a frank breech with well- 
flexed head. The fetus is average 
size. Her first baby weighed 7 lbs. 
and delivery was uncomplicated. 
The question was:“ Would you 
allow this woman to continue in 
labour or would you schedule her 
for an emergency cesarean sec­
tion?”
Results
Previous Cesarean Section
The majority of respondents 
(82%) indicated that they would 
permit a trial of labour. Respon­
dents who began practising obstet­
rics in the 1980s, had university 
affiliation, had anesthesia services 
available within 15 minutes, and 
were associated with a teaching 
hospital were most likely to permit 
a trial of labour.
In response to the question, 
“What proportion of previous ce­
sarean deliveries that you see at 
present do you deliver by cesarean 
section?” , 30% of obstetricians re­
ported performing a repeat CS on 
50% or less of their patients, 22% 
of obstetricians performed CS on 
50% to 74%, and 48% reported 
performing CS on more than 75% 
of patients who had previously un­
dergone CS. Of this last group, 
one-half performed a CS on all their 
patients who had a history of CS.
Responses to the hypothetical 
case were not congruent with actual 
practice as reported by respondents. 
Of the 107 obstetricians who re­
ported performing CS on more than 
50% of women who had previously 
undergone CS, 77% selected a trial 
of labour for the woman in the 
hypothetical case.
Breech Presentation
The responses to the hypotheti­
cal breech case were overwhelming­
ly in favour of allowing the woman 
to continue in labour; 98% of re­
spondents selected this option. In 
response to the question, “What 
proportion of breeches that you see 
at present do you deliver by cesare­
an section?”, 24% indicated that 
they perform CS on over 50% of 
cases of breech presentation and 
23% that they perform CS on 75% 
or more of patients with breech 
presentation. Again, reported prac­
tices differed from the responses to 
the hypothetical case. Of the 69 
obstetricians who reported perform­
ing CS on more than 50% of breech 
cases, 95% indicated that they 
would allow the hypothetical pa­
tient to continue labour.
In addition, physicians’ overall 
reported behaviour did not match 
their responses to the hypothetical 
cases. 18% chose a CS for the 
hypothetical case in which the pa­
tient had previously had a CS and 
2% chose the procedure for the 
hypothetical breech case. However, 
in practice, respondents reported 
performing a CS on an average of 
71% of their patients who had pre­
viously had a CS and 57% of pa­
tients who had a breech presenta­
tion.
Facilities
The availability of anesthesia ser­
vices and the teaching status of the 
hospitals were examined for those 
obstetricians who said they per­
formed a CS on more than 75% of 
women who had already had a CS 
or had a breech presentation. Al­
most half (46%) reported on-site 
anesthesia services, 30% had access 
to such services within 15 minutes 
and 20% within 16 to 30 minutes. 
Less than 5% had to wait more than 
30 minutes and none reported a 
delay of more than 60 minutes.
Although anesthesia services 
were generally available, the likeli­
hood of CS appeared to be related
to the waiting time for anesthesia. 
Of obstetricians in hospitals where 
the wait for anesthesia services was 
more than 15 minutes, 80% per­
formed a repeat CS on over 75% of 
previous section cases compared 
with only 37% when services were 
available in 15 minutes or less (x2 
= 19.14, p < 0.001). The differ­
ences were less marked but still 
notable for breech presentation; 
40% of respondents who had to 
wait more than 15 minutes for 
anesthesia services reported doing a 
CS on more than 75% of women 
with breech presentations compared 
with only 20% of obstetricians 
whose wait was 15 minutes or less.
Of all respondents, 30% worked 
in teaching hospitals and 70% in 
community hospitals. Obstetricians 
from teaching hospitals were less 
likely to do repeat CS than those 
working in community hospitals; 
only 21% of teaching-hospital ob­
stetricians compared with 61% of 
those from community hospitals re­
ported doing repeat sections on 
more than 75% of their patients 
who had previously had a CS. For 
breech presentation there was less 
difference; 19% of teaching hospital 
respondents and 27% of community 
hospital respondents performed CS 
on more than 75% of their patients 
who had a breech presentation. 
Physicians in teaching hospitals 
were also less likely than their 
colleagues in community hospitals 
to choose a CS in the hypothetical 
case of a woman having had a 
previous CS. For breech presenta­
tion, however, there was no differ­
ence between teaching and com­
munity hospital obstetricians.
Discussion
This survey confirmed an earlier 
finding that there are differences 
between physician responses to hy­
pothetical cases and actual practice
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patterns. Reported differences be­
tween teaching and community hos­
pitals for repeat CS are also con­
firmed. A Canadian study,19 which 
compared physicians’ surgical prac­
tices and their responses to hypo­
thetical cases demonstrated discrep­
ancies. The difference between re­
sponses to the hypothetical cases 
and actual practice is explained, in 
part, by the relatively unequivocal 
nature of the hypothetical cases. 
Moreover, a hypothetical case al­
lows the respondent to give a “text­
book” response, assuming an ideal 
situation and the availability of 
necessary facilities. Hypothetical 
cases also do not reflect external 
forces such as malpractice, patient 
preference and peer pressure.
Despite the relationship between 
the frequency of CS and the avail­
ability of anesthesia services, nei­
ther the increasing CS rate nor the 
frequency of CS reported in this 
survey can be fully attributed to the 
availability of anesthesia. In prac­
tice, even with anesthesia available 
in 30 minutes or less, more than 
half of those who have previously 
had a CS or who have a breech 
presentation are delivered by CS.
The facilities and services that 
should be available before allowing 
a trial of labour in cases of previous 
section or breech presentation were 
addressed in the final statement of 
the panel from the Canadian Na­
tional Consensus Conference on As­
pects of Cesarean Birth.10 The 
statement contained a section enti­
tled ’’Designation of appropriate 
hospital facilities”, in which the 
following paragraph appeared:
The panel recognized that rupture of 
the lower uterine segment may occa­
sionally be catastrophic for the woman 
and her infant, although this event 
occurs much less frequently than other 
acute obstetric emergencies. Therefore, 
hospitals providing obstetric care 
should ensure the availability of blood,
operating rooms, neonatal resuscita­
tion, and nursing, anesthetic and surgi­
cal personnel so that a cesarean section 
can be started within approximately 30 
minutes for any woman in labour, in­
cluding a woman undergoing a trial of 
labour.
The facilities and services re­
quired for safe obstetric care gener­
ally are the same as those required 
for trial of labour in a woman who 
has previously had a CS or who has 
a breech presentation. If a trial of 
labour cannot be carried out be­
cause of inadequate facilities, the 
consensus statement indicated that 
such hospitals should re-examine 
their ability to deal with all obstet­
ric practice.
For breech presentation, the 
trend toward delivery by CS may 
prove to be self-perpetuating. If 
obstetricians have limited oppor­
tunities to manage breech presenta­
tions by vaginal delivery, CS could 
become the standard method for 
breech delivery. In the hypothetical 
case of breech presentation, respon­
dents must have assumed the tech­
nical skill necessary for a vaginal 
delivery.
The administrative rules in hospi­
tals could influence physicians’ 
practice patterns by specifying obs­
tetric policies. However, evidence 
from a concurrent survey of CS 
policies in Ontario hospitals did not 
support this hypothesis. Of the hos­
pitals surveyed, only 50% had ex­
plicit obstetric policies for patients 
having a previous CS and only 40% 
for breech presentation.
We found that responses of ob­
stetricians to uncomplicated hypo­
thetical cases did not appear to 
agree with the self-reported practice 
patterns. They reported performing 
CS on the majority of their patients 
who had undergone a CS previously 
or who had a breech presentation. 
Although reasons for disagreement 
between hypothetical cases and ac­
tual practice have been suggested, 
factors responsible for repeat CS 
and CS for breech presentation are 
less obvious. The high rates do not 
appear to be attributable to the lack 
of anesthesia services or restrictive 
hospital policies. Patient and peer 
pressures and the fear of litigation 
may play a part. The Canadian 
consensus statement10 could serve 
to increase the acceptance of trial of 
labour for uncomplicated deliveries 
in women having previously under­
gone CS or having breech presenta­
tion and to stabilize or reduce CS 
rates for these two conditions.
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Histamine H2 Receptor Antagonist
ACTIONS AND 
CLINICAL PHARMACOLOGY
PEPCID® (famotidine) is a competitive inhibitor of 
histamine H2-receptors. The primary clin ically 
important pharmacologic activity of PEPCID® is 
inhib ition of gastric juice secretion. PEPCID® 
reduces the acid and pepsin content, as well as the 
volume, of basal, nocturnal, and stimulated gastric 
secretion.
INDICATIONS AND CLINICAL USE
PEPCID® (famotidine) is indicated in the treatment 
of the following conditions where a controlled 
reduction of gastric secretion is required for ulcer 
healing:
1. Treatment of acute duodenal ulcer;
2. Prophylactic use in duodenal ulcer;
3. Treatment of acute benign gastric ulcer;
4. Treatment of pathological hypersecretory 
conditions (e g., Zollinger-Ellison syndrome).
PEPCID® I.V. is indicated in some hospitalized 
patients with pathological hypersecretory con­
ditions or intractable ulcers, or as an alternative to 
the oral dosage forms for short-term use in patients 
who are unable to take oral medication.
CONTRAINDICATIONS
H ypersens itiv ity  to any com ponent o f th is  
medication.
PRECAUTIONS
Patients with Severe Renal Insufficiency
Dosing intervals may need to be prolonged in 
pa tien ts  w ith  advanced renal insu ffic ie ncy  
(creatinine clearance<10 mL/min.) to adjust for the 
longer elimination half-life of famotidine. (See 
CLINICAL PHARMACOLOGY and DOSAGE AND 
ADMINISTRATION.)
Drug Interactions
Studies with famotidine in man, in animal models, 
and in vitro have shown no significant interference 
with the disposition of compounds metabolized by 
the hepatic microsomal enzymes, e.g., cytochrome 
P450 system. Compounds tested in man have 
inc luded w arfarin, theophy lline , phenyto in, 
diazepam, am inopyrine and antipyrine. Indo­
cyanine green as an index of hepatic blood flow 
and/or hepatic drug extraction has been tested and 
no significant effects have been found.
Use in Gastric Ulcer
Gastric malignancy should be excluded prior to 
initiation of therapy of gastric ulcer with PEPCID®. 
Symptomatic response of gastric ulcer to PEPCID® 
therapy does not preclude the presence of gastric 
malignancy.
Use In Pregnancy
Reproductive studies have been performed in rats 
and rabbits at oral doses of up to 2000 and 
500 mg/kg/day, respectively (approximately 2500 
and 625 times the maximum recommended human 
dose, respectively), and have revealed no evidence 
of impaired fertility or harm to the fetus due to 
PEPCID®. There are, however, no adequate orwell- 
controlled studies in pregnant women.
Since the safe use of PEPCID® in pregnant women 
has not been established, the benefits of treatment 
with PEPCID® should be weighed against potential 
risks.
Nursing Mothers
Studies performed in lactating rats have shown that 
PEPCID® is secreted in breast milk. It is not known 
whether this drug is secreted in human milk. 
Nursing mothers should either stop this drug or 
should stop nursing.
Pediatric Use
Safety and effectiveness in children have not been 
established.
Use in Elderly Patients
No dosage adjustment is required based on age (see 
HUMAN PHARMACOLOGY, Pharmacokinetics).
ADVERSE REACTIONS
PEPCID® (famotidine) is usually well tolerated; 
most adverse reactions have been mild and 
transient. The adverse reactions listed below have 
been reported during clinical trials in 2333 patients. 
In those controlled clinical trials in which PEPCID® 
was compared to placebo, the overall incidence of 
adverse experiences in the group which received 
PEPCID®, 40 mg at bedtime, was similar to the 
placebo group. No antiandrogenic or other adverse 
hormonal effects have been observed.
The following adverse reactions have been reported 
at a rate of greater than 1% in patients on therapy 
with PEPCID® in controlled clinical trials, and may 
be causally related to the drug: headache (4.6%), 
dizziness (1.2%), constipation (1.2%) and diarrhea 
( 1.6% ) .
Other reactions have been reported in clinical trials 
but occurred under circumstances where a causal 
relationship could not be established. However, in 
these rarely reported events, that possibility cannot 
be excluded. Therefore, these observations are 
listed to serve as alerting information to physicians.
Gastrointestinal 8.0%
Nausea 1.6%
Vomiting 0.9%
Anorexia 0.5%
Abdominal discomfort 0.3%
Dry mouth 0.2%
Nervous System/Psychiatrlc 7.3%
Insomnia 0.6%
Somnolence 0.4%
Anxiety 0.3%
Paresthesia 0.3%
Depression 0.2%
Libido decreased 0.1%
Respiratory 4.4%
Bronchospasm <0,1%
Body as a Whole 3.0%
Fatigue 0.6%
Asthenia 0.3%
Fever 0.2%
Musculoskeletal 1-7%
Musculoskeletal pain 0.1%
Arthralgia 0.1%
Skin 1-7%
Pruritus 0.4%
Rash 0.3%
Alopecia 0.2%
Flushing 0.2%
Acne 0.1%
Dry skin 0.1%
Cardiovascular 1.0%
Palpitations 0.2%
Special Senses 0.9%
Taste disorder 0.1%
Tinnitus 0.1%
Orbital Edema <0.1%
Urogenital 0.9%
The adverse reactions reported for PEPCID® 
Tablets may also occur with PEPCID® I.V. In 
addition, transient irritation at the injection site has 
been observed with PEPCID® I.V.
Laboratory Abnormalities
Laboratory parameters may be affected during 
treatment with PEPCID®, but the changes are 
usually not considered serious. Among the 
laboratory changes that were reported during 
clinical trials were increases in AST, ALT, BUN, and 
serum creatinine. These changes were rarely of 
clinical significance.
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Only three patients had to be discontinued from 
therapy because of laboratory adverse experiences, 
however laboratory abnormalities were present at 
baseline.
SYMPTOMS AND TREATMENT 
OF OVERDOSAGE
There is no experience to date with deliberate 
overdosage. Doses of up to 640 mg/day have been 
employed in patients with pathological hyper­
secretory conditions with no serious adverse 
effects. In the event o f overdosage, treatment 
should be symptom atic and supportive. Un­
absorbed material should be removed from the 
gastrointestinal tract, the pa tient should be 
monitored, and supportive therapy should be 
employed.
The oral LD50 of famotidine in male and female rats 
and mice was >5000 mg/kg.
DOSAGE AND ADMINISTRATION 
DUODENAL ULCER 
Acute Therapy
The recommended adult oral dosage of PEPCID® 
(famotidine) for acute duodenal ulcer is 40 mg once 
a day at bedtime. Treatment should be given for 
4-8 weeks, but the duration of treatment may be 
shortened if healing can be documented. Healing 
occurs within 4 weeks in most cases of duodenal 
ulcer.
Maintenance Therapy
For the prevention of recurrence of duodenal ulcer, 
it is recommended that therapy with PEPCID® be 
continued with a dose of 20 mg once a day at 
bedtime, for a duration of up to  6-12 months 
depending on the severity of the condition.
BENIGN GASTRIC ULCER 
Acute Therapy
The recommended adult oral dosage for acute 
benign gastric ulcer is 40 mg once a day at bedtime. 
Treatment should be given for 4 to 8 weeks, but the 
duration of treatment may be shortened if healing 
can be documented.
PATHOLOGICAL HYPERSECRETORY CON­
DITIONS (SUCH AS ZOLLINGER-ELLISON  
SYNDROME)
The dosage of PEPCID® in pa tie n ts  w ith 
pathological hypersecretory conditions varies with 
the individual patient. The recommended adult oral 
starting dose for pathological hypersecretory 
conditions is 20 mg q6h. In some patients, a higher 
starting dose may be required.
Doses should be adjusted to individual patient 
needs and should continue as long as clinically 
indicated. Doses up to 160 mg q6h have been 
adm inistered to some pa tien ts  w ith  severe 
Zollinger-Ellison syndrome.
Intravenous Administration
In some hospitalized patients with pathological 
hypersecretory conditions or intractable ulcers, or 
in patients who are unable to take oral medication, 
PEPCID® I.V. may be administered. The recom­
mended dosage is 20 mg every 12 hours.
Intravenous injection therapy should be changed to 
oral treatment as soon as the acute situation is 
under control.
Concomitant Use with Antacids
Antacids may be given concomitantly if needed.
Dosage Adjustment for Patients with Severe Renal 
Insufficiency
In patients with advanced renal insufficiency, i.e., 
with a creatinine clearance less than 10 mL/min„ 
the elimination half-life of PEPCID® may exceed 
12 hours reaching approximately 24 hoursinanuric 
patients.
To avoid excess accumulation of the drug, the 
dosing interval of PEPCID® may be prolonged to 
36-48 hours as indicated by the patient's clinical 
response.
PHARMACEUTICAL INFORMATION
COMPOSITION
Tablets
Each tablet for oral administration contains either 
20 mg or 40 mg of famotidine.
Injection
Each mL of the solution for intravenous injection 
contains 10 mg of famotidine and the following 
inactive ingred ien ts: L -aspartic  acid 4 mg, 
mannitol 20 mg, and Water for Injection, q.s., 1 mL. 
The multidose injection also contains benzyl 
alcohol 0.9% added as preservative.
RECONSTITUTION 
Parenteral Products
Dilution of PEPCID® I.V. 
for Infusion
PEPCID®  I.V. 
Solution
VOL...4  of 
Compatible 
I.V. Solution
Final
Volume
Final
Concentration
Rate of 
Infusion
2  m L 3  m L 5  m L 4  m g /m L N o t  le s s  th a n  
2  m in u te s
2  m L 8 m L 10  m L 2  m g /m L N o t le s s  th a n  
2  m in u te s
2  m L 1 0 0 m L 10 2  m L 0 .1 9 6  m g /m L 1 5 -3 0  m in u te s
PEPCID® I.V. Solutions are compatible with:
Water for Injection
0.9% Sodium Chloride Injection 
5% Dextrose Injection 
10% Dextrose Injection 
Lactated Ringer's Injection 
Sodium Bicarbonate Injection 5%
STABILITY AND STORAGE 
RECOMMENDATIONS
PEPCID® I.V. Solution
Store at 2 - 8°C. Protect from light. If solution 
freezes, bring the solution to room temperature; 
a llow  s u ff ic ie n t tim e to  so lu b ilize  a ll the 
components.
Diluted PEPCID® I.V. Solutions should be used 
within 24 hours due to the possibility of microbial 
contamination during preparation.
NOTE: Parenteral drug products should  be 
inspected visually for particulate matter and 
d isco louration p rio r to  adm inistration 
whenever solution and container permit.
DOSAGE FORMS AND AVAILABILITY
Tablets  PEPCID® (fa m o tid in e  ta b le ts ) are 
D-shaped, film-coated tablets supplied as follows:
No. Ca 8102 - 20 mg beige c o lo u re d , 
coded 963. Available in bottles of 100 tablets. 
No. Ca 8103 - 40 mg light brownish orange, 
coded 964. Available in bottles of 100 tablets.
No Ca3539 - PEPCID® I.V., 10 mg per 1 mL, is a 
clear, colourless solution and is available as a non- 
preserved unit dose containing 2 mL of injectable 
solution. Available in 10 x 2 mL vials.
No. Ca3541 - PEPCID® I.V., 10 mg per 1 mL, is a 
clear, colourless solution and is available as a 
preserved m ultip le dose containing 4 mL of 
injectable solution. Available in 4 mL vials.
HUMAN PHARMACOLOGY
In both normal volunteers and hypersecretors, 
PEPCID® inhibited basal nocturnal and daytime 
gastric secretion, as well as secretion stimulated by 
a variety of stimuli, such as pentagastrin and food.
After oral administration, the onset of the anti- 
secretory effect occurred within one hour; the 
maximum effect was dose-dependent, occurring 
within one to three hours. Duration of inhibition of 
secretion was 10 to 12 hours. After intravenous 
administration, the maximum effect was achieved 
within 30 minutes. Single intravenous doses of 10 
and 20 mg inhibited basal nocturnal secretion fo ra  
period o f 10-12 hours. The 20 mg dose was 
associated with the longest duration of action in 
most subjects. Single oral doses of 20 and 40 mg 
inhibited basal nocturnal acid secretion in all 
subjects; mean gastric acid secretion was inhibited 
by 86% and 94%, respectively, fo ra  period of at least 
10 hours. Sim ilar doses given in the morning 
suppressed food-stimulated acid secretion in all 
subjects, with mean suppression of 76% and 84%, 
respectively, 3 to 5 hours after drug, and of 25% and 
30%, respectively, 8 to  10 hours a fte r drug; 
however, in some subjects who received the 20 mg 
dose, the antisecretory effect was dissipated earlier, 
within 6-8 hours. There was no cumulative effect 
with repeated doses. The basal nocturnal intra- 
gastric pH was raised by evening doses of 20 and 
40 mg of PEPCID® to mean values of 5.0 and 6.4, 
respectively. When PEPCID® was given in the 
morning, the basal daytime interdigestive pH at 3 
and 8 hours after 20 or 40 mg of PEPCID® was 
raised to about 5.0.
Fasting and postprandial serum gastrin levels may 
be s lig h tly  elevated du ring  periods o f drug 
antisecretory effect, and with chronic therapy an 
increase in gastric bacterial flora may occur. Gastric
emptying and exocrine pancreatic function are not 
affected by PEPCID®.
Other effects
Systemic pharmacologic effects of PEPCID® in the 
CNS, cardiovascular, respiratory o r endocrine 
systems have not been found to date. Serum 
prolactin levels do not rise after intravenous bolus 
doses of 20 mg PEPCID® and no antiandrogenic 
effects have been detected.
Pharmacokinetics
PEPCID® is incompletely absorbed. The bioavaila­
bility of oral doses is 40-45%. Bioavailability may be 
slightly increased by food, or slightly decreased by 
acntacids; however, these effects are of no clinical 
consequence. PEPCID® undergoes minimal first- 
pass metabolism. After oral doses, peak plasma 
levels occur in 1-3 hours. Plasma levels after 
multiple doses are similar to those after single 
doses. Fifteen to 20% of PEPCID® in plasma is 
protein bound. PEPCID® has an elimination half-life 
of 2.5-3.5 hours. PEPCID® is eliminated by renal 
(65-70%) and metabolic (30-35%) routes. Renal 
clearance is 250-450 mL/min., indicating some 
tubular excretion.
Twenty-five to 30% of an oral dose and 65-70% of an 
intravenous dose are recovered in the urine as 
unchanged com pound. The on ly  m e tabo lite  
identified in man is the S-oxide. There is a close 
relationship between creatinine clearance values 
and the elimination half-life of PEPCID®. In patients 
with severe renal insufficiency, i.e., creatinine 
clearance less than 10 mL/min., PEPCID® elimi­
na tio n  h a lf - li fe  may exceed 20 h o u rs  and 
adjustment of dosing intervals may be necessary 
(see PRECAUTIONS, DOSAGE AND ADMINIS­
TRATION). In e lde rly  patients, there are no 
clinically significant age-related changes in the 
pharmacokinetics of PEPCID®.
PRODUCT MONOGRAPH AVAILABLE 
ON REQUEST
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®Trademark Merck & Co., Inc./
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BOOK REVIEWS
continued from page 88
text focuses on reconstructive mi­
crosurgery, which incorporates both re­
plantation surgery and free tissue trans­
fers. The subject matter, therefore, is 
chiefly of interest to plastic and ortho­
pedic surgeons, subspecialists in the 
area of head and neck surgery and 
neurosurgeons interested in peripheral 
nerve surgery.
The text is divided into 10 sections; 
the portion on free tissue transfers and 
peripheral nerve surgery is the strong­
est. The chapters are quite brief, usual­
ly four to five pages long, with a wide 
range of references and very clear sche­
matic illustrations. The value of this 
text is that it is all-encompassing and 
highly specialized and emphasizes the 
most recent advances. I would recom­
mend it to those with a special interest 
in reconstructive microsurgery or repair 
of peripheral nerves. It is beautifully 
organized and is a superb text for 
obtaining new ideas. There is little 
doubt that this book belongs in the 
library of any surgeon doing recon­
structive microsurgery.
Rollin K. Daniel, MD, FACS
Ste. 308,
1441 Avocado,
Newport Beach.
CA 92660
PRINCIPLES OF BILIARY LITHO­
TRIPSY. Edited by Alexander S. Cass 
and LeRoy H. Stahlgren. 104 pp. II- 
lust. Futura Publishing Company, Inc., 
Mount Kisco, NY. 1989. $25 (US). 
ISBN 0-87993-349-6
Extracorporeal shock-wave lithotripsy 
was first used to treat gallstones in 
Germany in 1985. Many trials are now 
under way in North America and Eu­
rope to validate this new technique.
In this book, the authors first review 
the physics and mechanics of lithotrip- 
tors. They discuss the different methods 
of shock-wave generation, which in­
clude the spark-gap electrode generator 
system and the microexplosive, laser,
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piezoelectric and electromagnetic de­
vices. With the most up-to-date litho- 
triptors, the patient does not have to lie 
in a water bath for coupling of the 
shock waves. Water is separated from 
the patient by a thin membrane.
The second chapter is devoted to the 
use of lithotriptors for kidney stones. It 
is a concise review of indications, re­
sults and side-effects of the procedure.
Dr. Robert D. Mackie, one of the 11 
contributors describes, briefly, in chap­
ter 3, bile physiology and gallstone 
formation. He explains how sludge and 
small stones may be protected from 
expulsion from the gallbladder by the 
tenacious mucous coat and how factors 
promoting bile stasis in the gallbladder 
may also contribute to gallstone forma­
tion.
In chapter 4, ultrasonography is de­
scribed as the best gallstone imaging 
method for performing the procedure. I 
find ultrasonography very useful except 
in obese patients in whom neither the 
gallbladder nor the gallstone can be 
visualized.
After a brief overview, in chapter 5, 
of gallstone management either with 
biliary salts, solvents or surgery, chap­
ters 6 and 8 deal specifically with biliary 
extracorporeal shock-wave lithotripsy. 
Patient selection, results of treatment 
and side-effects are presented.
Most investigators limit lithotripsy to 
symptomatic patients having no more 
than three radiolucent stones, none 
exceeding 3 cm in diameter. We con­
firm the high stone fragmentation rate 
(greater than 90%) described. Over the 
last 8 months, we have treated 30 
patients who had a solitary radiolucent 
stone in the gallbladder, not exceeding 
3 cm in diameter. We noticed that small 
stones were more rapidly destroyed 
than larger ones. Although that treat­
ment may have to be repeated once, 
twice or even three times before suffi­
cient fragmentation (less than 5 mm in 
size) is obtained, patient acceptance of 
this technique is high because it is 
performed under intravenous analgesia 
with minimal pain and virtually no 
complications of clinical importance. 
We now perform the procedure on an 
outpatient basis.
We believe bile salts should be con­
sidered a necessary adjuvant therapy to
solubilize remaining fragments. The au­
thors report a stone clearance rate 
similar to that for renal lithotripsy, that 
is, more than 90%, a figure similar to 
ours. Only a few of our patients have 
completed treatment. In many cases 
small residual fragments are in the 
process of being dissolved by bile salts.
Although long-term follow-up data 
are insufficient to predict stone recur­
rence after lithotripsy, one may look for 
guidance to the results after dissolution 
therapy. In this book the authors men­
tion a possible 5-year recurrence rate of 
close to 50%.
Presently available lithotriptors with 
their technical characteristics and cost 
are described in chapter 7 which also 
deals with investment and operating 
costs, coverage and reimbursement in 
the United States. Since the technique 
is still considered experimental, there is 
presently no reimbursement in Canada 
for extracorporeal shock-wave lithotrip­
sy.
This book is a concise review of 
presently available data and should 
serve as introduction for any one inter­
ested in this new field of nonsurgical 
treatment of gallstones.
Yves-Marie Dion, MD, MSc, FRCSC
Professor o f Clinics,
Universite Laval,
Department o f Surgery,
Hopital St-Franpois d Assise,
Quebec, PQ
ORTHOPAEDICS AND FRACTURES. 
A Question and Answer Study Guide. 
E. Edmund Graham. 255 pp. Illust. 
Butterworths, Stoneham, Mass. 1988. 
$16.95 (US). ISBN 0-407-01188-9
C. Edmund Graham, visiting orthopedic 
surgeon at the Prince of Wales Hospital 
in Sydney, Australia, has authored this 
interesting new text.
The format is one of columns of 
questions on the left side of the page 
with answers on the right. The author 
recommends spending no more than 10 
seconds on each question before mov­
ing to the next. Peeking, of course, is
continued on page 156
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Augmentation Ileocystoplasty in Children 
With Myelodysplasia
Eric M. Webber, MD;* Paul G. Crofts, MD;* Carole Pomeroy, BSc;* Gerald U. Coleman, MD, FRCSCit 
William J. Arnold, MD, FRCPC;$ Hjalmar W. Johnson, MD, FAAP, FRCSCt
Over the past 8 years 20 children suffering from myelodysplasia were selected to 
undergo augmentation ileocystoplasty for urinary incontinence refractory to 
treatment by clean, intermittent catheterization and anticholinergic agents, or as 
part of urinary undiversion.
The children ranged in age from 5 to 17 years, and the follow-up ranged from 6 
months to 7 years. Three children underwent undiversion, two had vesicostomy 
closure and six had bladder outlet repair at the time of augmentation. In one patient, 
surgery was technically impossible.
Postoperatively 16 children were fully continent on clean, intermittent 
catheterization and anticholinergic medication. Three boys failed to achieve 
satisfactory continence.
Delayed perforation, a potentially serious complication, occurred in two patients 
several months postoperatively.
Au cours des 8 dernieres annees, 20 enfants souffrant de myelodysplasie ont ete 
choisis pour subir une ileocystoplastie d’augmentation de volume, pour une 
incontinence urinaire resistante aux traitements par catheterisme propre intermit­
tent ou par medication anticholinergique, ou dans le cadre d’une derivation urinaire.
L’age des enfants a varie de 5 a 17 ans, et le suivi s'etalait sur de 6 mois a 7 ans. 
Au moment de l’ileocystoplastie, trois enfants ont subi une derivation, deux ont eu 
une fermeture de vesicostomie et six eurent une reparation de l'orifice vesiculaire. 
La chirurgie fut techniquement impossible chez un patient.
En postoperatoire, 16 enfants sont devenus parfaitement continents, soit par 
catheterisme propre intermittent, soit par medication anticholinergique. Trois 
garfons n’ont pu atteindre une continence satisfaisante.
Une perforation tardive, complication potentiellement serieuse, est survenue chez 
deux patients plusieurs mois apres l'operation.
The majority of children who have a neurogenic bladder sec­
ondary to myelodysplasia achieve 
satisfactory urinary continence with 
clean, intermittent catheterization 
and anticholinergic medication. In 
the past, patients refractory to this
therapy often underwent urinary di­
version or suffered the ongoing 
inconvenience and social embarrass­
ment of incontinence. Now that the 
long-term results of diversion are 
available,1"3 attempts to maintain 
urinary tract continuity in conjunc­
tion with procedures to achieve 
continence have come to the fore­
front. In this paper, we report our 
8-year experience with 20 children 
who had a neurogenic bladder sec­
ondary to myelodysplasia and were 
selected for treatment by augmenta­
tion ileocystoplasty.
Patients and Methods
The meningomyelocele clinic at 
the B.C. Children’s Hospital carries 
out regular follow-up of 220 chil­
dren suffering from myelodysplasia; 
this includes those with menin­
gomyelocele, sacral agenesis and 
spinal cord tumour. Of these chil­
dren, 108 are maintained on clean, 
intermittent catheterization and an­
tibiotics for prophylaxis, with anti­
cholinergic agents as necessary to 
maintain continence. The remaining 
children suffer from persistent uri­
nary incontinence despite frequent 
catheterization and maximal doses 
of anticholinergic medication. Sev­
enteen of these children were select­
ed for augmentation ileocystoplasty 
between 1980 and 1988. In addi­
tion, three children with myelodys­
plasia who had previously had uri­
nary diversion (ileal loop conduit) 
underwent ileocystoplasty at the 
time of undiversion.
The children ranged in age from 
5 to 17 years. Augmentation ileo­
cystoplasty was successfully per­
formed on 19 children — 14 girls, 
ranging in age from 5 to 17 years 
(mean 12 years), and 5 boys, rang­
ing in age from 6 to 17 years (mean 
11 years). In one boy, surgery was 
technically impossible.
Preoperatively, all patients were
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assessed by history and physical 
examination, with emphasis on the 
method of urinary management, 
motivation and compliance with 
therapy. Radiologic evaluation in­
cluded renal and abdominal ul­
trasonography, voiding cystoure­
thrography and, in those children 
who had undergone urinary diver­
sion, loopography. The serum con­
centrations of urea and creatinine 
were used to assess renal function.
In patients with abnormal upper 
urinary tracts or serum creatinine 
levels, renal function was also eval­
uated by nuclear renography. 
Urodynamic studies included cys- 
tometrography, to evaluate bladder 
capacity and pressures, and urethral 
pressure profilometry, to estimate 
outlet resistance. Preoperative blad­
der capacity ranged from 75 to 250 
ml (mean 180 ml). A maximal 
urethral pressure of less than 25 
cm H20  was taken as an indication 
for bladder outlet repair. Five chil­
dren (three girls, two boys) had 
previously undergone bladder outlet 
repair — Burch urethrovesical sus­
pension for girls and a modified 
Young-Dees repair for boys — but 
had remained incontinent. Bladder 
cycling was instituted on those who 
had undergone diversion.
Augmentation cystoplasty was 
performed by anastomosing an iso­
lated, detubularized segment of dis­
tal ileum to the dome of the bladder 
as described by Goodwin and col­
leagues.4 In those who had previ­
ously undergone urinary diversion, 
the segment of ileum constituting 
the ileal loop was used as a patch to 
augment the bladder. At the time of 
augmentation, three children under­
went urinary undiversion and two 
had vesicostomy closure. Six girls 
with decreased outlet resistance 
(maximal urethral pressure less 
than 25 cm H20) on preoperative 
urodynamic studies underwent 
Burch urethrovesical suspension 
(Table I). Two patients had success-
136 CJS, VOL. 33, NO. 2, APRIL 1990
ful antireflux procedures (one ure­
teral reimplantation and one subu- 
reteric Teflon injection) at the time 
of augmentation for coexisting vesi­
coureteral reflux.
Results (Table II)
The augmentation ileocystoplasty 
was successfully carried out in 19 
of the 20 children. In one child 
extensive adhesions from previous 
abdominal surgery prevented ade­
quate mobilization of the ileum. A 
second attempt at mobilization of 
the sigmoid colon was also unsuc­
cessful and the procedure was again 
abandoned. This child remains in­
continent on clean, intermittent 
catheterization and anticholinergic 
medication.
The 19 patients have been fol­
lowed up for an average of 25 
months (range from 6 to 74 
months). All are on clean, intermit­
tent catheterization and, on this 
protocol, 16 (84%) who underwent 
augmentation ileocystoplasty have 
achieved full urinary continence, in­
cluding 6 girls who underwent con­
comitant bladder neck suspensions. 
Ten patients require anticholinergic 
medication to prevent nocturnal en­
uresis. Three boys have some de­
gree of incontinence. Two of them 
had unsuccessfully undergone a 
Young-Dees bladder neck recon­
struction. Compliance with clean, 
intermittent catheterization is a 
problem for one patient and the 
other two are being considered for 
implantation of an artificial sphinc­
ter.
In accordance with our clinic pol­
icy for myelodysplastic children on
Table I. Associated Procedures
Procedure No.
Urinary undiversion 3
Vesicostomy closure 2
Antireflux procedure 2
Bladder outlet repair 6
Female 6
Male 0
clean, intermittent catheterization, 
all the children receive antibiotics 
prophylactically. There is a 30% to 
35% incidence of asymptomatic bac- 
teruria, and the need for and effects 
of this prophylaxis are currently 
being investigated in a prospective 
study.
Fifteen patients who underwent 
urodynamic testing postoperatively 
showed on average a doubling of 
their preoperative bladder capacity. 
The mean postoperative bladder ca­
pacity was 380 ml (range from 100 
to 750 ml). All three incontinent 
boys also showed at least a dou­
bling of bladder capacity.
Renal function remained normal 
postoperatively in 17 children who 
had normal function preoperatively. 
One of two patients with impaired 
renal function preoperatively 
showed a progressive decline in 
function, while in the other renal 
function remained stable. In 10 
children who had a normal upper 
urinary tract preoperatively, radi­
ologic follow-up showed no change, 
and there was no worsening of 
hydronephrosis in the remaining pa­
tients. In two patients who required 
antihypertensive medication preop­
eratively, the pressure remained 
well controlled on the same medica­
tion postoperatively.
The average postoperative hospi­
tal stay was 20 days (range from 13 
to 49 days). Early complications in 
hospital were rare. One wound in­
fection occurred in the first week. A 
partial small-bowel obstruction oc-
Table II. Results and Complications
Result/complication No. (%)
Continent 16(84)
Incontinent 3(16)
Complications
Early
Wound infection 1 (5)
Partial bowel obstruction 1(5)
Urine leak 1(5)
Late
Pyelonephritis 2(11)
Decreased renal function 1(5)
Delayed perforation 2(11)
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curring 4 days postoperatively re­
solved with conservative, nonopera­
tive management. In one patient 
who underwent undiversion and 
ileocystoplasty, a urine leak devel­
oped from a ureteroureterostomy 
and persisted for 40 days. Mucus 
production is common in the early 
postoperative period and requires 
frequent, regular irrigations of the 
augmented bladder to prevent cath­
eter blockage. In patients who have 
an especially heavy production of 
mucus we have used the mucolytic 
agent acetylcysteine in the bladder 
irrigation solution. Mucus produc­
tion uniformly declines within a few 
months.
Late complications seldom oc­
curred. Two children with an abnor­
mal upper urinary tract preopera- 
tively had pyelonephritis, requiring 
hospital admission and treatment 
with intravenously administered an­
tibiotics. Two patients required ad­
mission for evaluation and treat­
ment of abdominal pain. In both 
instances this settled spontaneously 
and no cause was found. Postopera­
tive diarrhea has not been a prob­
lem.
Two patients suffered delayed 
perforation of the augmented blad­
der. This potentially fatal complica­
tion occurred 17 months postopera­
tively in one patient. The child 
presented with fever and abdominal 
pain which progressed to peritonitis 
and septic shock. At laparotomy a 
small perforation at the ileovesical 
anastomosis was identified and re­
paired primarily. The subsequent 
clinical course was uncomplicated. 
The other perforation occurred in a 
patient who underwent a 3-hour 
nonurologic surgical procedure 
without bladder catheterization in- 
traoperatively and for 8 hours post­
operatively. During that time pro­
gressive abdominal pain developed 
and upon catheterization only a 
small volume of urine was obtained. 
Laparotomy confirmed a perforation
which was repaired primarily. 
Discussion
Clean, intermittent catheteriza­
tion has proven to be a safe, effec­
tive method of providing urinary 
continence in the majority of myelo- 
dysplastic children with neurogenic 
bladders,5 especially when combined 
with anticholinergic agents and an­
tibiotics. Patients remaining incon­
tinent despite these measures com­
monly have high-pressure, low- 
capacity bladders or decreased out­
let resistance, or both. Bladder aug­
mentation, with or without bladder 
outlet procedures, has become in­
creasingly popular in the manage­
ment of these difficult cases, and 
has been safely performed for 40 
years.6 7 The segment of bowel used 
does not appear to influence the 
postoperative result.8-11 The de­
creased uninhibited contractions re­
cently demonstrated in bladders re­
constructed with detubularized 
bowel would appear to favour this 
approach.12 We used a cup patch of 
ileum in all cases and were not 
limited by mesenteric length, al­
though we could not mobilize any 
segment of bowel in one case. In 
the patients who underwent undi­
version we did not implant the 
ureters into the bowel segment of 
the augmented bladder but per­
formed ureteroureterostomies to 
the stumps of the native ureters.
Preoperative assessment is essen­
tial to determine the precise nature 
of the incontinence and to ensure 
that increasing bladder capacity will 
improve continence. In addition, 
preoperative urodynamic studies 
identify those patients who will ben­
efit from bladder outlet procedures. 
In patients with normal outlet re­
sistance and a small capacity blad­
der for their age, we have per­
formed augmentation ileocystoplas­
ty alone. Those who have maximal 
urethral pressures of less than 25
cm H20  require a bladder outlet 
procedure which can be combined 
with augmentation in those patients 
who also have small capacity blad­
ders. The degree of motivation of 
the child and family, as well as the 
ability and determination to perform 
self-catheterization regularly for life 
must play an important part in 
patient selection for augmentation, 
because this procedure will surely 
result in ineffective bladder empty­
ing. A successful outcome requires 
an increase in functional bladder 
capacity with an absence of 
high-pressure, uninhibited, detrusor 
contractions and adequate outlet 
resistance. These factors must be 
coupled with regular bladder empty­
ing by clean, intermittent catheter­
ization and can be assisted by the 
use of anticholinergic agents as 
needed. In our series, use of these 
techniques resulted in complete 
continence in 16 (84%) of 19 pa­
tients. This is comparable to the 
results of others who reported con­
tinence rates ranging from 82% to 
100%.1013-15 Bladder capacity was 
on average doubled in our series. 
Six of 14 girls also underwent ure- 
throvesical suspension procedures; 
all were subsequently continent. 
Those remaining incontinent after 
augmentation ileocystoplasty in our 
series were all boys. The reasons for 
lack of success can be attributed to 
poor compliance to clean, intermit­
tent catheterization and medication 
by one patient and to an incompe­
tent bladder neck despite a prior 
Young-Dees reconstruction in two 
others. These boys might benefit 
from placement of an artificial 
sphincter.
There have been relatively few 
complications associated with aug­
mentation ileocystoplasty in our se­
ries. We maintain all our patients 
on antibiotics for long-term sup­
pression of infection and have had 
only two cases of pyelonephritis, 
both in patients with persistent ve-
CJS, VOL. 33, NO. 2, APRIL 1990 137
WEBBER, ET AL.
sicoureteric reflux; renal function 
deteriorated in one patient.
Delayed perforation of the aug­
mented bladder is a potentially fatal 
complication that must be borne in 
mind when patients with an aug­
mented bladder present with ab­
dominal pain or fever. The underly­
ing cause may be chronic overdis­
tension of the augmented bladder 
associated with chronic bacteriuria 
and catheter trauma. In these perfo­
rations the cystogram may give 
negative results and because of im­
paired sensation in myelodysplastic 
patients who undergo augmentation 
cystoplasty they may be difficult to 
diagnose.1617
Conclusions
Augmentation ileocystoplasty is 
an effective treatment in carefully 
selected myelodysplastic patients 
who have persistent incontinence 
despite frequent, clean, intermittent 
catheterization and pharmacologic 
manipulation. Full preoperative 
evaluation of the patient’s personal­
ity and urodynamic studies to iden­
tify those who may benefit from 
bladder outlet procedures is essen­
tial to ensure the best result. The 
potential risk of delayed perforation 
of the augmented bladder must al­
ways be considered and careful 
long-term follow-up provided. 
Long-term commitment by the pa­
tient, family and health care person­
nel is necessary for success.
We thank Drs. J.S.T. Masterson and 
P.J. Moloney for allowing us to include 
their patients in this paper.
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Severe Secretory Diarrhea With Elevated 
Gastrin-Releasing Peptide Controlled by 
Somatostatin Analogue: a Case Report
Ritha Alhindawi, MD;* Mervyn Deitel, MD, FRCSC;*t John Kempston, MD, FRCPC;J 
Mansour Bendago, MD*
Gastrin-releasing peptide immunoreactivity has been seen in functioning endocrine 
tumours which are recognized as a major cause of secretory diarrhea. The authors 
describe a case of a 52-year-old woman who had secretory diarrhea (5 L/d) with 
markedly elevated gastrin-releasing peptide levels associated with islet cell 
hyperplasia. No tumour could be identified. The diarrhea was controlled by 
somatostatin analogue.
Une immunoreactivite au peptide qui libere la gastrine a ete observee dans des cas 
de tumeurs endocrines fonctionnelles, lesquelles sont reconnues comme cause 
importante de diarrhee secretaire. Les auteurs decrivent le cas d’une femme de 52 
ans qui souffrait de diarrhee secretaire (5 L/j); il y avait une augmentation marquee 
des taux de peptide qui libere la gastrine reliee a une hyperplasie des cellules des 
llots de Langerhans. Aucune tumeur n’a pu etre identifiee. La diarrhee fut maitrisee 
grace a un analogue de la somatostatine.
S ecretory diarrhea due to endo­crine tumours such as gas­
trinoma, glucagonoma and vipoma 
has been reported.1 An elevated 
level of secondary peptides, includ­
ing gastrin-releasing peptide (GRP), 
substance P, neurotensin and pan­
creatic polypeptide (PP) has been 
associated with these tumours.2 
However, no case of secretory diar­
rhea with GRP hypersecretion alone 
has been reported.
Case Report
A previously healthy, 52-year-old
Accepted for publication June 29, 1989
white woman was transferred to St. 
Joseph’s Health Centre in January 
1987 from another hospital. She 
had a 2-month history of diarrhea 
(up to 5 L/d) and weight loss (11 
kg). Physical examination revealed 
moderate dehydration. Admission 
electrolyte values were potassium 
2.0 mmol/L, sodium 120 mmol/L, 
chloride 92 mmol/L and calcium 
1.94 mmol/L. In hospital, her diar­
rhea continued at a rate of more 
than 2 L/d, even under fasting 
conditions. Preliminary investiga­
tions (Table I) suggested a secretory 
diarrhea of unknown etiology. 
Small-bowel biopsy showed infiltra­
tion of the lamina propria with 
chronic inflammatory cells. Biopsy 
cultures were normal. Gastric secre­
tory analysis and the pentagastrin 
test gave normal results. No ab­
sorption of D-xylose was found. The 
stool osmotic gap was 12 
mOsm/kg. Computed tomography 
of the entire body did not disclose a 
tumour.
Endocrine hormonal assay (EHA) 
(Table II) was measured by plasma 
radioimmunoassay (RIA) by Dr. 
T.M. O’Dorisio, Core Peptide Labo­
ratory, Ohio State University Hospi- 
al, using, respectively, rabbit anti­
sera no. 674 to synthetic porcine 
vasoactive intestinal polypeptide 
(VIP), rabbit antiserum 615-1054 
B-248-19 to human PP, rabbit anti­
body D-4 to somatostatin (1-14), 
rabbit antibody TR 208 to neuro­
tensin, rabbit antisera R-1C to sub­
stance P, rabbit antiserum LR-16 to 
synthetic GRP3 and goat antiserum 
G 1701 to human calcitonin.4 
Serum gastrin RIA was performed 
by Dr. P. Wong, Immunoassay Lab­
oratory, Toronto General Hospital, 
using rabbit gastrin antibody.5 The 
endocrine hormonal assay showed 
mild elevation of PP on admission 
and 1 month later (Table II).
A trial of a pancreatic enzyme 
supplement (Cotazyme 20 tab/d) 
was not helpful. The patient was 
put on loperamide 4 mg four times 
daily, with no improvement. The 
volume of diarrhea averaged 3.5 
L/d. Methylprednisolone, 20 mg 
three times daily intravenously for 4
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weeks, reduced the volume of diar­
rhea to 2.7 L/d. Five months after 
her admission, lower abdominal 
pain, distension and vomiting devel­
oped and the diarrhea continued. 
Endocrine hormonal assay found 
elevated levels of PP and substance 
P. Abdominal x-ray films were com­
patible with intestinal obstruction 
(Fig. 1). After she was managed 
conservatively for 10 days without 
improvement, a thorough explor­
atory laparotomy was done; no ab­
normality was found except that the 
pancreas was somewhat firm to pal­
pation. The body and tail of the 
pancreas and the spleen were re­
moved.
Histologic examination of the 
pancreas showed interstitial fibrosis 
and infiltration with chronic inflam­
matory cells. Islet cell hyperplasia 
was seen in several areas (Fig. 2). 
No mitotic figures or abnormalities 
were seen on electron microscopy. 
The islets showed positive im- 
munostaining for neuron-specific 
enolase and chromogranin (using
the avidin-biotin-peroxidase com­
plex technique), but negative for 
gastrin, VIP and serotonin. Im- 
munostaining was also negative for 
human luteinizing hormone alpha 
subunit, which is the biologically 
inactive glycoprotein component of 
several hormones and is thought to 
be a marker of malignancy in pan­
creatic endocrine tumours.6
Diarrhea continued as before, and 
2 weeks postoperatively she was 
started on somatostatin analogue 
(SMS 201-995), the dose gradually 
being increased to 1000 tig subcu­
taneously twice daily. At this point, 
the diarrhea decreased to 670 m l/d 
and she started to gain weight. 
Since admission, she had been sup­
ported with total parenteral nutri­
tion. She was discharged home in 
September 1987, on ambulatory 
home total parenteral nutrition and 
somatostatin analogue, 1000 tig 
subcutaneously twice daily.
At follow-up in January 1988, 
the diarrhea had decreased to 550 
m l/d and she had gained 8 kg. The
somatostatin analogue was gradual­
ly decreased, so that by August 
1988, at which time she was taking 
250 tig twice daily, the diarrhea had 
decreased to 30 ml/d. Repeated 
EHA found serum GRP and sub­
stance P to be markedly elevated 
(Table II), but the PP level had 
returned to normal. Neurotensin 
levels were moderately elevated.
In September 1988, she was ad­
mitted to hospital with sudden tem­
perature (39°C) and chills, due to 
TPN catheter sepsis with Candida 
albicans. The Hickman catheter was 
removed, the fever resolved rapidly 
and she was discharged eating oral­
ly, on somatostatin analogue 100 
Hg twice daily. Subsequently, the 
analogue was decreased to 50 tig 
twice daily, and when last seen in 
April 1989 she was having soft, 
formed stools.
Discussion
The continuous diarrhea of more 
than 2 L /d while fasting and a 
stool osmotic gap of 12 mOsm/kg 
substantiate that abnormal intesti­
nal secretion was responsible for 
this diarrhea. The lack of substan­
tial improvement with steroid thera­
py contrasts with the results ob-
FIG. 1. Upright film showing air-fluid 
levels and poverty of gas in colon.
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tained by Priest and Alexander,7 
who used steroids in the manage­
ment of diarrhea due to islet cell 
tumours with good results.
Elevated PP levels raised the sus­
picion of a pancreatic apudoma.8 
The clinical picture and electrolyte 
values on admission as well as the 
picture suggestive of intestinal ob­
struction raised the suspicion of 
vipoma,9 but the normal level of 
VIP ruled out this diagnosis. In 
some cases of Zollinger-Ellison 
syndrome, the diarrhea may precede 
the ulcer symptoms by up to 8 
years,10 but in our patient the nor­
mal serum gastrin level ruled out 
this diagnosis.
Nishiyama and colleagues11 de­
scribed a patient with refractory 
watery diarrhea and hypokalemia 
due to islet cell hyperplasia and 
increased immunohistochemical re­
activity to serotonin. We, thus, sug­
gest that in our patient the islet cell 
hyperplasia with hypersecretion of
GRP and of substance P (primarily 
or secondarily to GRP) was respon­
sible for the diarrhea, since both 
GRP and substance P stimulate gas­
trointestinal motility. Moreover, 
substance P stimulates water and 
electrolyte secretion.10 However, be­
cause the diarrhea existed before 
the elevation of these hormones, 
the hyperplastic pancreas or an en­
docrine tumour elsewhere was like­
ly secreting other unknown hor­
mones, which were responsible for 
the diarrhea and pancreatic hyper­
plasia by direct action or by increas­
ing GRP secretion. This hypothesis 
agrees with that of Bostwick and 
Bensch12 who found positive GRP 
staining in most neuroendocrine tu­
mours and concluded that GRP 
should be used as a marker for 
these tumours.
Woltering and associates2 de­
scribed a case of insulinoma and a 
case of glucagonoma with mild ele­
vation of secondary peptides (GRP,
PP, substance P and neurotensin); 
however, in our patient the normal 
levels and the negative immunos- 
taining for glucagon, gastrin, VIP 
and serotonin ruled out these diag­
noses. Furthermore, in our patient 
the GRP levels were much more 
elevated than in Woltering’s cases.2 
Our decision to remove the body 
and tail of the pancreas agrees with 
the recommendation of Verner and 
Morrison1 and others11 that subtotal 
pancreatectomy should be per­
formed if laparotomy reveals a 
grossly normal pancreas but no 
other site of tumour, because these 
tumours could be tiny and detect­
able only by histologic examination.
Somatostatin analogue, SMS 
201-995, is a synthetic octapeptide 
with a much longer half-life than 
naturally occurring somatostatin 
and can be active when given sub­
cutaneously.1314 It effectively treats 
the clinical manifestations of hor­
monal excess caused by neuroendo­
crine tumours of the gastro-entero- 
pancreatic axis, by decreasing blood 
flow and reducing all gastrointesti­
nal secretions. It also affects water 
and electrolyte transport in the 
small intestine toward absorption 
and decreases the release of gut 
hormones.2'13”16 The latter effect 
could explain the decrease of PP 
after the administration of SMS 
201-995. The dose was increased 
until a substantial beneficial effect 
was achieved at 1000 ng twice daily 
and this agrees with the action of 
Ellison and colleagues14 who also 
increased the dose until a desirable 
effect was achieved.
In summary, in our patient no 
tumour and no elevated primary 
peptide was found, but the GRP 
levels were markedly elevated ac­
companying islet cell hyperplasia. 
We conclude that hypersecretion of 
GRP was probably responsible for 
this diarrhea.
The authors are indebted to patholo­
gists Kalman Kovacs, Segundo Mariz
FIG. 2. Area showing hyperplasia of islet cells (arrows) (hematoxylin and eosin, 
original magnification X 400).
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and Fred Harris, and to gastroenterolo­
gist Joseph G.D. Anderson for valuable 
assistance and also to Thomas M. O’Do- 
risio, Ohio State University in Colum­
bus, for the hormonal analyses.
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SESAP VI Critique
Items 82-84
The sudden onset and severe pain associated with a perforated duodenal ulcer usually cause the patient to seek 
medical attention shortly after the development of symptoms. Simple ulcer plication is adequate and safe 
treatment for the acute problem. Both retrospective and prospective studies indicate a high recurrence rate, 
however, especially for patients with a long-standing history of ulcer disease. Numerous studies show a 
reduction in recurrence, morbidity, and mortality when definitive procedures are performed in good-risk patients. 
In a recent prospective randomized double-blind trial, 35 patients with simple closure had a recurrence rate of 
63% versus a recurrence rate of 3.8% for 24 patients randomly assigned to undergo simple closure plus proximal 
gastric vagotomy. The higher recurrence rate and higher morbidity often associated with simple closure may be 
attributed to the procedure being performed in poor-risk patients. However, an immediate, nonresective 
definitive operation such as proximal gastric vagotomy can be both safe and effective for patients who have 
perforations associated with chronic duodenal ulcer disease. Although other definitive procedures to manage 
peptic ulcer disease have been described, the low mortality and morbidity associated with proximal gastric 
vagotomy make this procedure appealing. Several reports indicate that the long-term ulcer recurrence rate after 
proximal gastric vagotomy is in the range of 10% to 20%.
82[B]83[B]84[A]
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Perforated Duodenal Ulcer in the Elderly 
Patient
N. Werbin, MD; H. Kashtan, MD; I. Wasserman, MD; T. Wiznitzer, MD, FACS
Acute perforation of a duodenal ulcer in a patient over of 70 years of age is 
associated with a high death rate. During a 10-year period, 35 such patients were 
operated on; in all omentopexy was performed. Two courses of the disease were 
observed: the first (19 patients) was defined by acute disease of less than 24 hours’ 
duration preceding surgery; the second (16 patients) was of longer duration, 
starting with various abdominal complaints and presenting more severely only after 
the first 24 hours. Postoperative death rates were 0% in the first group and 50% in 
the second. Other factors that were studied, including diabetes mellitus, presence of 
concomitant malignant diseases and intake of ulcerogenic drugs, had no significant 
effect on the outcome in these patients.
Chez les personnes de plus de 70 ans, les perforations aigues d’ulceres duodenaux 
sont reliees a un fort taux de mortalite. Au cours d’une periode de 10 ans, 35 
patients repondant a cette description ont ete operes; une omentopexie fut pratiquee 
dans tous les cas. La maladie a offert deux tableaux cliniques differents. Dans le 
premier cas (19 patients), on a observe une atteinte aigue apparaissant moins de 24 
heures avant l’operation; dans le deuxieme cas (16 patients), Devolution se fit sur 
une plus longue periode, debutant par divers malaises abdominaux qui s’aggra- 
verent seulement apres les premieres 24 heures. Le taux de mortalite postoperatoire 
fut de 0% dans le premier groupe et de 50% dans le second. Chez ces patients, les 
autres facteurs etudies, dont la presence de diabete sucre, d’un cancer ou la prise de 
medicaments ulcerogenes, n'ont montre aucune influence significative sur Tissue de 
la maladie.
F ree perforation of a duodenal ulcer is an emergency that 
should lead to surgery within 
hours. Time is an important factor 
both in survival and in the selection 
of a surgical procedure.1 There is 
still debate2-3 over the proper surgi­
cal approach, that is omentopexy or 
a definitive, acid-reducing proce­
dure, but it is relevant only if the 
patient’s condition is stable. There
can be no such a debate when the 
patient is old, suffers from possibly 
life-threatening diseases and pres­
ents late in the course of acute 
illness. In these instances, a short, 
life-saving procedure, omentopexy, 
is indicated.4
In a retrospective study we re­
viewed all patients over the age of 
70 years who were operated for 
perforated duodenal ulcer in our
department between 1978 and 
1987.
Patients and Methods
During the 10-year period 35 
patients over the age of 70 years 
were operated for free perforation 
of a duodenal ulcer. There were 18 
men and 17 women and the mean 
age was 77.5 years (range from 70 
to 94 years) (Table I).
Nine patients had a history or 
evidence of malignant disease (ex­
cluding the upper gastrointestinal 
tract) and four of them were being 
treated for their malignant disease 
at the time of admission. Seven 
patients had diabetes mellitus and 
seven had been treated with ulcero­
genic drugs before the perforation 
occurred.
Nineteen patients underwent op­
eration within 24 hours of the onset 
of pain or other symptoms; the 
other 16 were operated on after 
more than 24 hours. All patients 
underwent omentopexy. Seven had 
an additional gastrostomy.
The results were analysed by the 
X2 and Student’s t tests.
Results
No breakdowns in the omen­
topexy repair were observed. The 
overall death rate was 22.8% (8 of 
35), and included one patient who 
was discharged apparently in good 
condition but was readmitted sever-
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Table I. The Influence of Time and Sex on Operative Death Rate of Perforated Duodenal Ulcer in
the Elderly Patient
Male Female Totals
Deaths Deaths Deaths
Time, h No. % No. % No. % No. % No. % No. %
<24 11 61.2 0 _ 8 47.1 0 _ 19 54.3 0 _
>24 7 38.8 3 42.9 9 52.9 5 55.5 16 45.7 8 50.0
Totals 18 100.0 3 16.6 17 100.0 5 29.4 35 100.0 8 22.8
al days later in septic shock origi­
nating from a urinary tract compli­
cation. The other causes of death 
were acute myocardial infarction 
(two), pulmonary embolism (one), 
massive pneumonia (one) and sepsis 
(three cases).
Five (29.4%) of 17 women died 
compared with 3 (16.7%) of 18 men 
(NS). The mean age of the women 
who died was 82.6 years and of the 
men 75 years (NS).
Three (33.3%) of nine patients 
with concomitant malignant diseas­
es died compared with 5 (19.1%) of 
the 26 patients without malignant 
disease (NS).
Two (28.6%) of 7 patients who 
had taken ulcerogenic drugs before 
admission died postoperatively com­
pared with 6 (21.4%) of the 28 
patients who had not taken these 
drugs (NS). Three (42.9%) out of 7 
diabetic patients died postoperative­
ly compared with 5 (17.9%) of the 
28 nondiabetic patients (NS); all 
deaths were in those in whom the 
time between the onset of symp­
toms and surgery was longer than 
24 hours — a death rate of 50%. 
There was no death in patients who 
were treated within 24 hours from 
the onset of symptoms (p < 0.001).
More women than men were op­
erated on longer than 24 hours 
from the onset of the disease — 9 
(52.9%) of 17 and 7 (38.9%) of 18, 
respectively.
Discussion
More than one-third of patients
with acute perforation of an ulcer 
are elderly,5 and their relative num­
ber will probably increase in the 
future, due to aging of the popula­
tion.
From our experience with perfo­
rated ulcers in elderly patients, we 
can suggest two hypothetical 
courses of the disease. The first, 
and the more benign one, consists 
of acute free perforation that leads 
the patient to seek early medical 
help, resulting in early surgical in­
tervention and a low death rate (0% 
in our series). The second course 
begins with a clinical picture that 
does not cause the patient to seek 
help immediately — perhaps a 
sealed perforation with localized 
peritonitis that only in a later stage 
progresses to reperforation and ad­
mission to hospital with severe dif­
fused peritonitis. We cannot prove 
this assumption, but most of the 
patients who were admitted late in 
the course of their disease described 
a mild gradual onset of pain in 
contrast to those admitted within 
few hours.
Boey and colleagues1 pointed out 
three risk factors that predict the 
outcome of surgery in perforated 
duodenal ulcer. According to their 
series, in the presence of major 
medical illness, preoperative shock 
and long-standing perforation, the 
postoperative death rate may reach 
100%. We had a high death rate 
(50%) that was related only to one 
risk factor. Therefore, these pa­
tients should be carefully assessed 
to determine the feasibility of sur­
gery. Alternatives to surgery in the
management of acute duodenal 
ulcer perforation are well known,16 
and in some patients these might be 
the treatment of choice.
The course of the disease for 
diabetic patients in our series was 
not more severe, as is recognized in 
other acute diseases such as chole­
cystitis or appendicitis.7
We did not compare definitive 
surgery with omentopexy and we 
do not have any follow-up data to 
suggest that a definitive procedure 
would have been more appropriate, 
but we can rely upon the literature8 
and upon our own immediate good 
results to suggest that no more 
than minimal surgery is indicated in 
these patients.
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Dermatobia hominis Myiasis 
Masquerading as an Infected Sebaceous 
Cyst
Drew B. Schembre, MD;* Charles R. Spillert, PhD;* M. Yusuf Khan, MD;f 
Eric J. Lazaro, MD, FACS, FRCSCt
In an apparently routine case, what appeared to be infected sebaceous cysts of the 
scalp turned out to harbour botfly larvae imported from a tropical country. Although 
the parasite Dermatobia hominis is not indigenous to the United States, cutaneous 
myiasis caused by the fly is fairly common in Central and South America, and 
several cases have been reported in people returning or emigrating from these 
regions. The authors therefore suggest that infection resulting from D. hominis 
invasion be considered in persons who present with furuncular lesions and give a 
history of travel to endemic areas.
Dans ce cas apparemment sans histoire, ce qui semblait etre un kyste sebace infecte 
du cuir chevelu s’avera contenir des larves de mouches de la famille des Oestrides 
contractees dans un pays tropical. Bien que le parasite, le Dermatobia hominis, ne 
soit pas indigene aux Etats-Unis, la myiase cutanee causee par cette mouche est 
relativement frequente en Amerique Centrale et en Amerique du Sud, et plusieurs 
cas ont ete signales chez des personnes revenant ou emigrant de ces regions. Les 
auteurs suggerent done d’entretenir la possibility d’une infestation a D. hominis 
chez les personnes porteuses de lesions furonculeuses, dont l’anamnese revele un 
voyage dans une region endemique.
T he parasite Dermatobia hominis is not indigenous to the United 
States, but cutaneous myiasis 
caused by it has been seen in per­
sons returning or emigrating from 
indigenous areas of Central and 
South America. We describe a case 
in which the parasite was found in 
sebaceous cysts at the time they 
were surgically excised.
Case Report
A 33-year-old man presented
Accepted for publication Apr. 25. 1989
complaining of two “bumps” on his 
scalp which had grown slowly and 
had become increasingly painful 
over several days. He noted that 
they itched constantly and had re­
cently begun to discharge clear yel­
low fluid. He did not remember 
being bitten by insects or receiving 
any injury to the area. He denied 
any constitutional symptoms such 
as fever, chills, lymphadenopathy or 
weight loss, and indicated that his 
health was otherwise excellent. 
Four weeks earlier, he had returned 
from a vacation to Belize, a small
country on the Gulf coast of Central 
America.
Physical examination was re­
markable only for two round, raised 
lesions, 1 to 2 cm in size and about 
2 cm apart, on the superior right 
parietal area of the scalp. The 
lumps were uniformly tender, ery­
thematous and oozed serosanguine- 
ous fluid.
Radiologic studies of the head 
gave normal results. The initial di­
agnosis was infected sebaceous 
cysts and incision and drainage of 
the cysts was scheduled. Under 
local anesthesia, a small incision 
was made over each cyst. In both 
lesions there was no cheesy materi­
al but, instead, two fragments of 
firm, dark-red tissue, one measur­
ing 2 cm in diameter, the other 1 
cm, which were easily removed. The 
specimens were submitted for his- 
topathological examination. The 
wounds were left open and dress­
ings applied. Tissue samples were 
later reported as larvae from the 
human botfly Dermatobia hominis 
(Fig. 1).
Discussion
Although Dermatobia hominis is 
found throughout South and Cen­
tral America, in North America, 
furuncular myiasis caused by this 
insect remains a disease imported 
by immigrants and international 
travellers.1 Over the past 10 years, 
only a few cases of botfly myiasis
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have been reported in North Ameri­
ca. As in our case, due to the rarity 
of this affliction, it is almost always 
initially diagnosed as an infected 
cyst.1-3
Dermatobia ho minis, better 
known as the human botfly, is a 
comparatively large, winged insect, 
15 to 18 mm long, having a yellow 
face, dark-blue thorax and a metall­
ic-blue abdomen. The term “human 
botfly” is a misnomer, for although 
the fly occasionally affects humans, 
it is more commonly found in do­
mestic and wild animals.4
The life cycle of D. hominis is 
interesting in that the female does 
not bring her eggs directly to the 
host, but instead captures a mos­
quito or other blood-sucking ar­
thropod and glues a batch of 14 to 
25 ovoid eggs to its abdomen. The 
mosquito seems to be the favourite 
vector of the Central American bot­
fly, while its southern cousins pre­
fer as their intermediaries flies that 
bite, such as Stomoxys and Si- 
phona, or even ticks. When the 
mosquito or fly lands on a warm­
blooded host, the larvae emerge and 
invade the skin. The puncture sites
FIG. 1. Larva of Dermatobia hominis 
which was removed from lesion (origi­
nal magnification X 37.5).
created by the vector usually pro­
vide the portals of entry, although 
the larvae are capable of burrowing 
into the skin on their own. While 
penetration often takes less than 1 
hour, the larvae can remain viable 
for up to 20 hours. Development 
requires from 46 days to 3 months, 
after which the larvae work their 
way out of the skin and fall to the 
ground to pupate in the soil.5 
Hands, ankles, head and other ex­
posed areas are most commonly 
involved, but larvae have been re­
ported in such obscure places as the 
spermatic cord and in the left hemi­
sphere of an infant, where the para­
site presumably settled after migrat­
ing through a patent anterior fon- 
tanelle.3-4
Symptoms may present as early 
as the first week or may go unno­
ticed for many days. Dermatobia 
hominis invasion commonly pres­
ents as one or more small raised 
lesions which resemble mosquito 
bites. Patients usually first experi­
ence mild pruritis, which, with time, 
becomes increasingly severe, partic­
ularly at night. By the third week, 
the site may resemble a small furun­
cle which exudes a moderate 
amount of serous or serosanguine- 
ous fluid. As the larva continues to 
grow, local destruction of tissue 
and production of toxic byproducts 
cause throbbing pain and muscle 
soreness, in addition to nearly cons­
tant pruritis. Actual movement and 
rotation of the parasite may cause 
excruciating pain.4 By the time 
symptoms compel the patient to 
seek medical attention, the lesion 
frequently resembles a local pyo­
genic infection. Associated lym­
phangitis or lymphadenitis may oc­
cur, although constitutional symp­
toms, if present at all, are usually 
mild.1
On close observation, the posteri­
or end of the larva can often be 
seen protruding through the skin 
opening which it must keep patent
in order to breathe. On Gram’s 
staining of the drainage from this 
opening many polymorphonuclear 
leukocytes and specks of amber- 
coloured fecal material are often 
seen but rarely is there any superin­
fection.1 The mature larvae measure 
18 to 24 mm in diameter and have a 
characteristic inverted flask shape. 
Before the larvae emerge, the 
swollen lesion may attain the size of 
a ping pong ball, but emergence 
itself rarely involves any sensation.5
Traditional methods for removing 
the parasite involve blocking the 
larval air supply with tobacco juice, 
butter or mineral oil to stimulate 
premature emergence.35 However, 
particularly when the larva is dead, 
a different technique is advisable. 
Injection of lidocaine or other aque­
ous anesthetic into and around the 
lesion anesthetizes both the area 
and the parasite. After several min­
utes, a small linear incision can be 
made to expose the larva, which 
may then be removed with forceps. 
The wound should then be irrigated 
thoroughly with sterile saline. If no 
infection is evident, the wound may 
be closed with interrupted dermal 
sutures. If there is any suspicion of 
remaining foreign material or bac­
terial infection, The wound should 
be left open and a dry dressing 
applied tightly.5
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HISTORY OF SURGERY
Class of Onety-Seven:T w o Heroes of the 
Part II
Peter B. Samuels, MD, MSc, FRCSC, FACS
Frederick Banting and Norman Bethune were linked in time, place of birth, as 
classmates in medical college, veterans of World War I and heroes to different 
worlds. Both were surgeons, sharing the decisiveness that is characteristic of the 
profession. Both had their surgical ambitions frustrated. Banting, a failed 
orthopedist, was sidetracked to research; Bethune, a successful surgeon inactivated 
by tuberculosis, was directed by his interest in his disease to thoracic surgery. 
Frustrated in his battle for socialized medicine, Bethune went to war against the 
Fascists in Spain and the Imperialists in China. Banting discovered insulin, but did 
little else in original research. However, he organized research in Canadian 
universities which studied pilot safety in air warfare in World War II.
The two heroes died within 2 years of each other, Bethune of an infection 
contracted at surgery on wounded Chinese soldiers and Banting in a plane crash 
while on a secret mission carrying his research results to Great Britain.
Frederick Banting et Norman Bethune partageaient plusieurs points communs: nes 
au meme moment et dans la meme region, ils devinrent compagnons de classe a la 
faculte de medecine, veterans de la premiere guerre mondiale et heros de deux 
mondes differents. Les deux etaient chirurgiens, partageant l’esprit de decision qui 
characterise la profession. Les deux virent leurs ambitions de chirurgiens deques. 
Banting, un orthopediste rate, devia vers la recherche; Bethune un chirurgien qui 
avait du succes mais qui avait ete arrete par la tuberculose, se dirigea, consequence 
de son interet pour sa maladie, vers la chirurgie thoracique. Frustre dans sa bataille 
pour socialiser la medecine, Bethune s’engagea dans la guerre contre les fascistes 
d’Espagne et les imperialistes de Chine. Banting decouvrit l’insuline, mais il ne 
contribua pas beaucoup plus a la recherche innovatrice. Toutefois, il organisa dans 
les universites canadiennes la recherche sur la securite des pilotes engages dans les 
combats aeriens au cours de la deuxieme guerre mondiale. Ces deux heros 
moururent a 2 annees l’un de l’autre, Bethune d’une infection contractee au cours 
d’une operation sur un soldat chinois, Banting dans l’ecrasement de son avion, en 
mission secrete, alors qu’il allait livre les resultats de ses recherches en Grande-Bre- 
tagne.
I n the preceding part of this sto­ry, both Banting and Bethune 
had gone beyond their medical call­
ing to enter a political arena. In this 
part, Bethune enlists his talents in
the battle against fascism, leading 
him to active work in conflicts in 
Spain and China. Banting rejoins 
the Canadian Army but is not per­
mitted to join the action he seeks
and instead is put in charge of 
Canada’s military medical research.
Blood to the Front
In July 1936, the outbreak of 
civil war in Spain gave Bethune the 
opportunity to fight directly against 
Fascism and, at the same time, 
provide care for many war casual­
ties. He immediately offered his 
services to the Canadian Red Cross 
but was rebuffed. There was no 
intention on the part of the Red 
Cross to afford aid to the Republi­
can government in Spain. Bethune 
read in a Canadian socialist maga­
zine of a plan to establish a Spanish 
hospital and medical aid committee, 
so he left for Toronto the next day, 
after wiring the editor of the publi­
cation that he was coming. He 
found the idea that the editor had 
proposed had no basis in fact. But 
since he was looking for money to 
go to Spain, he wasted no time. 
Working with the editor, he inter­
ested prominent antifascists of var­
ied political hues and worked with 
them to form the Committee to Aid 
Spanish Democracy. Bethune com­
mitted himself to this enterprise. He 
was, by this time, a Communist 
party member. He resigned his posi­
tion at Sacre-Coeur Hospital in 
Montreal in October 1936 and 
sailed from Quebec City with a 
quantity of medical supplies and 
money and with an introduction to 
the Spanish prime minister, Cavel- 
lero. His battle with the establish-
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ment had become a full-time battle 
against Fascism.
In early November, Bethune ar­
rived in Madrid and met with his 
contact, Henning Sorensen, a Cana­
dian journalist. Not long after, he 
was interrogated by the military 
police as a suspected Fascist and 
possible fifth columnist. Bethune’s 
gestalt — British upper class mili­
tary moustache, close cropped hair 
— was not that of a revolutionary.
Bethune soon evaluated the state 
of the military medical service. It 
was too disorganized to afford him 
a significant place. A glaring defi­
ciency in their set up was at once 
apparent to him. What they needed 
was a blood transfusion service, a 
bank filled with typed blood from 
volunteers. He contacted the Span­
ish authorities who received his idea 
with enthusiasm, so he left Spain 
for France and England where he 
collected equipment and learned the 
latest techniques in blood typing, 
storage and transfusion.
On his way back, the French 
customs extracted a heavy duty on 
the equipment. When Bethune con­
tacted the Canadian Embassy he 
was sabotaged by diplomats who 
declared that the Committee to Aid 
Spanish Democracy had no official 
status in Canada and was a Com­
munist organization. Bethune was 
furious and did not hesitate to name 
names when he returned to Canada 
after his Spanish service.
In December, just a month after 
his first arrival, the Servicia Cana- 
diense de Transfusion de Sangre 
was under way. It grew so rapidly 
that within months his service sup­
plied blood to every military sector. 
One great innovation was to bring 
the blood to the wounded soldier in 
the field or in the casualty dressing 
station, saving many lives that 
would have been lost during a pro­
longed evacuation to a military hos­
pital. Another innovation was to set 
up a roster of regular civilian do­
nors of all blood types so that a 
supply of blood was always on 
hand. An extension of his idea of 
bringing blood to the wounded sol­
dier in the field were the medics of 
World War II. His ideas were em­
braced by the western allies but 
rejected by the Fascist forces. The 
paramedic ambulance services of 
the present day are extensions of 
Bethune’s original ideas. The Israeli 
army has carried Bethune’s idea to 
its logical extension. They send 
physicians into the conflict with 
each fighting group.
Bethune’s ambulances (he drove 
one of them at every opportunity) 
aided in the evacuation of civilians 
from the advancing front. He loved 
danger and for him a brush with 
death was particularly exhilarating.
Revolutionary War Surgeon
In 1937, the military incorporat­
ed his previously independent orga­
nization into a general transfusion 
service with Bethune under the di­
rectorship of two Spanish doctors. 
Bethune had become a star with the 
foreign press and that stirred re­
sentment. His presence became an 
embarrassment to the Canadian 
Communist bureaucracy and he was 
prevailed upon to return to Canada 
to make a fund-raising tour.
He was a forceful speaker who 
had a just and urgent cause. Be­
thune’s speaking tour spanned Can­
ada and the United States and was a 
great success. But he was a mixed 
blessing for the doctrinaire Commu­
nists who exploited his reputation 
and fund-raising abilities but feared 
his unorthodox approach and his 
intolerance of party discipline.
In 1937, Japan invaded China, a 
country that was already a battle­
ground with the Kuomintang under 
Chang Kai Shek fighting both the 
various warlords and the Commu­
nists under Mao Zedung. Bethune
recognized that this revolutionary 
situation in the most populous 
country in the world was a momen­
tous event. He convinced the disen­
chanted Canadian and American 
Communists to arrange for him to 
go to China so that he could set up 
medical care for Mao Zedung’s 
forces. When his plan was ap­
proved, Bethune used his persua­
sive powers to obtain funds for the 
expedition from wealthy liberals in 
the United States and Canada. As 
soon as money became available, he 
secured supplies which he knew 
from experience would be essential 
in setting up a medical corps.
Bethune’s supporters arranged 
for a Canadian nurse, Jean Ewen, 
who had worked at mission hospi­
tals in China and was sympathetic 
to the Communist cause, and an 
American doctor, who proved to be 
an alcoholic, to accompany him. On 
the Pacific voyage, the American 
doctor, who for some reason was 
placed in charge of the funds, drank 
most of the money away. When the 
party arrived at Hong Kong, he left, 
taking the remaining money with 
him, for he had had no intention of 
making the difficult and dangerous 
trip to join Mao’s rebel forces in the 
north of China.
Undeterred, Bethune and Jean 
Ewen set off on the long journey to 
the north. They flew from Hong 
Kong to Hankow and from there 
started out by train to join Mao’s 
forces in Yenan. Jean was subjected 
to a baptism of fire shortly after 
they left, but stood up to it well, 
reassured by the ever-brave Be­
thune. Forced from the trains by 
Japanese bombing, they progressed 
slowly on foot and by mule train 
encountering strafing attacks by Ja­
panese bombers. Frequently under 
bombardment by Japanese artillery, 
it took them 3 months to travel the 
800 miles to Sian.
Bethune tended to wounded sol­
diers and civilians as best he could.
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On Mar. 3, 1938, they made con­
tact with the 8th Route Army in Ho 
Chin. Staying just ahead of the 
invading Japanese, they arrived in 
Sian on Mar. 19 after walking 225 
miles, stopping only to rest and 
acquire supplies. A week after their 
arrival they set out for Yenan, the 
headquarters of the Communist 
forces. They reached them on Mar. 
30. Shortly after they arrived, Be- 
thune was summoned to a historic 
meeting with Mao Zedung.
Mao was the younger of the two 
by 3 years. Despite their different 
native cultures there were similari­
ties between the two. Both were 
from farm country and had been 
rebellious in their student years. 
Despite this they both became 
teachers. Mao came early to his 
battle with the establishment and 
led a revolutionary movement 
against it. Bethune had made a 
tentative approach and was gradual­
ly transformed from an eccentric
En route to Chin-Ch'a-Chi with Dr. Brown and  soldiers.
Young Ho is on top of the truck. When the truck was stuck, 
Bethune jumped out of the cab and, up to his ankles in  the 
m ud, began to push. The Chinese were amazed. They were 
accustomed to foreigners who let the Chinese do the dirty' 
work.
FIG. 1. Bethune and Brown in China. 
(Reproduced by permission from Stew­
art R: The Mind of Norman Bethune, 
Fitzhenry & Whiteside, Toronto, 
1977 .)
conservative to a dedicated Commu­
nist. Both were charismatic, literary 
and poetic. Mao, of course, was a 
master of Marxism and practical 
politics, whereas Bethune was ideal­
istic and interested in politics only 
when it enhanced his personal 
goals.
Bethune convinced Mao that Be- 
thune’s place was in the north with 
the troops who were in direct con­
tact with the Japanese. It was ar­
ranged that he would be sent to 
join the troops in the Chi border 
region. He worked in Yenan for 
several months taking care of 
troops. Dr. Richard Brown, a sur­
geon from an Anglican mission, 
volunteered to join him. They left 
by truck carrying supplies that Be­
thune had left in Hong Kong and 
that Brown had retrieved and 
brought to him (Fig. 1). When 
Bethune arrived at the front, he 
immediately established headquar­
ters and began to set up facilities 
for the care of vast numbers of 
troops and civilians under his care.
Bethune was a veteran of two 
wars. World War I was essentially a 
static war with opposing front lines 
and movement of wounded to hos­
pital establishments at the rear. In 
the Spanish Civil War there was 
more mobility. But nothing pre­
pared Bethune for the extreme mo­
bility of guerilla warfare. He con­
vinced the Chinese military to help 
him build a model hospital only to 
see it overrun and destroyed by the 
Japanese in the tidal flow of the 
forces.
However, Bethune was pragmatic 
and quick to react to a new situa­
tion. He devised mobile operating 
equipment that could be packed up 
like a visiting circus and moved on 
mule and horseback to the next site 
where it was needed and could 
quickly be broken down and taken 
away when necessary.
His acceptance and his influence 
on the Chinese devolved from his
character. Peasants who made up 
the 8th Route Army could not 
speak to Bethune, but they could 
see that when a truck bogged down 
in the mud Bethune’s shoulder was 
there helping to free it. They saw 
that this Caucasian who saved Chi­
nese lives through his surgical skill 
was learned, inventive and a natural 
leader and dressed in the clothes of 
an ordinary Chinese soldier and ate 
the food that they ate.
Bethune lived the role of a revo­
lutionary hero to the hilt. His work- 
filled days and the sheer necessity 
of his presence spared him from the 
usual conflicts in which bureaucra­
cy embroiled him. Faced with an 
impossible situation he was able 
through the power of his personali­
ty and originality to forge the be­
ginnings of medical care for the 
rag-tag Chinese communist troops. 
Filth was a major enemy and he set 
his helpers to clean up the sur­
roundings, the sick, the wounded 
and themselves. He combatted med­
ical ignorance by giving illustrative 
lectures and by precept and exam­
ple. He set up schools for practical 
nursing, wound tending and mili­
tary surgery. Within months he was 
able to train cadres who could 
staunch hemorrhage, clean wounds, 
splint limbs and salvage the sal­
vageable by primitive but essential 
treatment. Chinese physicians of 
varying levels and backgrounds he 
quickly trained for military surgery.
Typing away on his portable 
typewriter every moment that he 
could spare, he wrote texts of bat­
tlefield care, nursing manuals and 
operative procedures. He made do. 
He had the cooperation of a fantas­
tically hard-working, intelligent and 
thoroughly motivated group of Chi­
nese soldiers.
Bethune understood motivation 
well. He introduced wound stripes 
and widow’s medals, and letters of 
condolences were sent to the rela­
tives of the fallen.
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With his mobile operating unit he 
and Dr. Brown stayed close to the 
casualties. They operated long 
hours on the wounded, soon ex­
hausting their precious supply of 
anesthetics, antiseptics, suture 
materials and dressings. Brown had 
another commitment and after 3 
months he had to leave and Be- 
thune was alone. Bethune wrote to 
a friend, “We are completely sur­
rounded by Japanese, north, east, 
west and south. They hold all the 
towns on the railway. In this great 
area of 13 million people with 
15 000 armed troops I am the only 
qualified doctor.”1 On one occasion, 
Bethune operated for 69 consecu­
tive hours. His letters to his friends 
pleading that he be sent magazines 
and books underlines his almost 
complete isolation. In another letter 
he wrote, “ I don’t think I have been 
so happy in a long time. I am 
content. I am doing what I want to 
do. Why shouldn’t I be happy? See 
what my riches consist of. First, I 
have important work that occupies 
every minute of my time from 5:30 
in the morning to 9:00 at night. I 
am needed. More than that, to 
satisfy my bourgeois vanity I have a 
cook, a personal servant, my own 
house, a fine Japanese horse sad­
dled. I have no money nor the need 
of it. I am treated like a kingly 
comrade. Everything is given to me. 
No wish, no desire is left unful­
filled.”2-3
The greatest legacy that Bethune 
left to the Chinese was the impor­
tance of good technique. He 
stressed the importance of patient 
care and produced manuals on how 
to do it couched in terms that his 
sparsely educated soldiers could un­
derstand.
It is probable that Bethune’s 
demonstrations of the worth of 
properly trained paramedical per­
sonnel led to the use and accep­
tance of the “barefoot doctors” 
who minister to the immediate
needs of the commune in China 
today yet recognize and refer more 
serious cases.
The constant work, primitive liv­
ing conditions and inadequate food 
aged and weakened Bethune. Pho­
tographs taken of his arrival in 
China in the winter of 1938 show a 
sturdy man in middle years with a 
distinguished bearing. One and a 
half years later he seemed frail and 
elderly. In this weakened state, op­
erating without gloves on, in in­
fected cases, his fingers often be­
came infected and finally, late in 
October, one infection led to septi­
cemia and death on Nov. 12, 1939. 
His death was commemorated 5 
weeks after he died in an essay by 
Mao Zedung. This was the begin­
ning of his enshrinement in the 
pantheon of heroes of the Chinese 
people. His passing was noted in 
Canada only by those nearest and 
dearest to him. His heroism was 
recognized by the Chinese at once 
and, in 1940, a splendid tomb and 
memorial park were dedicated to 
him. He is commemorated in a 
number of postage stamps showing 
him at work operating; his biogra­
phy, Pai Ch’Uen is available on 
every newsstand in China. In 1952, 
his story was told to the western 
world by Ted Allen and Sidney 
Gordon in a book The Scalpel, the 
Sword* and the Canadian govern­
ment has belatedly and grudgingly 
acknowledged his contributions. 
The Bethune Foundation, with 
headquarters in Montreal, was es­
tablished to commemorate Bethune 
and perpetuate his ideals.
While Bethune had been strug­
gling to initiate antisepsis in filthy 
troops and filthy habitations and to 
provide primitive wood and iron 
splints for broken limbs, Banting 
was applying his practical mind to 
the organization of research to 
make flying higher and faster safe 
for the pilot. The limiting factor in 
the speed and the maneuverability
of military aircraft was not the 
machine, but the man.
The Last Adventure
The work in aviation medicine 
went well. A newly devised “G” suit 
was able to protect pilots from the 
stresses of dives and aerobatics. 
New measures against decompres­
sion sickness and night blindness in 
pilots had been devised. Banting 
knew that his role in expediting the 
cooperation of the Canadian univer­
sities, which had led to these inno­
vations, had been fulfilled. He want­
ed to be back in the conflict; like 
Bethune, he sought the camarade­
rie of arms. His rapport with British 
scientists was not very good. They 
tended to favour Best, who had a 
truly formalized training, much of it 
under the aegis of British scientists. 
Best had been scheduled to go and 
confer with the British scientific 
establishment in order to effect a 
coordinated war effort, but family 
problems prevented him from tak­
ing this trip. Banting immediately 
seized the opportunity to substitute 
for Best as the emissary to the 
British establishment.
It is not known if Banting fully 
understood the hazards of flying 
the North Atlantic in winter in a 
Hudson bomber being ferried to 
Great Britain. Not many of these 
flights had been accomplished and 
there had been three crashes. Ban­
ting was nervous about the flight, 
but in any case, he said his good­
byes, left Toronto and waited at the 
Newfoundland Air Station in the 
middle of February for the plane 
that was to take him to Great 
Britain. While there he relaxed and 
made friends with the medical and 
aviation personnel at the station. To 
one of them he intimated a forebod­
ing he had mentioned to his friends 
in Montreal and Toronto. He said, 
“Wilson, I’m scared.”5 He carried
K  ,
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with him on the flight no essential 
data, no samples of the Canadian 
“G” suit. Any number of persons 
could have undertaken the trip. 
Shortly after takeoff in the Hudson 
bomber, Banting’s premonition 
proved true. One engine failed and 
the other faltered. The pilot turned 
back. He ordered his three passen­
gers to bail out, but Banting did not 
have a parachute. Besides, the 
chances of survival either in the 
water or on land in the midst of a 
midwinter blizzard was question­
able. The plane crashed in the fro­
zen waste of Newfoundland, hard 
against a solitary tree in the area. 
The pilot survived and two of the 
three passengers died on impact. 
Banting was gravely injured and 
although he regained consciousness 
he died 16 hours later. He made a 
great effort to dictate to the pilot 
the crux of the Canadian findings. 
It was a futile effort, but he tried to 
the last to carry out his duty.
Banting’s loss was immediately 
and profoundly felt throughout 
Canada and the world. For Canada, 
it was especially poignant. Banting 
had presented the world with a gift 
whose magnitude was recognized at 
once. The man and his country 
were identified for all time as the 
source of this bounty.
Banting and Bethune, linked in 
time, place of birth, as college class­
mates, veterans of World War I and 
heroes to different worlds, ended 
their lives while relatively young 
and in possession of all their pow­
ers. They died in the pursuit of 
goals which were all-important to 
each. Professor Bliss of Toronto 
has suggested that the strong 
Methodist upbringing of Banting 
and the Evangelical ministers who 
parented Bethune may have con­
tributed to the fervour with which 
they pursued their goals and their 
dedication even to the point of 
sacrificing their lives.6 Yet neither 
of these men observed the conven­
tional forms of the Christian reli­
gion and Bethune was anti-reli­
gious. As to self-sacrifices, their 
letters and diaries close to their 
deaths reveal a strong love for life 
and continued plans on how they 
were going to live it.
They were both physically tough 
and proud of it, decisive, generous, 
unforgiving and vindictive. They 
were both fearless romantics who 
were supremely pragmatic.
These men were surgeons. Sur­
geons are said to have identifiable 
character traits. Even the most be­
nign surgeon is, in a sense, aggres­
sive. On occasion they are contem­
plative but they are always decisive. 
In both of these men their surgical 
ambitions were frustrated and their 
reaction to the frustration deter­
mined their great contributions. Be­
thune, a successful surgeon inacti­
vated by tuberculosis, was directed 
by his ailment to thoracic surgery. 
Frustrated by society in his battle 
for socialized medicine he went to 
war directly against the crystallized 
enemy, the Fascist in Spain and the
Imperialist in China. Banting, after 
his first peak, was an adequate but 
not an exceptional research worker. 
He took up the challenge of the war 
against Fascism by organizing re­
search to implement all-important 
air warfare, then flew off to present 
the results of several years’ en­
deavours to his colleagues. There 
are any number of emissaries who 
could have been sent, but he, like 
Bethune, wanted to be in the thick 
of the action. Both of them never 
hesitated to risk life and limb in the 
pursuit of their ideals. What Leo 
Eloesser wrote in memory of Be­
thune can be applied to both men, 
“What better end could any man 
have than this fellow member of 
ours who spent his life and met his 
death in the service of his ideals — 
Humanity and Freedom.”7
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CEFOTAN + IM/IV
(cbfotbtane disodique sterile U.S.P.)
Un choix rentable pour 
un traitement parenteral aux 
cephalosporines tres efficace
CLASSIFICATION THERAPEUTIQUE
Antibiotique
ACTION
Le cbfotbtane disodique est un antibiotique semi-synthbtique de la famille 
des cephalosporines (cbphamycines), resistant aux beta-lactamases. Des 
etudes in vitro indiquent que I’effet bactericide du cetotetane rbsulte de son 
action au niveau de la synthbse de la paroi cellulaire bacterienne par inhibition 
de la reticulation du peptidoglycane. Des etudes avec le cetotetane marque 
au ,4C ont montre qu'au moment d'atteindre les proteines fixatrices cibles de 
la penicilline (PBP) dans la paroi interne, I’antibiotique marque se lie princi- 
paiement aux PBP 3 et ensuite aux PBP 1A et 1B. Le cetotetane, comme 
d'autres cbphamycines, ne se lie pas aux PBP 2.
La demi-vie d’eiimination plasmatique du cetotetane est de 3 b 4,6 heures suite 
A I’administration intraveineuse ou intramusculaire. Chez les sujets normaux, 
de 51 e 81 % de la dose administree sont excretes inchanges par le rein dans 
les 24 heures. La principale autre voie d’eiimination est la voie biliaire.
INDICATIONS ET USAGE CLINIQUE
CEFOTAN (cetotetane disodique) est indiqub dans le traitement des infections 
suivantes causees par des souches sensibles des germes specifies :
Infections urinaires causees par E. co li et les Klebsiella (y compris K. pneu­
moniae), Proteus mirabilis et Proteus A indole positif.
Infections des voies respiratoires interieures causees par Streptococcus 
pneumoniae (precedemment D. pneumoniae), Staphylococcus aureus (y 
compris les souches productrices et non productrices de penicillinase), 
Haemophilus influenzae (y compris les souches resistantes A I’ampicilline), 
les Klebsiella (y compris K. pneumoniae) et E. coli.
Infections cutanees causees par Staphylococcus aureus (y compris les 
souches productrices et non productrices de penicillinase), Staphylococcus 
epiderm idis, Streptococcus pyogenes et le genre Streptococcus (b I’exclusion 
des enterocoques) et E. coli.
Infections gynecologiques causees par Staphylococcus aureus (y compris 
les souches productrices et non productrices de penicillinase), Staphylococ­
cus epiderm idis, le genre Streptococcus (A I'exclusion des enterocoques), E. 
coli, Proteus mirabilis, Neisseria gonorrhoeae, les cocci gram-positifs et les 
bacilles gram-negatifs anabrobies, les Bacteroides (A I’exclusion de B. dista- 
sonis, B. ovatus et B. thetaiotaomicron).
Infections intra-abdominales causees par E. coli, les bacilles gram-negatifs 
anaerobies, les Bacteroides (excluant B. distasonis, B. ovatus et B. thetaiotao- 
m icron).
Infections des os et des articulations causees par Staphylococcus aureus.
Une culture bacteriologique doit etre faite dans le but d ’isoler et d’identifier 
I’agent pathogene et de determiner sa sensibility A CEFOTAN. Le traitement 
peut etre amorce avant que les tesultats de I’antibiogramme ne soient connus. 
Par la suite, une fois les tesultats de I’antibiogramme connus, le traitement 
doit etre adapte en consequence.
CONTRE-INDICATIONS
CEFOTAN (cetotetane disodique) est contre-indique chez les patients qui 
ptesentent des reactions allergiques de type 1 (p. ex. urticaire, oedeme de 
Quincke, bronchospasme ou choc anaphylactique) aux antibiotiques du 
groupe des cephalosporines.
MISES EN GARDE
AVANT D’UTILISER LE TRAITEMENT CEFOTAN (cetotetane disodique), BIEN 
SE RENSEIGNER AUPRES DU PATIENT POUR DETERMINER S’lLA DEjA 
MANIFEST^ UNE REACTION ALLERGIQUE AU CEFOTETANE DISODIQUE, 
AUX CEPHALOSPORINES, AUX PENICILLINES OU A D’AUTRES MEDICA­
MENTS. CEFOTAN DOIT ETRE ADMINISTRE AVEC CIRCONSPECTION 
AUX PATIENTS QUI SONT SENSIBLES A LA PENICILLINE. LES ANTIBIO­
TIQUES, Y COMPRIS CEFOTAN, DOIVENT ETRE ADMINISTRES AVEC 
PRUDENCE A TOUT PATIENT QUI A MANIFESTS UNE FORME QUEL- 
CONQUE D’ALLERGIE, SURTOUT AUX MEDICAMENTS. SI CEFOTAN 
ENTRAiNE UNE REACTION ALLERGIQUE, EN CESSER L’ADMINISTRA- 
TION. LES CAS DE REACTIONS ALLERGIQUES AIGUES PEUVENT 
NECESSITER L’ADMINISTRATION D’EPINEPHRINE ET LE RECOURS A 
D’AUTRES MESURES D’URGENCE.
LA COLITE PSEUDO-MEMBRANEUSE A EtE ASSOClEE A L’UTILISATION 
DES CEPHALOSPORINES, Y COMPRIS CEFOTAN, (ET A D’AUTRES ANTI­
BIOTIQUES A LARGE SPECTRE); PAR CONSEQUENT, IL EST IMPORTANT 
DE TENIR COMPTE DE CE DIAGNOSTIC CHEZ LES PATIENTS QUI PRE- 
SENTENT DE LA DIARRHEE DUE A L’USAGE D’ANTIBIOTIQUES.
Le traitement par des antibiotiques A large spectre peut modifier la flore 
intestinale normale du c6lon et ainsi favoriser la proliferation de Clostridium. 
Des etudes indiquent que la toxine produite par Clostridium difficile est Tune 
des principales causes de colite assoctee A I’usage d’antibiotiques.
Les cas de colite Ibgbre peuvent tepondre A I’artet du traitement seul.
Dans les cas modetes ou graves, un apport comptementaire en liquides, en 
electrolytes et en proteines est indiqub. Si I’arret du traitement ne soulage pas 
la colite ou si le cas est grave, I’administration orale de vancomycine constitue 
le traitement de choix de la colite pseudo-menbraneuse due A C. d ifficile  
associee A I’usage d'antibiotiques. D’autres causes devraient 6galement etre 
prises en consideration.
PRECAUTIONS
G en e ra te s  : I’utilisation prolong6e de CEFOTAN (cetotetane disodique) 
peut entrainer la proliferation de germes tesistants et de germes initialement 
sensibles au medicament. La surveillance adequate des patients est essen- 
tielle. En cas de surinfection pendant le traitement, prendre les mesures 
appropriees.
CEFOTAN peut etre associe A une baisse de I’activite prothrombique. Les 
patients A risque sont ceux qui souffrent d ’insuffisance tenale ou hbpatique, 
de carence alimentaire, les personnes Sgbes et les personnes atteintes du 
cancer. Les temps de prothrombine doivent etre surveiltes chez les patients A 
risque et on doit administrer de la vitamine K au besoin.
CEFOTAN doit etre administte avec circonspection chez les patients qui ont 
des antecedents de maladie gastro-intestinale, surtout de colite.
II peut se produire une reaction du type disulfirame, caracterisee par des 
bouffbes de chaleur, de la transpiration, des cbphalbes et de la tachycardie, 
s’il ya ingestion d’alcool (bibre, vin, etc.) dans les 72 heures suivant I’adminis­
tration de CEFOTAN. Les patients doivent etre mis en garde contre I’ingestion 
de boissons alcoolisbes suite A Tadministration de CEFOTAN.
Les patients souffrant d'insuffisance rbnale (dont la clairance de la crbatine 
est infbrieure ou bgale A 30 ml/min) doivent recevoir une posologie spbciale, 
telle que recommandbe sous POSOLOGIE et ADMINISTRATION.
Interactions mbdicamenteuses
En raison du potentiel nbphrotoxique et ototoxique des aminosides, la fonction 
rbnale doit etre surveillbe de prbs, particulibrement chez les patients qui 
regoivent des doses blevbes d’aminosides ou qui sont sous traitement pro- 
longb. Bien qu’b ce jour, rien de tel ne se soit produit avec I’administration de 
CEFOTAN, une augmentation de ia nbphrotoxicitb a btb notbe suite A I’admi- 
nistration concomitante de cbphalosporines et d’aminosides. Toutefois, A ia 
dose recommandbe, il est peu probable que CEFOTAN soit associb A une 
augmentation de la nbphrotoxicitb.
Interactions mbdicamenteuses lors d ’analyses de laboratoire
Un rbsultat faussement positif de glycosurie peut se produire avec des 
solutions de Benedict ou de Fehling.
Des concentrations blevbes de cbfotbtane peuvent fausser les rbsultats des 
taux de crbatinine sbriques et urinaires obtenus par la rbaction de Jaffb, et 
entrainer une augmentation artificielle des taux de crbatinine notbs.
Grossesse
L’innocuitb de CEFOTAN dans le traitement defections chez la femme 
enceinte n’a pas btb btablie. L’usage de CEFOTAN chez la femme enceinte 
doit faire I’objet d’une bvaluation des avantages par rapport aux risques 
possibles pour la mbre et le foetus. Des btudes portant sur la reproduction ont 
btb menbes chez les rats et les si nges A des doses jusq u'b 20 fois supbrieu res 
A la dose de cbfotbtane recommandbe chez I’humain et n’ont rbvblb aucune 
anomalie de la fertilitb ni atteinte du foetus. Par contre, il n’existe aucune 
btude comparative adequate portant sur la femme enceinte. Etant donnb que 
les btudes sur la reproduction animale ne sont pas toujours representatives 
de la rbponse humaine, ce mbdicament ne doit etre administrb pendant la 
grossesse qu’en cas d’absolue nbcessitb.
Alla item ent
Le cbfotbtane est excrbtb A faible concentration dans le lait maternel. On doit 
administrer CEFOTAN avec prudence chez la femme qui allaite.
Nourissons et enfants
L’innocuitb et I’efficacitb du cbfotbtane n’ont pas btb btablies chez les 
enfants.
REACTIONS in d Es ir a b l e s
Lors d ’btudes cliniques, les effets secondaires suivants ont btb associbs au 
traitement CEFOTAN (cbfotbtane disodique).
Gastro-intestinaux ; des symptomes gastro-intestinaux se sont produits 
chez 1,5 % des patients, les plus frbquents btant la diarrhbe (1 sur 80) et la 
nausbe (1 sur 700).
Hbm atologiques : des rbsultats hbmatologiques anormaux se sont produits 
dans 1,4 % des cas et comprenaient de I'bosinophilie (1 sur 200), des tests de 
Coombs directs positifs (1 sur 250) et de la thrombocytose (1 sur 300). Une 
thrombocytopbnie et une leucopbnie transitoires ont btb notbes.
Hbpatiques : une blbvation du taux d ’enzymes hbpatiques s’est produite 
dans 1,2%  des cas et comprenait une augmentation de la transaminase 
glutamino-pyruvique (SGPT) (1 sur 150), de la transaminase glutamique 
oxalo-acbtique (SGOT) (1 sur 300), de la phosphatase alcaline (1 sur 700) et 
de la lacticodbshydroxygbnase (LDH) (1 sur 700).
A lle rg iques : des rbactions d’hypersensibilitb ont btb rapportbes chez 1,2 % 
des patients et comprenaient des rashes (1 sur 150) et des dbmangeaisons 
(1 sur 700). Au cours de la pbriode qui a suivi la mise en marchb de CEFOTAN, 
des rbactions anaphylactiques ont btb notbes.
Locaux : des effets locaux ont btb rapportbs chez moins de 1 % des patients 
et comprenaient une phlbbite au point d'injection (1 sur 300) et de I'inconfort 
(1 sur 500).
YMPT6MES ET TRAITEMENT DU SURDOSAGE
ce jour, aucun cas de surdosage avec CEFOTAN (cbfotbtane disodique) 
n'a btb rapportb. En cas de surdosage, traiter le sujet de fapon symptomatique. 
CEFOTAN peut btre bliminb par dialyse.
POSOLOGIE ET ADMINISTRATION
POSOLOGIE : adultes: la posologie adulte usuelle est de 1 ou 2 g de 
CEFOTAN (cefotetane disod ique) administtes par voie intraveineuse ou intra- 
musculaire aux 12 heures durant 5 4 10 jours. La posologie juste et la voie 
d’administration doivent etre determin6es d ’aprbs I’etat du patient, la gravity 
de I’infection et la sensibilite de I'agent pathogene. Le traitement peut etre 
amorce avant que les tesultats de I’antibiogramme ne soient connus.
Adm inistration intraveineuse : la voie intraveineuse est preferable chez 
les patients qui ptesentent une bacteriemie, une septicbmie bacterienne ou 
d’autres infections graves ou 4 potentiel fatal, ou chez les patients 4 risque, 
particuiierement en presence de choc avbrb ou imminent.
GUIDE POSOLOGIQUE GENERAL DE CEFOTAN
Type d ’infection
Dose
quotidienne
Frequence et 
voie d ’adm inistra tion
Infections urinaires 1 4 4 g 500 mg aux 12 heures, IV ou IM 
1 ou 2 g aux 24 heures, IV ou IM 
1 ou 2 g aux 12 heures, IV ou IM
Autres foyers d’infection 2 4 4 g 1 ou 2 g aux 12 heures, IV ou IM
Infections graves 4 g 2 g aux 12 heures, IV
Infections k  potentiel fatal 6gt1 3 g aux 12 heures, IV
>-> ►
'  t t  La posologie quotidienne maximale ne doit pas excbder 6 g.\
\
INSUFFISANCE RENALE
En presence d’une insuffisance renale, recourir 4 un schema posologique 
reduit. Le tableau posologique suivant peut etre utilise.
GUIDE POSOLOGIQUE CHEZ LES INSUFFISANTS RENAUX
A*
Clairance de la 
creatinine m l/m in. Dose Frequence
> 30 dose usuelle recommandee** aux 12 heures
> 10 4 30 dose usuelle recommandbe** aux 24 heures
<  10 dose usuelle recommand6e** aux 48 heures
** La dose est determinhe par le type et la gravite de I’infection, et par la 
sensibility de I’agent pathogbne.
On peut dgalement maintenir I’intervalle constant aux 12 heures mais teduire 
de moitie la dose usuelle recommandbe chez les patients dont la clairance de 
la creatinine est de 10 4 30 ml/min, et la teduire au quart chez les patients dont 
la clairance de la creatinine est inferieure k 10 ml/min.
Si seuls les taux seriques de creatinine sont disponibles, la clairance de la 
creatinine peut etre calcuiee k I’aide de la formule suivante. Les taux seriques 
de creatinine doivent representer la fonction renale k un etat d ’equilibre.
Clairance de la creatinine (m l/m in ):
Unites tradltionnelles
Hommes : poids (kg) x (140 - 4ge)
72 x creatinine serique 
(mg/100 ml)
Unites S.l.
poids (kg) x (140 - 4ge)
0,8 x creatinine serique 
(/zmol/l)
Femmes : 0,9 x valeur chez les hommes
Le cefotetane est dialysable et recommande pour les patients qui sont sous 
hemodialyse intermittente, au quart de la dose usuelle recommandee toutes 
les 24 heures entre les jours de dialyse, et k la moitie de la dose usuelle 
recommandee les jours de dialyse.
Enfants
L’innocuite et I’efficacite n’ont pas ete etablies chez I’enfant.
ADMINISTRATION 
Voie intraveineuse
Pour I’administration intraveineuse intermittente, injecter en 3 k 5 minutes 
une solution d’eau sterile pour injection contenant 1 ou 2 g de CEFOTAN. Le 
produit peut bgalement §tre injecte k I’aide d ’un dispositif de perfusion sur 
une pbriode de temps plus btendue dans le systeme de tubulures par lequel 
le patient report dkjk d’autres solutions intraveineuses.
Pour ce genre de perfusion, il est preferable d ’utiliser des aiguilles k  ailettes 
ou des aiguilles du type utilise pour les veines du cuirchevelu. Toutefois, lors 
de la perfusion de la solution contenant CEFOTAN, il est conseilte d ’inter- 
rompre temporairement I’administration d’autres solutes par la meme voie 
de perfusion.
NOTE : les solutions de CEFOTAN ne doivent pas §tre ajoutees k  des solutions 
contenant des aminosides. Si CEFOTAN et des aminosides doivent etre 
administtes Sun m§me patient, les administrer sepatement et non pas en une 
seule injection mixte.
Voie intramusculaire
CEFOTAN doit etre injecte en pleine masse musculaire, dans la fesse par 
exemple (gluteus maxim us). S’assurer de bien retirer legbrement le piston de 
la seringue pour bviter que la solution ne sort injectee par inadvertance dans 
un vaisseau sanguin.
RENSEIGNEMENTS PHARMACEUTIQUES
Chimie
Marque de commerce : CEFOTAN t
Denomination commune : cefotetane disodique sterile USP 
Nom chimique : CEFOTAN est le sel disodique de [6R-(6cr, 7a ))-7-
[[[4-(2-amino-1 -carboxy-2-oxoethylidene)-1, 
3-dithietan-2-ylJcarbonyl] amino]-7-methoxy-3- 
[((1 -methyl-1 H-tetrazol-5-yl)thio] methyl]-8-oxo- 
5-thia-1 -azabicyclo [4.2.0]oct-2-ene-2-acide 
carboxylique.
Molecule : Ci7HisN7Na20aS4 
Poids moteculaire : 619,56
Description
Poudre de couleur blanche k  jaune p4le hautement soluble dans I’eau. La 
solution varie de incolore k  jaune selon la concentration et renferme environ 
80 mg (3,5 mEq) de sodium par gramme de cefotetane actif. Le pH des solu­
tions frafchement reconstituees se situe habituellement entre 4,5 et 6,5.
RECONSTITUTION
Usage intram uscu la ire
Reconstituer avec de I’eau sterile pour injection, de la solution saline isotonique 
USP, du chlorhydrate de lidocaine k 0,5 %, ou du chlorhydrate de lidocaine k 
1,0 %. Bien agiter pour dissoudre et laisser reposer jusqu’4 ce que la solution
sort claire. Q uantite Volume C oncentra tion
Teneur du de d iluant d isponible m oyenne
flacon 4 a jou te r (ml) approx, (ml) approx, (m g/m l)
1 9 2 2,5 400
2 g 3 4,0 500
Usage intraveineux
Reconstituer avec de I’eau sterile pour injection, du chlorure de sodium k  0,9 % 
pour injection ou du dextrose k 5 % pour injection. Bien agiter pour dissoudre 
et laisser reposer jusqu’4 ce que la solution sort claire.
Q uantite Volume C oncentra tion
Teneur du de d iluant d isponible m oyenne
flacon 4 a jou te r (ml) approx, (ml) approx, (m g/m l)
1 9 10 10,5 95
2 9 10 - 20 11 • 21 182 - 95
Une solution pteparbe avec de I’eau sterile pour injection peut etre dilu te 
davantage avec I’une des « solutions pour perfusions intraveineuses » 
suivantes jusqu’4 I’obtention du volume requis.
Solutions pour pe rfus ions intraveineuses
Chlorure de sodium k  0,9 % pour injection 
Dextrose k 5 % pour injection 
Dextrose k 10 % pour injection 
Solution de Ringer 
Solution de Ringer-lactate
Chlorure de sodium k 0,9 % et dextrose k 5 % pour injection 
Chlorure de sodium k  0,225 % et dextrose k 5 % pour injection 
Solution de Ringer et dextrose k  5 % pour injection 
Solution de Ringer-lactate et dextrose k  5 % pour injection 
Sucre inverti k  10 % pour injection 
Bicarbonate de sodium k  5 % pour injection 
Lactate de sodium pour injection, solution molaire 4 1 /6  
Solution d’lsolyte-S
Compatibilife et s tab ility
Reconstitub tel que dbcrit plus haut (Reconstitution), CEFOTAN conserve une 
activity satisfaisante durant 24 heures k  la temperature ambiante (25°C) ou 
durant 72 heures au rbfrigbrateur (5°C).
Toute portion inutilisbe doit etre jetee. CEFOTAN ne doit pas etre melange avec 
d’autres agents antimicrobiens.
NOTE : lorsque la solution et son contenant le permettent, les medicaments 
parenteraux doivent etre verifies visuellement avant leur administration pour 
deceler toute decoloration ou la presence de particules.
FORMES POSOLOGIQUES  
Presentation
CEFOTAN (cefotetane disodique) est offert sous la forme d’une poudre seche, 
de couleur blanche k jaune p4le, dans des flacons renfermant I’equivalent de 
1 et 2 g de cefotetane actif pour administration intraveineuse ou intramuscu­
laire. La dose de 1 g (N° 961) est offerte en flacons de 10 ml, et la dose de 2 g 
(N° 962), en flacons de 20 ml. Les flacons doivent etre entreposes k des 
temperatures inferieures k 25°C k I’abri de la lumiere.
LABORATOIRES AYERST
Division de Ayerst, McKenna & Harrison, Inc 
Montr6al, Canada 
t  Conditions par Ayerst, sous licence de 
Yamanouchi Pharmaceutical Co. Ltd., propStaire de la marque de commerce.
Ayerst
sterile ceftizoxime sodium
THERAPEUTIC CLASSIFICATION
Antibiotic
ACTION
In vitro studies indicate that the bactericidal action of ceftizoxime results from inhibition of 
cell-wall synthesis in aerobic and anaerobic gram-positive and gram-negative organisms. In 
vitro, ceftizoxime shows a strong affinity for penicillin-binding proteins la, lbs and 3 of E. coli.
INDICATIONS AND CLINICAL USES
CefizoxTM (sterile ceftizoxime sodium) may be indicated in the treatment of the infections 
listed below when caused by susceptible strains of the designated microorganisms:
LOWER RESPIRATORY TRACT INFECTIONS caused by Streptococcus sp. (including S. 
pneumoniae but excluding enterococci); Klebsiella sp.; Proteus mirabilis; Escherichia coli; 
Haemophilus influenzae (including ampicillin-resistant strains); Staphylococcus aureus 
(including penicillinase-producing but excluding methicillin-resistant strains); Serratia sp.; 
and Enterobacter sp.
URINARY TRACT INFECTIONS caused by Escherichia coli; Staphylococcus epidermidis; 
Pseudomonas aeruginosa; Proteus mirabilis; Klebsiella sp.; Serratia marcescens; and 
Enterobacter sp.
Due to the nature of the underlying conditions which usually predispose patients to Pseudo­
monas infections of the urinary tract, a good clinical response accompanied by bacterial 
eradication may not be achieved despite evidence of in vitro sensitivity.
INTRA-ABDOMINAL INFECTIONS caused by Escherichia coli; Staphylococcus epidermidis; 
Streptococcus sp. (excluding enterococci); Klebsiella sp.; Bacteroides sp. (including B. 
fragilis)', Peptococcus sp.; and Peptostreptococcus sp.
SEPTICEMIA caused by Streptococcus sp. (excluding enterococci but including S. pneu­
moniae]>; Staphylococcus aureus (excluding methicillin-resistant strains); Escherichia coli; 
Bacteroides sp. (including B. fragilis); Klebsiella sp.; and Serratia marcescens.
SKIN STRUCTURE INFECTIONS caused by Staphylococcus aureus (excluding methicillin- 
resistant strains); Staphylococcus epidermidis; Escherichia coli; Klebsiella sp., (including K. 
pneumoniae); Streptococcus sp. (excluding enterococci but including Group A B-hemolytic 
Streptococcus pyogenes); Proteus mirabilis; Serratia sp.; Enterobacter sp.; Bacteroides sp. 
(including B. fragilis); Peptococcus sp., and Peptostreptococcus sp.
BONE AND JOINT INFECTIONS caused by Staphylococcus aureus (excluding methicillin- 
resistant strains); Proteus mirabilis; Peptococcus sp.; and Peptostreptococcus sp.
Specimens for bacteriologic culture should be obtained prior to therapy in order to identify 
the causative organisms and to determine their susceptibilities to ceftizoxime. Therapy with 
CefizoxTM may be initiated before results of the susceptibility studies are known. However, 
modification of the treatment may be required once these results become available.
CONTRAINDICATIONS
CefizoxTM (sterile ceftizoxime sodium), is contraindicated in persons who have shown 
hypersensitivity to ceftizoxime or other members of the cephalosporin group of antibiotics.
WARNINGS
Before therapy with CefizoxTM (sterile ceftizoxime sodium) is instituted, careful inquiry 
should be made to determine whether the patient has had previous hypersensitivity 
reactions to cephalosporins, penicillins, or other drugs. CefizoxTM should be given 
cautiously to penicillin-sensitive patients. Antibiotics, including CefizoxTM, should be 
administered with caution to any patient who has demonstrated some form of allergy, 
particularly to drugs. If an allergic reaction to CefizoxTM occurs, its administration should 
be discontinued. Serious acute hypersensitivity reactions may require epinephrine and other 
emergency measures.
Pseudomembranous colitis has been reported with the use of CefizoxTM (and other anti­
biotics). Therefore, it is important to consider this diagnosis in patients administered 
CefizoxTM who develop diarrhea.
Treatment with broad-spectrum antibiotics alters normal flora of the colon and may permit 
overgrowth of Clostridia. Studies indicate a toxin produced by Clostridium difficile  is one 
primary cause of antibiotic-associated colitis.
Mild cases of colitis may respond to drug discontinuance alone. Moderate to severe cases 
should be managed with fluid, electrolyte and protein supplementation as indicated. When 
the colitis is not relieved by drug discontinuance or when it is severe, consideration may be 
given to the administration of oral vancomycin or other suitable therapy. Other possible 
causes of colitis should also be considered.
PRECAUTIONS
General: Transient elevations of BUN and serum creatinine have been observed in clinical 
studies. However, there is no other evidence that CefizoxTM (sterile ceftizoxime sodium) has 
produced alterations in renal function. Renal status should be periodically evaluated, 
especially in seriously ill patients.
Prolonged use of CefizoxTM may result in the overgrowth of nonsusceptible organisms 
including species originally sensitive to the drug. Careful observation of the patient is 
essential. If superinfection occurs during therapy, appropriate measures should be taken. 
CefizoxTM should be administered with caution to individuals with a history of gastro­
intestinal disease, particularly colitis.
Impaired Renal Function: Since ceftizoxime is excreted primarily in the urine, patients with 
impaired renal function (i.e., creatinine clearance £1.32 mUs or ^ 7 9  mL/min) should be 
placed on a special dosage schedule recommended under DOSAGE AND ADMINISTRATION. 
Normal dosages in these individuals are likely to produce excessive serum concentrations 
of ceftizoxime.
Drug Interactions: The concomitant administration of some cephalosporins and amino­
glycosides has caused nephrotoxicity. The effect of administering CefizoxTM concomitantly 
with aminoglycosides is not known.
Pregnancy: The safety of CefizoxTM in pregnancy has not been established. The use of 
CefizoxTM in pregnant women requires that the likely benefit from the drug be weighed 
against the possible risk to the mother and fetus. The pharmacokinetics of CefizoxTM jn 
pregnant patients has not been investigated. Reproduction studies performed in rats and 
rabbits have revealed no evidence of impaired fertility or harm to the fetus caused by cefti­
zoxime. Animal reproduction studies, however, are not always predictive of human 
response.
Labour and Delivery: The safety and efficacy of CefizoxTM Use during labour and delivery 
has not been investigated.
Nursing Mothers: Ceftizoxime is excreted in human milk in low concentrations (less than 
4% of serum concentrations at 1 hour after dosing). The clinical significance of this is 
unknown; therefore caution should be exercised if CefizoxTM \$ to be administered to a 
nursing woman.
Infants and Children: The safety of CefizoxTM jn infants less than 6 months of age has not 
been established. In children six months of age and older, treatment with CefizoxTM h^S , 
been associated with transient elevated levels of eosinophils, SGOT, SGPT and CPK 
(creatine phosphokinase). The CPK elevation may be related to intramuscular J 
administration.
Elderly Patients: The elimination of ceftizoxime may be reduced due to an age-dependent 
reduction in renal function.
ADVERSE REACTIONS * ~
CefizoxTM (sterile ceftizoxime sodium) is generally well tolerated. ^
Adverse Incidence Incidence
Reaction < 1 %  > 1 % b u t< 5 %
Hypersensitivity: Rash
Pruritus
Fever
*
Liver: Transient elevation of SGOT, 
SGPT and alkaline phosphatase
Blood: Neutropenia
Leukopenia
Thrombocytopenia
Transient eosinophilia
Thrombocytosis
Positive direct Coombs’ test
Renal: Transient elevation 
of BUN and creatinine
Local: Injection site: burning, cellulitis, 
phlebitis (with IV administration), 
pain, induration, tenderness, 
parasthesia ■<
Genitourinary: Vaginitis
Gastro­
intestinal:
Diarrhea, Nausea, Vomiting, Pseudomembranous colitis
No disulfiram-like reactions have been reported with CefizoxTM
TREATMENT OF OVERDOSAGE
No case of acute overdosage has been reported to date; consequently there is no speciwfc, 
information available on symptoms or treatment. In cases of suspected overdosage, 
supportive therapy should be instituted according to symptoms. Serum ceftizoxime level^ 
can be reduced by hemodialysis.
DOSAGE AND ADMINISTRATION ^
CefizoxTM (sterile ceftizoxime sodium) may be administered either intramuscularly or intra­
venously after reconstitution.
Dosage and route of administration should be determined by the condition of the patient, 
severity of the infection and susceptibility of the causative organism(s). The intravenous 
route may be preferable for patients with bacterial septicemia, or other severe or • 
threatening infections.
The usual course of treatment should be 7-14 days, and should normally continue at least 4&  
hours after evidence of bacterial eradication has been obtained. For B-hemolytic strepto­
coccal infections, a minimum of 10 days of treatment is recommended.
DOSAGE
Adults: The recommended daily dosage of CefizoxTM is 1 to 12 grams administered iit 
equally divided doses every 8 or 12 hours (see Table 1 below).
TABLE 1
Type of Infection Daily Dose 
(Grams)
Frequency and Route
\  '
Uncomplicated 
Urinary Tract
1 500mgq12h, IVorIM
Other Sites 2-3 1 g q8h orq12h, IV or IM
-~S -
Severe or 
Refractory
3-6 1 g q8h, IV or IM, to 
2g q8h or q12h, IV or IM*
Life-Threatening 9-12 3or4g  q8h IV
‘ When administering 2 g intramuscularly, the dose should be divided and injected in­
different large muscle masses.
Because of the serious nature of urinary tract infections due to Pseudomonas aeruginosa-  
and because many strains are only moderately susceptible to CefizoxTM, higher dosage 
may be appropriate when urinary tract infections are caused by these organisms. Other 
therapy should be instituted if the response is not prompt.
Adults with Impaired Renal Function: In patients in whom the creatinine clearance isj 
1.32 mUs (79 mL/min) or less, the dosage of CefizoxTM must be reduced. Following an initial 
loading dose of 500 mg to 1.0 g IM or IV, the maintenance dosing schedule presented in 
Table 2 should be followed in patients with reduced renal function. 1 A
T A B L E  2
R e c o n s t itu t io n  T a b le  fo r  S ta n d a rd  V ia ls  -  I .M .  In je c t io n
Renal
Function
Creatinine Less Severe
Clearance Infections
mL/s mL/min
Life-Threatening
Infections
Mild
Impairment
0.83-1.32 50-79 500 mg 
q8h
750 mg to 1.5 g 
q8h
Moderate to severe 
impairment
5-49 250 or 500 mg 
q12h
500 mg to 1.0 g 
q12h
Hemodialysis 
patients*
0-0.07 500 mg q48h or 500 mg to 1.0g 
250 mg q24h q48h or 500 mg
q24h
'In patients undergoing hemodialysis no additional supplemental dosing is required. 
DOSING, HOWEVER, SHOULD BE  SCHEDULED SO THAT THE PATIENT RECEIVES THE 
►DOSE AT THE END OF THE DIALYSIS. When started 24 hours after administration of 1 g of 
CefizoxTM, hemodialysis has been shown to reduce serum levels by 50%.
► When only the serum creatinine level is available, creatinine clearance may be calculated 
from the following formulae (for patients 18 years and over only). The serum creatinine level 
^should represent renal function at the steady state.
M ale s :
- Creatinine Clearance 
(mL/min)
►
Creatinine Clearance 
(mUs)
Weight (kg) x (140 - age)
72 x serum creatinine (mg/100 mL)
Weight (kg) x (140 - age)
49 x serum creatinine ( /xmol/L) 
F e m a le s : 0.85 of the above values
In fa n ts  a n d  C h ild ren : The following dosage schedule is recommended:
T A B L E  3
^Age Group Unit Dosage Frequency and Route
k Infants (6 mo-2 yrs.),
and 50 mg/kg IV or IM q6horq8h, IV or IM
Children (2-12 yrs.)
The pediatric dosage should not exceed the maximum adult dosage for serious infections. 
A D M IN IS T R A T IO N
In tra m u s c u la r: The reconstituted solution of CefizoxTM should be injected well within the 
body of a relatively large muscle, such as the gluteus. When administering 2 g IM doses, the 
 ^ jjjose should be divided equally and then injected into different large muscle masses.
In trav en o u s: Injection (bolus): The reconstituted solution of CefizoxTM should be injected 
,slowly over 3 to 5 minutes, directly or through the tubing system by which the patient is 
receiving another compatible intravenous solution. During administration of the solution 
containing CefizoxTM, it is desirable to temporarily discontinue administration of the other 
■^ solution.
k Intermittent or continuous infusion: The further diluted reconstituted solution of CefizoxTM 
w  should be administered over a 20 to 30 minute period.
N O TE : CefizoxTM solutions should not be physically mixed with any other drug. There is a 
j  isnown incompatibility with aminoglycoside antibiotics. Therefore, they should not be 
physically mixed with CefizoxTM solutions nor administered at the same site.
P H A R M A C E U T IC A L  IN F O R M A T IO N
C H E M IS T R Y
T ra d e  N a m e : CEFIZO XTM  
F J o p e rN a m e : C e ftiz ox im e  S od ium
C h e m ic a l N a m e : Sodium [6R-(6c*, 7B(Z)]]-7-[[(2,3-dihydro-2-imino-4-thiazolyl) 
(5nethoxyimino)acetyl]amino]-8-oxo-5-thia-1-azabilcyclo[4.2.0] oct-2-ene-2- 
carboxylate
_ > § tru c tu ra l F o rm u la :
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COOM.
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JOT -4HkJ
o le c u la r  F o rm u la : C -|3 H i 2 N 5 0 5 S 2 N a  
M o le c u la r  W e ig h t: 4 0 5 .3 8
D e s c rip tio n : Ceftizoxime Sodium is a white to pale yellow crystalline powder.
'c o m p o s it io n :  CefizoxTM vials contain ceftizoxime sodium (expressed in terms of free 
k  acid). The sodium content of each gram of CefizoxTM js approximately 60 mg (2.6 mEq 
■  sodium ion).
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R E C O N S T IT U T IO N
^ STANDARD VIALS (1 GRAM and 2 GRAMS)
F o r In tra m u s c u la r  In je c tio n : Reconstitute with Sterile Water for Injection or Bacteriosta­
tic Water for Injection.
Solutions of CefizoxTM range from colourless to pale yellow, depending upon the diluent 
?ihd volume used. The solution should be discarded if it becomes cloudy. The pH of 
shly reconstituted solutions usually ranges from 6.0 to 8.0.
K solution of 1 g CefizoxTM in 13 mL Sterile Water for Injection is isotonic.
Vial
Approximate Approximate
Diluent to be Available Average
Size Added to Vial Volume Concentration
1 9 3.0 mL 3.7 mL 270 mg/mL
29 6.0 mL 7.4 mL 270 mg/mL
Shake well until dissolved.
F o r  In tra v e n o u s  In je c t io n :  Reconstitute only with Sterile Water for Injection.
R e c o n s t itu t io n  T a b le  fo r  S ta n d a rd  V ia ls  - I.V . In je c t io n
Vial
Approximate Approximate
Diluent to be Available Average
Size Added to Vial Volume Concentration
1 g 10 mL 10.7 mL 95 mg/mL
2g 20 mL 21.4 mL 95 mg/mL
Shake well until dissolved.
F o r In tra v e n o u s  In fu s io n : Reconstitute as for intravenous injection. Further dilute the 
reconstituted solution to 50 to 100 mL with one of the “ Solutions for Intravenous 
Infusion” (see below).
T A B L E  4: S o lu t io n s  fo r  In t ra v e n o u s  In fu s io n
Sodium Chloride Injection 
5 %  or 10% Dextrose Injection
5 %  Dextrose and 0.9%, 0.45% or 0.2% Sodium Chloride Injection
Ringer’s Injection
Lactated Ringer’s Injection
10% Invert Sugar in Sterile Water for Injection
5 %  Sodium Bicarbonate in Sterile Water for Injection
5 %  Dextrose in Lactated Ringer’s Injection ONLY when reconstituted with 4 %  Sodium 
Bicarbonate Injection.
S T A B IL IT Y  O F  S O L U T IO N S
S to ra g e :  All reconstituted solutions and those further diluted should be used within 24 
hours if stored at room temperature or within 48 hours if refrigerated. These storage limits 
are from the time of the initial reconstitution.
In c o m p a tib ility :  CefizoxTM should not be added to blood products, protein hydrolysates 
or amino acids. CefizoxTM should not be mixed together with an aminoglycoside.
D O S A G E  F O R M S
A v a ila b ility :  CefizoxTM jS available as a sterile powder in Standard Vials of 1 gram or 
2 grams, containing ceftizoxime as sodium salt.
S to ra g e : CefizoxTM powder for injection should be stored at room temperature (15°-30°C).
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'As indicated in the manufacturer's product monograph. Cefizox. Smith Kline & French Canada Ltd.. 1988 
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3Lou M.A. etal.: 14th International Congr. Chemother.. Kyoto. Japan. June 1985, pp 2378-2379.
4Neu H.C., Chin N X : The activity and beta-lactamase stability of cefotetan compared to other beta-lactam antibiotics 
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easy, but the author’s format avoids 
wasting time in seeking an answer 
through an index or searching papers 
and textbooks. It is, in fact, a method 
for reviewing knowledge at the last 
minute before an examination or in 
limited spare time. Almost all aspects of 
orthopedics and fractures are covered in 
the 255 pages of this soft-cover book. 
The coverage is not, however, in great 
depth; this would be impossible in a 
text this long. The questions the author 
poses are the kind encountered at oral 
examinations. A pictorial section at the 
end, consisting of x-ray fdms also has 
questions and answers.
Although this book is a useful addi­
tion to the orthopedic literature, it is 
not clear at which level of training or 
expertise it would be most effective. It 
would certainly be extremely helpful for 
orthopedic nurses, medical students and 
those preparing for board and fellow­
ship examinations in related specialties. 
It may fall short of the depth of knowl­
edge required by senior orthopedic resi­
dents.
These comments aside, the book is a 
very interesting and informative way of 
reviewing an extensive subject.
Charles Sorbie, MB, ChB, FRCS(Edin), 
FRCSC
Professor and Head,
Department o f Surgery.
Queen's University,
Kingston, Ont.
PEDIATRIC NEUROSURGERY. Sur­
gery of the Developing Nervous Sys­
tem. 2nd edition. Edited by Robert L. 
McLaurin, Joan L. Venes, Luis Schut 
and Fred Epstein. 604 pp. Illust. W.B. 
Saunders Company Canada Limited, 
Toronto, 1989. $215.95. ISBN
0-7216-2748-X.
Under the auspices of the pediatric 
section of the American Association of 
Neurological Surgeons and with four 
outstanding editors the first edition 
(1982) has been updated with extensive
new information to reflect the dramatic 
expansion of pediatric neurosurgery in 
the intervening years.
Written by 75 contributors, the book 
contains 54 chapters, divided into six 
parts: developmental abnormalities, hy­
drocephalus, trauma, neoplasms, infec­
tions, and vascular diseases and miscel­
laneous diseases. There is an excellent 
index at the end of the book and a 
manageable number of references, both 
classic and current, at the end of each 
chapter.
The illustrations, all black and white, 
are selected with great care, and most 
of them serve well their purpose to 
enhance the clarity of the text. In some 
cases, however, the point would have 
been more clearly made had colour 
illustrations been used. The high-qual­
ity editing and the work of the illustra­
tion coordinator rescues the text from 
the undesired variety of styles in writ­
ing, art work and photography, the 
usual drawbacks of multiauthored 
books.
Although this book is outstanding in 
most of its features, I found the ac­
count of miscellaneous diseases, partic­
ularly the chapters on epilepsy and on 
movement disorders, incomplete. Sur­
gery for these two conditions has 
gained renewed interest lately and this 
could have been emphasized in a more 
detailed discussion of some of the treat­
ment modalities. On the other hand, 
developmental abnormalities, trauma 
and neoplasms are superbly handled 
and they represent the greatest strength 
of this very informative book.
Enlarging the scope of the first edi­
tion of this basic reference book on 
diseases of the nervous system in the 
pediatric age group was timely and the 
editors did a great service to those who 
deal with sick children. This new, much 
improved volume should be a standard 
text in the library of neurologists, neu­
rosurgeons and pediatricians.
Leslie P. Ivan, MD, FRCSC, FACS
Coordinator o f Postgraduate Surgical 
Education,
University o f Ottawa,
Ottawa Civic Hospital,
1053 Carling Ave.,
Ottawa. Ont.
K 1 Y 4 E 9
NEUROLOGICAL EMERGENCIES. 
S.D. Shorvon. 108 pp. Illust. Butter- 
worths, Stoneham, Mass. 1989. $22.95 
(US). ISBN 0-407-00873-X
This book in 10, short, well-written 
chapters covers all the principal neuro­
logic emergencies. It gives the reader a 
feel of how physicians actually go about 
treating the entities involved.
Unfortunately, it really does not give 
sufficient information to undertake the 
specific therapies and investigations 
suggested. For example, I think one 
would be inclined to forego oculoves- 
tibular testing rather than proceed pre­
cisely according to the description in 
the text. The treatments for a number 
of entities do not correspond to what is 
currently suggested in North America. 
For example, in the chapter on coma 
the possibility of narcotic overdose is 
not sufficiently emphasized.
The section on meningitis does not 
point out the important role of third- 
generation cephalosporins nor is the 
reader made aware of the difficulties 
associated with cerebrospinal fluid pen­
etration of gentamicin. The chapter on 
brain abscesses emphasizes the impor­
tance of urgent surgical intervention 
whereas in North America most brain 
abscesses are treated initially with anti­
biotics. The chapter on acute spinal 
cord injuries does not consider the 
important use of high-dose steroids, 
particularly when a metastatic tumour 
is involved.
In the chapter on status epilepticus 
diazepam is given a predominant role, 
contrary to the position taken in North 
America. Paraldehyde is mentioned as a 
first-line medication, whereas in Canada 
it is considered a third-line medication, 
if used at all. The doses of phenytoin 
recommended may be too high for some 
smaller adults and inadequate for many; 
doses are best expressed in mg/kg. 
Furthermore, the table that describes 
the medications used in status epilep­
ticus contains errors in organization 
that make it unusable. According to the 
author, this book is designed for the 
general practitioner, emergentologist or 
the resident in neurology or neurosurg­
ery. I would suggest this book may give 
a family doctor an overview of what is
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happening in the treatment of emergen­
cy neurologic conditions. It certainly is 
not adequate for the emergentologist or 
for a resident in neurology or neuro­
surgery.
H.E. Rabinovitch, MD, CM, FRCPC 
Ste. B l l ,
770 Broadview Ave..
Ottawa. Out.
THE DOCTOR AND THE LAW. 2nd 
edition. H.E. Emson. 240 pp. Illust. 
Butterworths Canada Ltd., Toronto, 
1989. $49.50. ISBN 0-409-88875-3.
Coincidentally, this compact and de­
lightful publication came across my 
desk while 1 was searching for an 
informative source of reference material 
in the wide arena of medicolegal issues.
This is the second edition of the 
book by Dr. Emson, Professor and 
Head of Pathology at the University of 
Saskatchewan School of Medicine.
Physicians and surgeons need a 
ready reference to medicine and law, 
and this book fills their requirements. 
Scanning the table of contents, I found 
a full list of topics of a general and 
specific nature in the areas of making 
law, the adversary system, licensure, 
ethics and discipline. Excellent but brief 
sections cover federal and provincial law 
with rights and responsibilities. Struc­
ture of courts, giving evidence, coro­
ners and examiners are some chapter 
contents, which are briefly yet succinct­
ly given in a light and readable fashion.
Subjects often discussed and ques­
tions often put to the Canadian Medical 
Protective Association have to do with 
malpractice and negligence, consent 
and report. Individual chapters on these 
subjects are informative and practical 
and will serve as a basis for practice and 
teaching.
The sections on sex and the law, life 
issues, alcohol and drugs are covered 
rapidly, but I find that the author is 
always trying to be practical, which 
makes up for the limited space and 
constraint of time that prevents in- 
depth coverage of deep and controver­
sial issues.
No other book that I have seen 
covers all these areas including the 
doctor’s place in hospital and office as 
well in 235 pages. A section of notes 
and basic references are given to those 
wishing further study, and a reasonable 
index helps the reader to locate points 
of interest.
In reading through this book, I often 
found myself reflecting on the basic 
aspects of surgical practice in relation 
to the ever-present concepts of law and 
ethics which are as real as diagnosis 
and treatment in today’s society.
Books like The Doctor and the Law 
are now important reading for the medi­
cal and surgical practitioner. This book 
belongs on our study or office desk.
Nis Schmidt, MD, MSc, FRCSC
Clinical Professor,
Department o f  Surgery,
University o f British Columbia,
St. Paul's Hospital.
1081 BurrardSt.,
Vancouver, BC,
V6Z1Y6
PIONEERS OF CARDIOLOGY IN 
CANADA 1820-1970. The Genesis of 
Canadian Cardiology. Harold N. Se- 
gall. 525 pp. Illust. Hounslow Press, 
Willowdale, Ont. 1988. $45. ISBN 0 -  
88882-105-0
Consideration of the cardiovascular spe­
cialties in 1989 brings to mind high- 
technology laboratories (in which angi­
ography, cardiac ultrasonography and 
radionuclide imaging take place), so­
phisticated surgical approaches to con­
genital and acquired diseases of heart 
and vessels, and aggressive pharmaco­
logic approaches to the therapy of 
acute myocardial infarction and cardiac 
failure. Reading this book makes one 
realize how recently most of our cur­
rent approaches have been developed. 
In the 150 years covered in this book, 
however, some enormously important 
discoveries were made, discoveries that 
laid the foundations for the modern 
diagnosis and treatment of cardiovascu­
lar disease.
Because this book developed from 
the work of the archivist of the Canadi­
an Cardiovascular Society, the reader 
might expect a parochial viewpoint. In
fact, Dr. Segall cleverly weaves in his 
descriptions of the important interna­
tional figures and their contributions. 
The enormous genius and influence of 
such individuals as William Osier, 
Thomas Lewis and Paul Dudley White 
are apparent as is the significance of 
the development of electrocardiography 
and roentgenography, and the advances 
made possible by the understanding of 
cardiac embryology.
The basic information for this book 
was provided by those members of the 
Canadian Cardiovascular Society who 
responded to a questionnaire circulated 
in the mid-1960s. Dr. Segall used this 
and his own extensive personal knowl­
edge of Canadians interested in the 
cardiovascular system to produce this 
overview of the development of cardio­
logy and cardiac surgery in Canada. 
Some gaps, of course, exist since the 
response to the questionnaire (as usual) 
was not complete. Overall, however, the 
book provides an important record of 
Canadians’ contributions to progress in 
this discipline.
Specific chapters are devoted to such 
areas as the development of electrocar­
diography, cardiac roentgenology, car­
diac surgery and cardiac catheteriza­
tion, to the concepts of monitoring, 
pacing and coronary care — the last 
two being disciplines to which Canadi­
ans have made prominent contributions.
This book is of value to all who are 
interested in our medical past; it is 
particularly pertinent to those involved 
in the cardiovascular sciences. Al­
though the organization is somewhat 
disjointed and there is some repetition, 
the style overall is personal and engag­
ing. It is written by a senior, highly 
respected member of the cardiovascular 
community who has experienced many 
exciting developments during his more 
than 90 years. He has been successful 
in transmitting much of that excitement 
in his book. I certainly enjoyed reading 
it.
Eldon R. Smith, MD, FRCSC
Professor o f  Medicine and Medical 
Physiology.
University o f  Calgary,
Foothills Hospital.
Calgary, Alta.
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The Surgical Examination of Children.
J.M. Hutson and S.W. Beasley. 271 pp. 
Illust. Butterworths, Stoneham, Mass. 
1988. $95 (US). ISBN 0-433-00051-1
Thoracic Surgery. Edited by H. Pichl- 
maier and F.W. Schildberg, 460 pp. 
Illust. Springer-Verlag New York, Inc., 
Secaucus, NJ. 1989. $375 (US). ISBN 
0-387-18464-3
Trauma. Pathogenesis and Treatment. 
Edited by Stephen Westaby. 414 pp. 
Illust. Heinemann Medical Books, Ox­
ford; Butterworths, Stoneham, Mass. 
1989. $125 (US). ISBN 0-433-35502- 
6
Urologic Pathology With Clinical and 
Radiologic Correlations. Edited by 
Ayten Someren. 753 pp. Illust. Macmil­
lan Publishing Company, New York. 
1989. $125 (US). ISBN 0-02-413750- 
2
Vascular Disorders of the Upper Ex­
tremity. 2nd edition. Revised and en­
larged. Edited by Herbert 1. Machleder. 
409 pp. Future Publishing Company, 
Inc., Mount Kisco, NY. 1989. $55 (US). 
ISBN 0-87993-347-X
Vascular Surgery, Third Edition. Vol­
ume 1. Edited by Robert B. Rutherford. 
905 pp. Illust. W.B. Saunders Compa­
ny, Philadelphia. 1989. $279.95 (US) 
(set). ISBN 0-7216-2065-5
Vascular Surgery, Third Edition. Vol­
ume 2. Edited by Robert B. Rutherford. 
862 pp. Illust. W.B. Saunders Compa­
ny, Philadelphia. 1989. $279.95 (US) 
(set). ISBN 0-7216-2065-5
Wound Healing. Problems in Genera! 
Surgery, Volume 6, April-June 1989. 
Edited by Harold Ellis and Peter M. 
Lamont. 167 pp. Illust. J.B. Lippincott 
Company, Philadelphia. 1989. Price not 
stated. ISSN 0739-8328
s 0Mefoxin*n
(sterile cefoxitin sodium, MSD Std.) 
A N T IB IO T IC
ACTION
In vitro studies demonstrate that the bactericidal 
action of cefoxitin, a cephamycin derived from 
cephamycin C, results from the inhibition of 
bacterial cell wall synthesis. Evidence suggests 
that the methoxy group in the 7ar position is 
responsible for the resistance of cefoxitin to 
degradation by bacterial beta-lactamases.
INDICATIONS AND CLINICAL USES
TREATMENT
The treatment of the following infections when 
due to susceptible organisms:
1 - Intra-abdominal infections such as peritonitis
and intra-abdominal abscess
2 - Gynecological infections such as endo­
metritis and pelvic cellulitis
3 - Septicemia
4 - Urinary tract infections (including those
caused by Serratia marcescens and Serratia 
spp.)
5 - Lower respiratory tract infections
6 - Bone and jo in t infections caused by
Staphylococcus aureus
7 - Soft tissue infections such as cellulitis,
abscesses and wound infections
Appropriate culture and susceptibility studies 
should be performed to determine the suscepti- 
b il ity  of the causative organ ism (s) to 
MEFOXIN®. Therapy may be started while 
awaiting the results of these tests, however, 
modification of the treatment may be required 
once these results become available.
Organisms particularly appropriate for therapy 
with MEFOXIN® are:
Gram positive
Staphylococci, penicillinase producing and 
non-producing
Streptococci excluding enterococci
Gram negative (beta-lactamase producing and 
non-producing strains)
Escherichia coli
Klebsiella species (including K. pneumoniae) 
Proteus, indole positive and negative 
Haemophilus influenzae 
Providencia species
Anaerobes
Bacteroides fragilis
MEFOXIN® may also be appropriate for the 
treatment of infections involving susceptible 
strains of both aerobic and anaerobic bacteria.
MEFOXIN® is not active against Pseudomonas 
spp., most strains of enterococci, many strains 
of Enterobacter cloacae, and methicillin- 
re s is ta n t s ta p h y lo c o c c i and L is te r ia  
monocytogenes.
Clinical experience has demonstrated that 
MEFOXIN® can be administered to patients who 
are also receiving carbenicillin, gentamicin, 
tobramycin, or amikacin (see PRECAUTIONS 
and ADMINISTRATION).
PROPHYLACTIC USE
MEFOXIN® may be administered periopera- 
tively (preoperatively, intraoperatively and post- 
operatively) to patients undergoing vaginal or 
abdominal hysterectomy and abdominal surgery 
when there is a significant risk of postoperative 
infection or where the occurrence of post­
operative infection is considered to be especially 
serious.
In patients undergoing cesarean section, intra­
operative (after clamping the umbilical cord) 
and postoperative use of MEFOXIN® may 
reduce the incidence of surgery related post­
operative infections.
®Trademark Merck & Co., Inc./ 
Merck Frosst Canada Inc., R.U.
Effective prophylactic use depends on the time 
of administration. MEFOXIN® usually should be 
given one-half to one hour before the operation. 
Prophylactic administration should usually be 
stopped within 12 hours. It has been generally 
reported that continuing administration of any 
antibiotic beyond 24 hours following surgery 
increases the possibility of adverse reactions 
but, in the majority of surgical procedures, does 
not reduce the incidence of subsequent 
infection.
If signs of postsurgical infection should appear, 
specimens for culture should be obtained for 
identification of the causative organism(s) so 
that appropriate treatment may be instituted.
CONTRAINDICATIONS
MEFOXIN® is contraindicated in persons who 
have shown hypersensitivity to cefoxitin or to 
the cephalosporin group of antibiotics.
WARNINGS
Before therapy with MEFOXIN® is instituted, 
careful inquiry should be made to determine 
whether the patient has had previous hyper­
sensitivity reactions to MEFOXIN®, cepha­
losporins, penicillins or otherdrugs. MEFOXIN® 
should be given with caution to penicillin- 
sensitive patients.
There is some clinical and laboratory evidence 
of partial cross-allergenicity between cepha- 
mycins and the other beta-lactam antibiotics, 
penicillins and cephalosporins. Severe reactions 
(including anaphylaxis) have been reported 
with most beta-lactam antibiotics.
Pseudomembranous colitis has been reported 
w ith  v ir tu a lly  all a n tib io tic s  in c lu d in g  
MEFOXIN®. This colitis can range from mild to 
life threatening in severity. Antibiotics should 
therefore be prescribed with caution in indi­
viduals with a history of gastrointestinal disease, 
particularly colitis. It is important to consider a 
diagnosis of pseudomembranous colitis in 
patients who develop diarrhea in association 
with antibiotic use. While studies indicate that a 
toxin produced by Clostridium difficile is one 
primary cause of antibiotic-associated colitis, 
other causes should also be considered.
Any patient who has demonstrated some form of 
allergy, particularly to drugs, should receive 
antibiotics including MEFOXIN® with caution.
If an allergic reaction to MEFOXIN® occurs, 
administration of the drug should be dis­
continued. Serious hypersensitivity reactions 
may require treatment with epinephrine and 
other emergency measures.
PRECAUTIONS
The total daily dosage should be reduced when 
MEFOXIN® is administered to patients with 
transient or persistent reduction of urinary 
output due to renal insufficiency (see DOSAGE 
AND ADMINISTRATION) because high and 
prolonged serum antibiotic concentrations can 
occur from usual doses.
In patients treated with MEFOXIN® a false­
positive reaction to glucose in the urine may 
occur with Benedict’s or Fehling's solutions but 
not with the use of specific glucose oxidase 
methods.
Using the Jaffe Method, falsely high creatinine 
values in serum may occur if serum concen­
trations of cefoxitin exceed 100 pg/mL. Serum 
samples from patients treated with MEFOXIN® 
should not be analyzed for creatinine if with­
drawn within two hours of drug administration.
High concentrations of cefoxitin in the urine 
may interfere with measurement of urinary 17- 
hydroxy-corticosteroids by the Porter-Silber 
reaction, and produce false increases of modest 
degree in the levels reported.
Increased nephrotoxicity has been reported 
fo llow ing  concom itant adm in is tra tion of 
cephalosporins and aminoglycoside antibiotics. 
Prolonged use of MEFOXIN® may result in the 
overgrowth of non-susceptible organisms. 
Repeated evaluation of the patient's condition is 
essential and if super-infection occurs during 
therapy, appropriate measures should be taken. 
Should an organism become resistant during 
antibiotic therapy, another antibiotic should be 
substituted.
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Use in Pregnancy
The safety of MEFOXIN® in the treatment of 
infections during pregnancy has not been 
established. If the administration of MEFOXIN® 
to pregnant patients is considered necessary, its 
use requires that the anticipated benefits be 
weighed against possible hazards to the fetus. 
Reproductiveand teratogenic studies have been 
performed in mice and rats and have revealed no 
evidence of impaired fertility or harm to the fetus 
due to MEFOXIN®.
Nursing Mothers
Cefoxitin is excreted in human milk.
Children
In children 3 months of age or older, higher 
doses of MEFOXIN® (100 m g/kg/day and 
above) have been associated with an increased 
incidence of eosinophilia and elevated SGOT.
ADVERSE REACTIONS
MEFOXIN® is generally well tolerated. Adverse 
reactions rarely required cessation of treatment 
and usually have been mild and transient.
Local Reactions
Thrombophlebitis has occurred with intra­
venous administration. Some degree of pain and 
tenderness is usually experienced after intra­
muscular injections using water. Induration has 
occasionally been reported.
Allergic
M aculopapular rash, u rtica ria , p ruritus, 
eosinophilia, fever and other allergic reactions 
have been noted.
Gastrointestinal
Symptoms of pseudomembranous colitis can 
appear during or after antibiotic treatment. 
Nausea and vom iting have been reported rarely. 
Blood
Eosinophilia, leukopenia, neutropenia, hemo­
lytic anemia, and thrombocytopenia and bone 
marrow depression have been reported. Some 
individuals, particularly those with azotemia, 
may develop positive direct Coombs tests 
during therapy with MEFOXIN®.
Liver Function
Transient elevations in SGOT, SGPT, serum 
LDFI, and serum alkaline phosphatase and 
jaundice have been reported.
Cardiovascular Function 
Fiypotension.
Renal Function
Elevations in serum creatinine and/or blood 
urea nitrogen levels have been observed. As 
with the cephalosporins, acute renal failure has 
been reported rarely. The role of MEFOXIN® in 
changes in renal function tests is difficult to 
assess, since factors predisposing to prerenal 
azotemia or to impaired renal function have 
often been present.
TREATMENT OF OVERDOSE
Other than general supportive treatment, no 
specific antidote is known. MEFOXIN® can be 
eliminated by dialysis in patients with renal 
insufficiency.
DOSAGE AND ADMINISTRATION
MEFOXIN® may be administered intravenously 
or intramuscularly as required. (See complete 
m onograph on A D M IN IS TR A TIO N  and 
RECONSTITUTION.)
Intravenous Administration
The intravenous route is preferable for patients 
with bacteremia, bacterial septicemia, or other 
severe or life-threatening infections, or for 
patients who may be poor risks because of 
lowered resistance resulting from such debili­
tating conditions as m alnutrition, trauma, 
surgery, diabetes, heart failure, or malignancy, 
particularly if shock is present or impending. 
TREATMENT DOSAGE 
Adults
The usual adult dosage is 1 g or 2 g of 
MEFOXIN® every 6 to 8 hours. Dosage and 
route of administration should be determined by 
severity of infection, susceptib ility  of the 
causative organisms, and condition of the 
patient. The usual adult dosages are shown in 
the Table below.
Usual Adult Dosage
Type of Daily Frequency
infection Dosage and Route
Uncomplicated 3-4 g 1 g every 6-8 h
forms* of in- I.V. or I.M.
fections such as
pneumonia,
urinary tract
infection, soft
tissue infection
Moderately 6-8 g 1 g every 4 h
severe or severe or
infections 2 g every 6-8 h I.V.
Infections 12 g 2 g every 4 h
commonly or
needing anti- 3 g every 6 h I.V.
biotics in higher 
dosage (e.g. gas 
gangrene)
’ Including patients in whom bacteremia is absent or 
unlikely
Therapy may be started while awaiting the 
results of susceptibility testing.
Antibiotic therapy for group A beta-hemolytic 
streptococcal infections should be maintained 
for at least 10 days to guard against the risk of 
rheumatic fever or g lomerulonephritis. In 
staphylococcal and other infections involving a 
collection of pus, surgical drainage should be 
carried out where indicated.
Adults with Impaired Renal Function
MEFOXIN® may be used in patients with 
reduced renal function but a reduced dosage 
should be employed and it is advisable to 
monitor serum levels in patients with severe 
impairment.
In adults with renal insufficiency, an initial 
loading dose of 1 g to 2 g should be given. After 
a loading dose, the following recommendations 
for maintenance dosage may be used as a guide:
MAINTENANCE DOSAGE OF 
MEFOXIN® IN ADULTS 
WITH REDUCED RENAL FUNCTION
RENAL
FUNCTION
CREATININE
CLEARANCE
mL/min
DOSE FREQUENCY
Mild
impairment 50-30 1-2 g every 8-12 h
Moderate
impairment 29-10 1-2 g every 12-24 h
Severe
impairment 9-5 0.5-1 g every 12-24 h
Essentially 
no function <5 0.5-1 g every 24-48 h
At presen t there  is in s u ff ic ie n t data to 
recommend a specific dosage for children with 
impaired renal function. However, if the adminis­
tration of MEFOXIN® is deemed to be essential 
the dosage should be modified consistent with 
the recommendations for adults (see Table 
above).
PROPHYLACTIC USE
For prophylactic use, a three-dose regimen of 
MEFOXIN® is recommended as follows:
Vaginal or abdominal hysterectomy and 
abdominal surgery
2g  administered intram uscularly or in tra ­
venously just prior to surgery (approximately 
one-half to one hour before initial incision).
The second and th ird 2 g doses should be 
administered at 2-6 hour intervals after the 
initial dose.
Cesarean Section
The first dose of 2 g should be administered 
intravenously as soon as the umbilical cord has 
been clamped. The second and third 2 g doses 
should be given intravenously or intramus­
cularly four hours and eight hours after the first 
dose.
AVAILABILITY
MEFOXIN® is supplied as sterile powder in 
boxes of 10 vials:
3356 Ca - 1 g cefoxitin as sodium salt
3357 Ca - 2 g cefoxitin as sodium salt 
Storage
MEFOXIN® in the dry state should be stored 
below 30°C. The dry material as well as 
solutions tends to darken, depending on storage 
conditions; product potency, however, is not 
adversely affected.
PRODUCT MONOGRAPH AVAILABLE 
ON REQUEST
(332-a,4,89)
3386
| PAAB | | l
MSD
MERCK
SHARft
DOHME
C A N A D A
P.O. BOX 1005, POINTE-CLAIRE 
DORVAL, QUEBEC H9R 4P8
In patients undergoing hemodialysis, the 
loading dose of 1 - 2 g should be given after each 
hemodialysis, and the maintenance dose should 
be given as indicated in the Table above.
Neonates (Including Premature Infants), Infants 
and Children (See WARNINGS for Neonates 
under ADMINISTRATION in the complete 
monograph.)
Premature Infants 
with Body Weights 
Above 1500 g 20-40 mg/kg every 12 h I.V.
Neonates
0-1 week of age 20-40 mg/kg every 12 h I.V.
1-4 weeks of age 20-40 mg/kg every 8 h I.V.
Infants
1 month to 2 years 20-40 mg/kg every 6 h or
of age every 8 h I.M. or I.V.
Children 20-40 mg/kg every 6 h or 
every 8 h I.M. or I.V.
In severe infections, the total daily dosage in 
infants and children may be increased to 
200 mg/kg, but not to exceed 12 g per day. 
MEFOXIN® is not recommended for the therapy 
of meningitis. If meningitis is suspected, an 
appropriate antibiotic should be used.
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CLASSIFIED ADVERTISING
As a further service to its readers the Canadian Journal of Surgery is pleased to accept suitable classified advertisements. The deadline is 1 
month before issue date. Regular classified rates (for each insertion): $50.00 for the first 40 words or less, additional words 65<f each (additional 
$20.00 for frame). Special Display under 100 words, 2'/» in. X 2 in., $120.00. $15.00 charge (first insertion only) for CJS box numbers. Display 
rates available on request.
Copy should be mailed to the Canadian Journal o f Surgery, PO Box 8650, Ottawa, Ontario K1G 0G8.
GENERAL SURGICAL ONCOLOGY FEL­
LOWSHIP: ON -  The Division of General 
Surgery at the Toronto General Branch of the 
Toronto Hospital is offering a 1 year clinical 
fellowship available beginning July 1, 1990. 
This fellowship provides excellent exposure 
to complex general surgical oncological prob­
lems including reoperative Gl cancer surgery, 
endocrine malignancies, and head and neck 
cancers. The fellow will also have the oppor­
tunity to be involved in ongoing clinical trials 
in adjuvant therapy of breast and colorectal 
cancers and will be encouraged to initiate at 
least one new prospective or retrospective 
study with appropriate resources provided. 
Block rotations of 6-8 weeks in the Depart­
ments of Radiotherapy and Chemotherapy are 
also an integral component of this program. 
The fellow is also expected to take a minor 
part in the training of residents in general 
surgery. This fellowship is intended for indi­
viduals who have completed a general sur­
gery residency and are eligible for certifica­
tion. Send enquiries and curriculum vitae to: 
Dr. J. Ali, Director, Postgraduate Educa­
tion, Department of Surgery, Banting Insti­
tute, Room 311, 100 College St., Toronto, 
ON M5G 1 L5. -S90-03
HEAD OF ORTHOPEDIC DIVISION: ON -
Applications are invited for the above posi­
tion. The Orthopaedic Services at The Toron­
to General Hospital and Toronto Western 
Hospital are being amalgamated, creating a 
single division sited at The Toronto Western 
Hospital. Applicants must show evidence of 
proven ability in the organization of patient 
care, research, teaching, and other aspects of 
academic surgery. The candidate should have 
the capacity to lead a large, multi-facetted 
program. This joint hospital-university ap­
pointment represents an exciting opportunity 
for program development in orthopedic sur­
gery. In accordance with Canadian immigra­
tion requirements, this advertisement is di­
rected to Canadian citizens and permanent 
residents. Applications, with accompanying 
curriculum vitae, should be addressed to: Dr. 
Alan R. Hudson, Surgeon-in-Chief, The To­
ronto Hospital, 585 University Ave., Bell 
Wing 1-636, Toronto, ON Canada M5G 
2C4. -S 90-11
GENERAL/THORACIC AND GENERAL/ 
VASCULAR SURGEON: SK — To join group 
of three general surgeons and one general 
vascular surgeon to service the respiratory 
medical and vascular units at the Regina 
General Hospital. For further information 
please contact: Dr. D.A. Dunn, 550, 1809 
Rose St., Regina, SK. Tel: (306)
757-0484. -S90-12
HANTS COMMUNITY HOSPITAL
WINDSOR, NOVA SCOTIA
GENERAL SURGEON
Required for a 120-bed community hospital located in the beautiful 
ANNAPOLIS VALLEY 
The Hants Community is located in 
WINDSOR
THE GATEWAY TO THE ANNAPOLIS VALLEY
Excellent recreational facilities, including skiing and golfing. It is 
approximately 45 minutes from Halifax and serves a population of 25 000.
Applicants must be Canadian certified or eligible. Additional training in 
minor orthopedics and gynecology a definite asset.
Reply to:
W.E. Skerry, Administrator 
Hants Community Hospital 
Windsor, Nova Scotia 
BON 2T0
_____________________ Tel: (902) 798-8351 _________  S-90-7
CLASSIFIED ADVERTISING
Unlike a tabloid or newspaper that is read today and discarded 
tomorrow, an advertisement in the Classified Advertising section 
of CJS is read today and reread tomorrow.
CJS is the only Canadian publication exclusively for surgeons.
No other Canadian surgical publication reaches over 9000 
subscribers every 2 months, giving wide coverage for your 
advertising dollar.
Average issue readership of CJS (81 %) is among the highest of 
any medical journal in Canada, and the latest readership 
studies confirm the best and most cost efficient way to reach 
Canadian surgeons is through the pages of CJS.
LET CJS CLASSIFIED ADS WORK FOR YOU - c js -1
The Calgary 
General Hospital m A
Bow Valley Centre 
Peter Lougheed Centre
General Surgeon
The Calgary General Hospital invites 
applications for a position in General 
Surgery. The successful applicant will be 
expected to have specialized training and 
interest in thoracic or peripheral vascular 
surgery and to participate in undergraduate 
and post-graduate teaching and research. 
The candidate should be a Fellow of the 
Royal College of Physicians and Surgeons 
of Canada and be eligible for licensure by 
the College of Physicians and Surgeons of 
Alberta.
The Calgary General Hospital is a 940-bed 
teaching hospital affiliated with the 
University of Calgary.
In a c c o rdanc e  with im m ig ra t io n  
requirements, preference will be given to 
Canadian ci t izens and permanent  
residents.
Reply, including curriculum vitae and the 
names of three referees, to:
Director, Department of Surgery
The Calgary General Hospital -  Bow Valley Centre
841 Centre Avenue E. Calgary, Alberta T2E 0A1
—S-90-10
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HEAD
DIVISION OF CARDIOVASCULAR SURGERY 
VICTORIA HOSPITAL
CHILDREN’S HOSPITAL OF WESTERN ONTARIO 
London, Ontario
Victoria Hospital, an 841-bed tertiary care teaching 
hospital affiliated with the Faculty of Medicine, 
University of Western Ontario, invites applications for 
the position of Head of the Division of Cardiovascular 
Surgery. The centre currently provides both adult and 
pediatric surgery for southwestern Ontario and is 
undergoing immediate expansion to meet regional 
cardiovascular surgery needs.
The successful candidate will have an FRCSC, be 
eligible to practise in Ontario, be recognized as a 
skilled surgeon and teacher, have demonstrated 
superior leadership and planning abilities, and maintain 
active interest in clinical and laboratory research.
Deadline for receipt of applications is April 30, 1990.
Interested candidates should forward their curriculum 
vitae in confidence to:
Glenn S. Bartlett 
Chief Operating Officer 
Victoria Hospital 
375 South Street 
London, Ontario
N6A 4G5 s-90-8
Requires An
ORTHOPAEDIC
SURGEON
The Nanaimo Regional General Hospital is 
searching for an orthopaedic surgeon to join four 
others on the medical staff. Our 436-bed regional 
referral hospital provides community hospital 
services for an immediate population of 85,000 
and secondary referral services for a population 
of 250,000.
Nanaimo is a scenic harbour city with exceptional 
recreational opportunities on the east coast of 
Vancouver Island. We are looking for a surgeon 
who is interested in establishing a busy, general 
orthopaedic practice in this very desirable location.
Interested othopaedic surgeons should forward 
a curriculum vitae and the names of three references 
to: Dr. B. Johnstone, Medical Coordinator, 
Nanaimo Regional General Hospital, 1200 
Dufferin Crescent, Nanaimo, B.C. V9S 2B7, at 
their earliest convenience.
—S-90-9
ORDER FORM_________________ BOX NO.: YES □  NO □
ADVERTISEMENT: NO. OF INSERTIONS:
INVOICE:
ALL ADVERTISEMENTS FROM OUTSIDE CANADA MUST BE PREPAID. 
ADDRESS ORDERS TO: Classified Advertising,
Canadian Journal of Surgery,
PO Box 8650, Ottawa, ON K1G 0G8
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HEAD, DIVISION OF THORACIC SURGERY 
MOUNT SINAI HOSPITAL, TORONTO, ONTARIO
Mount Sinai Hospital, a 526-bed acute care, general teaching hospital, fully affiliated with Canada’s largest 
Faculty of Medicine at the University of Toronto, requires a Division Head of Thoracic Surgery. The Division 
of Thoracic Surgery is a university-based program under the overall direction of Dr. Martin McKneally, 
Professor of Thoracic Surgery.
The Division of Thoracic Surgery has a complement of 3 full-time staff surgeons and 20 beds, including 4 fully 
equipped step-down beds. The Division’s major clinical and research thrust is in oncology and it also 
participates in the University’s Lung Transplantation Program. The planned relocation of the Ontario Cancer 
Institute/Princess Margaret Hospital, Canada’s premier oncology centre, next door to the Mount Sinai 
Hospital will further stimulate development in oncology. Both institutions are renowned for their research 
endeavours and the successful integration of these endeavours with patient care programs. The Division is 
also committed to a very active undergraduate and postgraduate teaching program.
The successful candidate will have an FRCSC or equivalent; be eligible to practise medicine in Ontario; will 
be recognized as a skilled thoracic surgeon and an outstanding teacher; will have a background in research 
and be interested in and capable of furthering existing and planned research programs; will have effective 
leadership abilities, with previous experience in an administrative position.
The successful candidate would be eligible for a senior academic appointment.
In accordance with Canadian immigration regulations, this advertisement is directed to Canadian citizens and 
permanent residents of Canada.
Applications for this position will close May 11, 1990.
Interested candidates should forward their curriculum vitae to:
CHAIRMAN
SEARCH COMMITTEE FOR A HEAD, DIVISION OF THORACIC SURGERY
MOUNT SINAI HOSPITAL
600 UNIVERSITY AVENUE, ROOM 346
TORONTO, ONTARIO CANADA M5G 1X5
— S90-13
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TEXAS A&M UNIVERSITY 
College of Medicine
TEMPLC CAMPUS
The Department of Neurologic Surgery of the Scott 
and White Institutions and Texas A&M University 
College of Medicine is seeking applications for 
senior staff physician faculty in the Sections of 
Pain/Stcreotaxic Surgery or Neurosurgical Oncology. 
Residency or post residency experience and a 
defined interest in either subspecialty area together 
with a broad capability and interest in general 
neurosurgical disorders is desired. Basic and clinical 
research opportunities are available commensurate 
with previous experience. Medical student and 
resident teaching/daily responsibilities are required. 
The main campus is located in central Texas, north 
of Austin in the approximate center of the Dallas/ Ft. 
Worth, San Antonio, Houston triangle and benefits 
from easy access to other surrounding universities 
(Southwestern University, Georgetown; University of 
Mary Hardin-Baylor, Belton; Baylor University, 
Waco.)
For further information, please send curriculum 
vitae and references to:
Mitchell Smigicl, M.D.
Chairman, Neurologic Surgery 
Scott and White, Texas A&M University 
College o f Medicine 
2401 South 31st Street 
Temple, TX 76508
— S90-06
I SCOTT&  WHITE
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